Congenital Diaphragmatic Hernia and Extracorporeal Membrane Oxygenation by Staak, F.H.J.M. van der
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/140993
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
ö'cni-ta 
.UK 
В^^^^^^^^^^^^^^^^Нб 
• 
ÉÜ 
ЯКЯяБЕВ 
• 

Congenital Diaphragmatic Hernia 
and 
Extracorporeal Membrane Oxygenation 

Congenital Diaphragmatic Hernia 
and 
Extracorporeal Membrane Oxygenation 
Een wetenschappelijke proeve op het gebied 
van de Medische Wetenschappen 
PROEFSCHRIFT 
ter verkrijging van de graad van doctor 
aan de Katholieke Universiteit Nijmegen, 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen op 
dinsdag 18 november 1997 
des namiddags om 1.30 uur precies 
door 
Francisais Henricus Johannes Maria van der Staak 
geboren op 17 september 1946 
te Vught 
Promotor: Prof. dr. С. Festen 
Co-promotor: Dr. W.B. Geven 
Manuscript commissie: Prof. dr. F. Verheugt 
Prof. dr. M. van de Bor 
Prof. dr. B. Oeseburg 
Aan mijn ouders 
Voor Nicole 
Amber, Max 
Barbara en Boukje 
Financial support for the publication of this thesis was received from : 
W.L. GORE & ASSOCIATES 
IMMUNO BV 
INTERNATIONAL TECHNIDYNE CORPORATION 
JOSTRA MEDIZINTECHNIK AG 
Nijmegen University Press 
ISBN 90 5710 033 9 
Contents and Abbreviations 
Vili 
Prologue XIII 
Part I Introduction 
Chapter 1 Congenital Diaphragmatic Hernia 3 
Chapter 2 Extracorporeal Membrane Oxygenation 23 
Chapter 3 Study outline 41 
Part II Severity Assessment and prediction of outcome for neonates with 
Congenital Diaphragmatic Hernia 
Chapter 4 Is preoperative risk assessment of newborns with Congenital 
Diaphragmatic Hemia possible by means of chest X-rays? 47 
Chapter 5 Do we use the right entry criteria for Extracorporeal Membrane 
Oxygenation in Congenital Diaphragmatic Hemia? 55 
Part III Extracorporeal Membrane Oxygenation in the treatment of 
Congenital Diaphragmatic Hernia 
Chapter 6 Experience with delayed repair of Congenital Diaphragmatic 
Hernia during Extracorporeal Membrane Oxygenation in an 
European Center 67 
Chapter 7 Improving survival for patients with high-risk Congenital 
Diaphragmatic Hemia by using Extracorporeal Membrane 
Oxygenation 77 
¡χ 
Part IV Complications and pitfalls in the treatment of Congenital Diaphragmatic 
Hernia 
Chapter 8 Surgical repair of Congenital Diaphragmatic Hemia during Extra­
corporeal Membrane Oxygenation. Hemorrhagic complications and 
the effect of tranexamic acid 93 
Chapter 9 Surgical repair of an aortic coarctation in a patient after treatment 
with Extracorporeal Membrane Oxygenation 107 
Chapter 10 Recurrent Congenital Diaphragmatic Hemia; which factors are involved? 115 
Part V Follow-up 
Chapter 11 Congenital Diaphragmatic Hemia treated with Extracorporeal Membrane 
Oxygenation: outcome and early morbidity in the survivors 131 
Part VI Closing remarks 
Chapter 12 Epilogue 151 
Summary 171 
Samenvatting 181 
Dankwoord 187 Curriculum Vitae 192 
Abbreviations 
AaD02 
ACT 
BAER 
BPDP02 
CDH 
CHD 
CLD 
СРВ 
CRAD 
CT 
CT-scan 
DIC 
DQ 
EACA 
ECC 
ECLS 
ECMO 
ELSO 
Fi02 
GER 
HFJV 
HFOV 
HFPPV 
HR 
HUS 
ICH 
ITPV 
kPa 
LES 
MQ 
MAP 
MAS 
MCT 
MDI 
mm Hg 
NO 
NT 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
-
= 
= 
= 
= 
-
= 
= 
= 
= 
= 
= 
= 
-
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
alveolar to arterial oxygen pressure gradient 
activated clotting time 
brainstem auditory evoked response 
best postductal pa02 
congenital diaphragmatic hernia 
congenitale hernia diaphragmatica 
chronic lung disease 
cardiopulmonary bypass 
chronic reactive airway disease 
conventional treatment 
computer tomography 
disseminated intravasal coagulopathy 
developmental quotient 
epsilon aminocaproic acid 
extracorporeal circulation 
extracorporeal life support 
extracorporeal membrane oxygenation 
extracorporeal life support organization 
fraction of inspired oxygen 
gastroesophageal reflux 
high frequency jet ventilation 
high frequency oscillatory ventilation 
high frequency positive pressure ventilation 
high risk 
head ultrasonography 
intracranial hemorrhage 
intratracheal pulmonary ventilation 
kiloPascal (1 kPa ~ 7,5 mm Hg) 
lower esophageal sphincter 
motor quotient 
mean airway pressure 
meconium aspiration syndrome 
medium chain triglycerides 
mental developmental index 
millimeters mercury (pressure) 
nitric oxide 
not traceable 
(difference) 
ΟΙ 
OR 
ΡΙΟ, Ρ25 
PaC02 
PAC02 
PAI 
Pa02 
PA02 
PAP 
Pbaro 
PDA 
PEEP 
PFC 
pH 
рн2о 
PIE 
PIP 
PLV 
PPHN 
PTFE 
PVR 
RBC 
RDS 
Sa02 
SCV 
SD 
TEA 
TPA 
TRH 
UK 
V/Q-ratio 
VA-ECMO 
VI 
VV-ECMO 
X-ray 
= 
= 
= 
= 
= 
-
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
-
= 
= 
= 
= 
oxygenation index (MAP χ Fi02 χ 100/PaO2) 
oddsratio 
percentile (10th,25th respectively) 
arterial partial carbondioxide pressure 
alveolar partial carbondioxide pressure 
plasminogen activator inhibitor 
arterial partial oxygen pressure 
alveolar partial oxygen pressure 
pulmonary arterial pressure 
atmospheric pressure 
persistent ductus arteriosus 
positive end exspiratory pressure 
persistent fetal circulation 
negative logarithm of free hydrogen ion concentration 
partial vapour pressure (47 mm Hg at 37°C) 
pulmonary insterstitial emphysema 
peak inspiratory pressure 
partial liquid ventilation 
persistent pulmonary hypertension of the newborn 
polytetrafluoroethylene (Goretex R) 
pulmonary vascular resistance 
red blood cells 
respiratory distress syndrome 
arterial oxygen saturation 
superior cavai vein 
standard deviation 
tranexamic acid 
tissue plasminogen activator 
thyrotropine releasing hormone 
United Kingdom 
ventilation/perfusion ratio 
venoarterial ECMO 
ventilation index (= ventilatory rate χ MAP) 
venovenous ECMO 
radiographic examinations 

Prologue 
A congenital diaphragmatic hernia (CDH) concerns a developmental anomaly, in which there 
is an incomplete formation of the diaphragm. Generally, this anomaly is classified into 2 
categories according to the location of the defect 
1 the ventral or retrosternal defect, usually designated as a hernia of Morgagni and 
2 the posterolateral defect, usually designated as a hernia of Bochdalek. 
Although Bochdalek originally described a herniation through the tngonum lumbocostal his 
name is erroneously attached to all forms of posterolateral defects. This thesis is exclusively 
dealing with the congenital posterolateral defect, which constitutes a serious malformation 
that may cause severe respiratory distress and death immediately after birth. 
Despite improvements in perinatal and neonatal care, in artificial ventilation and in neonatal 
transportation the mortality rate for this anomaly has been remained continuously high in the 
past 3 or 4 decades -amounting to 50 to 60% in high risk infants. Those infants have symp-
toms of respiratory distress within 6 hours after birth In view of these disappointing results 
alternative modes of therapy were explored, among which extracorporeal membrane oxygena-
tion (ECMO). 
ECMO is a technique in which the blood circulates outside the body (extracorporeal) and in 
which the gas exchange of the blood occurs across a semipermeable membrane of an "artifi-
cial lung" (the membrane oxygenator). Since the blood is constantly in contact with the 
foreign surface of the extracorporeal circuit there is an increased risk of clot formation. Thus 
in order to prevent those clots anticoagulation therapy is required. However, that therapy 
ensues risk of bleeding complications. Not only for these risks as well as for the aggressive 
(invasive) nature of this technique, ECMO treatment is considered as a therapy of last resort. 
It is only applied in infants who are unresponsive to other extreme measures (maximal con-
ventional therapy) and who would very likely die. 
However problems for such last-resort therapy are how to identify those patients who have no 
likelihood of survival using other less invasive and less risky therapies and at which point in 
the course of the illness the last-resort therapy has to be implemented. Because ECMO is used 
only in patients who are most likely to die otherwise, the results are usually described in terms 
of simple survival. Nevertheless long-term quality of life is also important. 
XIV 
This thesis presents clinical studies of congenital diaphragmatic hernia in relation to the use 
of extracorporeal membrane oxygenation The core of this thesis is formed by published 
papers concerning outcome prediction and patient selection for ECMO, the early experience 
and the improving survival with ECMO and complications encountered m the treatment of 
congenital diaphragmatic hernia, and a submitted paper regarding the early morbidity and 
outcome of ECMO CDH survivors. These papers are preceded by introductory chapters on 
congenital diaphragmatic hernia and on extracorporeal membrane oxygenation. 
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1.1 Introduction 
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1.1 Introduction 
Congenital Diaphragmatic Hemia entails a developmental defect in which the usual closing 
process of the diaphragm has been arrested or disturbed before birth. An incompletely closed 
diaphragm results in a free communication between the pleural and peritoneal cavity and 
allows abdominal viscera to move into the thorax. Various parts of the diaphragm can be 
affected. Generally congenital diaphragmatic hernias are divided into 2 categories according 
to the location of the defect: 
a. in the retrosternal area: the foramen of Morgagni 
b. in either posterolateral portion, along the old pleuroperitoneal canal: the foramen of Boch-
dalek. 
The posterolateral hemia is the most common diaphragmatic defect - it comprises 85% of all 
congenital diaphragmatic hernias' - and remains a critical problem in neonatal surgery, since 
it is associated with a high mortality2 9. 
The congenital posterolateral diaphragmatic hernia is a distinct entity and constitutes the 
subject of this discussion. In the following text congenital diaphragmatic hemia (CDH) 
without further indication means a posterolateral hemia. 
The cause of the closing defect of the diaphragm is still unknown10"'2. 
The reported incidence of CDH varies from 1 in 2400 to 1 in 5000 liveboms2·4·'3'4. CDH may 
be accompanied by other malformations in about 50% of the cases1,4'5 '7. Most common 
associated malformations are neural tube defects and cardiac defects, especially in 
stillboms'41518'20. Diaphragmatic defects have been reported in association with chromosomal 
defects (most commonly trisomies 18 and 21)", as part of a syndrome'5·20"23 and as a familial 
occurence24"27. Left sided defects occur more frequently than right sided defects (80% to 
20%)'6. 
Serious clinical symptoms of respiratory distress may occur in CDH-patients shortly after 
birth. The respiratory insufficiency is responsible for a mortality rate of 40% to 60%2,3. 
Despite a succesful repair of the defect and despite all advances and enormous efforts in 
neonatal care, including prenatal diagnosis, neonatal transport, intensive care treatment and 
anaesthesiology, this mortality rate seems to increase rather than to drop2 3 ' 2 8 · 2 9 . 
Gross' suggestion, that babies and children with diaphragmatic hernias can be cured of their 
malformation in 90% to 95% of the cases by surgical repair, did not come true30. 
The management of CDH-patients turned out to be more complex than the simple surgical 
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closure of the diaphragmatic defect and the withdrawal of abdominal viscera from the thora-
cic cavity The pathophysiology of this anomaly appeared to be more complex 
1.2 Pathophysiologic considerations 
1.2.1 Historical Concept mechnical compression 
In the early days of paediatric surgery it was thought that the pathologic condition in CDH 
patients was a pure mechnical problem11 12. Since there is no complete separation between the 
thoracic and abdominal cavity the pleural cavity is filled with abdominal viscera Postnatally 
the protruded intestines fill with air after the first breath and exert pressure upon the lungs and 
mediastinum. The lung on the affected side may be completely collapsed, the heart has been 
pushed to the opposite side of the chest and the contralateral lung is generally partially 
compressed. 
"The seventy of symptoms and the speed with which they appear depend on the extent to 
which the abdominal viscera are drawn into the chest and on the degree to which the lungs are 
compressed" (Gross 1946). Hence Gross stated, that "surgical intervention should be employ-
ed as soon as the diagnosis is made"3' 
The abdominal viscera should be pulled down out of the chest in order to alleviate the respira-
tory embarassment. In those days rapid expansion of the collapsed lung seemed to be highly 
desirable as well as "to suck the air out of the pleural cavity, which allows the mediastinum to 
return to a normal position and gives maximum aeration of the lungs"11. However emergency 
surgery did not provide the success that was expected, since there was another pathologic 
phenomenon- pulmonary hypoplasia. 
1 2.2 Pulmonary hypoplasia 
Pulmonary hypoplasia as the underlying secundary pathophysiological abnormality in con-
genital diaphragmatic hernia was described by Campanale and Rowland33 
It was supposed that the prenatal compression of the protuded abdominal viscera on the lung 
buds causes hypoplasia of the developing lungs. Experimentally it was shown that artificially 
induced pressure on developing lung tissue may cause hypoplasia34. The seventy of the 
hypoplasia should depend on the stage of development which the lungs had achieved at the 
time of the expenment34 35. Although the term hypoplasia is not well defined it is obvious 
that lung development in babies with diaphragmatic hernia is abnormal36. 
Several studies have been performed to describe and to quantify the "degree" of pulmonary 
6 Chapter 1 
hypoplasia 1415 "41. It has been shown that not only the lung weight in reference to the body 
weight is reduced in CDH-patients ' 3719, but also that each of the functional systems within 
the lung is affected ^4 2 . Areechon and Reíd found a reduced number of conducting airways -
especially on the affected side - and concluded that the bronchial branching was arrested 42. 
In connection with the reduction of the number of airway generations a reduction in the 
volume and number of alveoli was found as well181942 
In addition to the reduced respiratory exchange surfaces the air-blood interface is thickened m 
comparison to normal lungs 4'. It was demonstrated in animal studies that although type II 
pneumocytes - which are considered to be responsible for the production of surfactant - are 
increased in the lungs of lambs with CDH, the type II cells are immature with less lamellar 
bodies which are responsible for the storage of surfactant M 45 Besides these structural paren-
chymal abnormalities, functional parenchymal abnormalities are present as well. Not only 
may the surfactant production be impaired, but the composition of surfactant may be aberrant 
as well as having a decreased phosphatidylcholine content4' '", Both conditions can result in a 
less efficacious surfactant system in CDH. On the other hand animal studies have suggested 
that the antioxidant defense system may be impaired in neonates with CDH 47 ^ . Last but not 
least vascular development has been involved m the pulmonary hypoplasia of congenital 
diaphragmatic hernia ^49 5'. The numbers of conventional and supernumerary arterial bran-
ches are reduced in lungs of CDH patients, whereas there is a markedly increased muscle 
mass within the media. These abnormalities - underdevelopment of the pulmonary vascular 
bed and maldevelopment with excessive musculansation - lay the morphological foundation 
of another important pathophysiological phenomenon pulmonary hypertension 52. 
1.2.3 Pulmonary Hypertension 
According to the aforementioned morphological findings (see 1.2.2) it was generally assumed 
that the high mortality m diaphragmatic hernia patients was due to pulmonary hypoplasia. 
However, the clinical course, frequently seen in CDH patients following repair of the di-
aphragmatic defect argues against the "pulmonary hypoplasia theory" as the cause of respira-
tory insufficiency and death. 
Many infants show an adequate oxygenation in the immediate postoperative period, lasting 
for up to 24 to 36 hours, followed by deterioration and subsequently death "5 5 . 
This period of adequate oxygenation after surgical repair was described by Collins et al as the 
"honeymoon period" " . They believed that "a dynamic pathophysiologic event must account 
for the terminal anoxemia rather than an absolute deficiency of lung parenchyma". 
It was hypothesized that the clinical deterioration could be attributed to a rise in the pulmona-
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ry vascular resistance, resulting in a state of fetal circulation with right-to-left shunting 
through the ductus arterious, foramen ovale and intrapulmonary vessels5'55. Cardiac cathete-
rization and angiography confirmed the presence of these phenomena ,6,57. This condition had 
been described in other neonates without CDH previously and termed persistent pulmonary 
hypertension of the newborn (PPHN) or "PFC" syndrome (persistent fetal circulation)58 59. 
Besides a maldevelopment and an underdevelopment (see 1.2.2) a maladaptation of the 
pulmonary vascular bed may be responsible for a severe pulmonary hypertension in CDH-
patients 52. An exaggerated response of the anatomically abnormal pulmonary vascular bed 
can occur as a result of numerous factors among which hypoxia, acidosis and can initiate a 
condition of progressive hypoxemia which is responsible for the high mortality among CDH-
infants. 
1.2.4 Transthoracic Pressure Gradient 
The hypothesis that overexpansion of the lungs might be a major cause of progressive pulmo-
nary insufficiency led to several studies concerning the pathophysiologic consequences of 
transthoracic and transpleural pressure gradients on pulmonary function ^-61. 
It was demonstrated in animal experiments in which the postoperative state of infants with 
CDH was mimicked that overdistention and a mediastinal shift resulted in a progressive 
respiratory insufficiency with an immediate decrease in Pa02 and increase in PaC02 60H. 
Cloutier supposed that the postoperative reversion to fetal circulation was due to the rapid 
expansion of both hypoplastic lungs. In his opinion this complication was preventable 62. In an 
experimental study in lambs it was demonstrated that there is a positive correlation between 
the transpulmonary pressure gradient employed and the pulmonary interstitial emphysema 
(PIE) found at morphometry M. 
Considering these results he suggested that using low ventilatory pressures and not draining 
the pleural cavity resulted in less barotrauma to the lungs and might prevent one of the 
components of the pulmonary hypertension. 
1.3 Treatment strategies and therapeutic aspects 
Through the years management strategies for CDH have been determined by what was known 
or what was conceived with respect to the pathophysiology. 
g Chapter 1 
1.3.1 Emergency Surgery 
Surgical repair of the diaphragmatic defect with removal of intestines from the thoracic cavity 
seemed the straight forward solution 30"32. Supposing that the respiratory problems were 
caused by compression of the ipsilateral lung, relief of the compression should allow the lung 
to expand and should improve respiration. The principal drawback hampering a successful 
outcome was thought to be the need for major surgery in infants arriving in an already critical 
condition Having knowledge of lung hypoplasia and being aware of the presence of prenatal 
developmental factors as major determinants of outcome, the belief that CDH was a surgical 
emergency remained. The approach to the problem was more or less pragmatic. 
After elimination of lung compression as a source of respiratory embarrassment, the most 
optimal condition for a good and unhampered respiration was created. 
When sufficient lung tissue was present, the infant survived. But when the lung compression 
was relieved and the infant died, the amount of lung tissue was considered to be unable to 
support extrauterine life. 
However, with that approach a third category of patients could be identified- the "honeymoon-
ers", in whom abnormalities of the pulmonary vascular bed and nght-to-left shunting determi-
ned the clinical picture and the clinical course 53. According to Pringle 36 there appear to be 3 
clearly defined groups. 
1. Those patients who present with few or no respiratory symptoms. They almost all survive. 
2. Those patients that can never be adequately oxygenated and die shortly after birth, regard-
less of the kind of treament 
3. Those infants that initially appear to do well or respond very well to intubation and ventila-
tion but who later develop PPHN. This group has a rather poor survival. 
Urgent, probably lifesaving, surgical repair continued but therapeutic efforts were concentra-
ted on the management of PPHN53 65. 
Treatment protocols included hyperventilation, alkalinization and muscle paralysis whereas 
several vasoactive drugs were tried in an attempt to manipulate the pulmonary circulation 53 M 
61
. In individual cases a temporary (and sometimes a definite) reversion of the pulmonary 
hypertension could be achieved, but survival on the whole did not improve. 
1.3 2 Delayed Surgery 
Up to the 1980s emergency surgical repair was the cornerstone of the therapeutical approach. 
Changing insights in the pathophysiology of CDH brought about a major revolution in the 
treatment of CDH with a strategy of delayed surgery after a period of preoperative stabilizati-
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on5 9 (table 1). This approach was prompted by studies demonstrating adverse effects on 
thoracic compliance and gas exchange following surgical repair of CDH 68 69. Although 
delayed surgery has become the widely accepted approach to CDH-management, it is unclear 
whether this strategy has significant impact on survival5 9. 
Table 1 Conventional Preoperative Stabilization 
nasotracheal intubation 
mechanical positive pressure ventilation with hyperventilation 
and with oxygen up to 100%, if necessary 
muscle relaxation with pancuronium 
sedation with midazolam and/or fentanyl 
gastrointestinal decompression by nasogastric tube 
manipulation of the systemic circulation with vasoactive drugs 
(dopamine, dobutamine or isoprenaline) 
manipulation of pulmonary circulation (tolazohne) 
It was assumed that the surgical stress and the mechanical effects of hernia repair elicit or 
aggravate pulmonary hypertension and nght-to-left shunting. It seemed better to avoid a 
surgical procedure until the unstable pulmonary circulation became less reactive 
However, clear criteria for how long operation should be deferred are lacking, it is more or 
less a matter of clinical judgment and prolonged experience 6 7. 
Using echocardiographic monitoring of pulmonary arterial pressure (PAP) Haugen et al 
recommend postponement of the operation until pulmonary vascular resistance (PVR) has 
decreased 70. Reduction of PVR was presumed when PAP had fallen to a level of 25 to 55 
mmHg and a bidirectional or nght-to-left shunt through the ductus arteriosus was reversed to 
a left-to-nght shunt By continuous measurements of physiological variables Moffitt et al 
have attempted - as part of their study - to identify the achievement of medical stabilization 
7
'. There is conflicting evidence whether delayed surgery results in an improvement in survi-
val compared to emergency surgery In only 2 series of CDH-patients treated with delayed 
surgery has a reduced mortality been reported s 6 All other series have not noted a major 
difference in survival8 9 n . Two randomized controlled trials did not show any difference in 
survival between delayed versus immediate repair either7174 
IO Chapter I 
1.3.3 Miscellaneous Management Aspects 
Being aware of the presence of lung hypoplasia in all its gradations, several refinements in the 
therapeutic management of CDH have been advocated. 
Since hypoplastic lungs are susceptible to barotrauma special surgical approaches have been 
proposed to avoid overexpansion of the hypoplastic lung. In order to control excessive 
intrathoracic pressure gradients "balanced" thoracic drainage and mediastinal stabilization by 
an expansion prosthesis are employed 7S 76. For the same purpose a chest tube attached to an 
underwater seal is recommended postoperatively instead of chest drainage with suction 62. 
Reconstruction of the dome of the diaphragm with the use of a prosthetic patch should be 
pursued in every diaphragmatic defect77. 
Hyperventilation as the mainstay treatment for all causes of PPHN including CDH has been 
abandoned because of hearing loss and the associated barotrauma resulting from aggressive 
ventilatory management. A pressure-limited ventilation ignoring hypercapnia has been 
advocated ("permissive hypercapnia ventilation")78,79. 
Other ventilatory techniques without high airway pressures are currently used to avoid 
barotrauma: high-frequency oscillation ventilation (HFOV) ^8 4 high-frequency jet ventilation 
(HFJV)85 and intratracheal pulmonary ventilation (ITPV)86. Experience with ITPV in new-
boms is very limited 87. In HFOV and HFJV improvement of gas exchange has been achieved 
by increasing ventilator rates (to the range of 100 to 600 breaths per minute) rather than by 
increasing airway pressures. The greatest experience has been accumulated with HFOV, but 
the place of HFOV in CDH-treatment has yet to be elucidated: neither in the hierarchy of 
CDH-treatment nor in terms of efficacy and contribution to improved survival80"84. 
A relative surfactant deficiency as component of the lung hypoplasia has been documented in 
human studies as well as in animal studies ^88. Correction of this deficiency could be achie-
ved by two alternative ways: by surfactant replacement therapy or by the prenatal administra-
tion of steroid therapy with or without thyrotropin releasing hormone (TRH)89-92·134-136. 
Application of surfactant replacement therapy in newborn infants could have a beneficial 
effect but the success is not unequivocal51"95. Prophylactic surfactant therapy is probably more 
efficacious than the administration of surfactant as a rescue therapy 89. 
The use of liquid instead of gas as a ventilation medium in respiratory failure is still in its 
infancy. Preliminary clinical studies showed improvement in oxygenation and compliance in 
neonates with RDS as well as with CDH ^99. The usefulness of liquid ventilation therapy in 
CDH is waiting for further evaluation. 
Intensive research into vasoactive mediators, which play a role in pulmonary hypertension of 
the newborn or which can cause selective pulmonary vasodilatation are in progress. The roles 
Congenital Diaphragmatic Hernia 11 
of thromboxanes, Prostaglandine and leukotnenes have been investigated lco '01 The results of 
prostacyclin administration in the clinical situation are disappointing. The effect of prostacy-
clin appeared to be only transient,04 l05. The discovery that nitric oxide (NO) has a similar 
biological activity of endothehal-denved relaxing factor and as a dilator of smooth muscle has 
proceeded into a rapid introduction of NO into clinical medicine '06 "2. 
Experimental studies suggested a pivitol role of NO in the transitional circulation m "4 
Studies in which NO has been used as a rescue therapy in newborn infants with PPHN docu-
mented a reversal of ductal shunting due to a decreased pulmonary artery pressure and an 
increase of arterial oxygen pressure '°7109. The response to NO may be dramatic and no 
adverse effects from NO have been reported so far, but not all infants respond to NO The 
application of NO in infants with CDH has been reported in case reports and small series. The 
results are inconsistent108 " ° " 2 Double-blind, randomized controlled clinical trials using 
nitric oxide in the treatment of PPHN are ongoing 
1.4 Assessment of severity of disease and prediction of outcome in CDH 
The complex nature of CDH, in which lung hypoplasia and persistent pulmonary hypertensi-
on may be present in varying degrees, hampers the quantitation of the severity of the disease. 
Many attempts have been made to define the severity of the clinical condition in order to 
identify the patients with the highest risk, to monitor the clinical course, to determine the need 
for more aggressive therapy, to predict outcome, to compare clinical studies and patient 
groups and to enable the evaluation of the efficacy of different treatment modalities ' 's '". 
Over the years several studies have been performed to predict outcome in babies with CDH 
based on the evaluation of arterial blood gases and pH "5,22 Boix-Ochoa stated that patients 
with initial pH values below 7.0 and paC02 values above 100 mmHg had a bad prognosis and 
all died "6. Mishalany used the arterial pH on admission to predict survival "7. A pH > 7.2 
was attended by a 100% survival. In patients with a pH between 7.0 and 7.2 on admission the 
survival chance was 50%, whereas the survival rate was only 11% for patients with an initial 
pH below 7.0 Raphaely and Downes used the alveolar- arterial oxygen gradient (AaD02) for 
prediction (see Table 2) survivors had a mean AaD02 of 260 mm Hg after surgical repair 
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Table 2 Calculation of the alveolar to arterial oxygen pressure difference ( AaD0 2) 
AaD0 2 =PA0 2 -Pa0 2 
in which: 
Pa0 2= arterial partial oxygen pressure which can be measured by a bloodgas analysis 
PA0 2= alveolar partial oxygen pressure which can be calculated according to the "alveolar 
air equation" of Comroe, in which PA0 2 is substituted by: 
1 - Fi0 2 
PA0 2 = Pi0 2 - PAC0 2 (Fi0 2 + ) 
R 
in which: 
- PAC0 2 = partial alveolar carbon dioxide pressure 
- Pi0 2 = partial inspiratory oxygen pressure 
- Fi0 2 = fraction of inspired oxygen 
- R = respiratory exchange ratio (mostly 0.8) 
assuming that: 
- the inspiratory partial carbon dioxide pressure (PiC02) is zero. 
- the alveolar partial carbon dioxide pressure (PAC02) is equal to the arterial 
partial carbon dioxide pressure (PaC0 2), supposing that there is an efficacious 
(artificial) ventilation. 
and calculating Pi0 2 as: 
Pi0 2 = F i 0 2 (Pbaro- PH 2 0) 
in which: 
- Pbaro = atmospheric pressure in mmHg 
- PH 2 0 = vapour pressure (being 47 mmHg at 37 ° С ) 
results in: 
1 - Fi0 2 
AaD0 2 = Fi0 2 (Pbaro -PH20) - PaC0 2 (Fi0 2 + ) - Pa0 2 
R 
a n d i f F i 0 2 = 1.0, in: 
AaD02 = Pbaro - PH20 - PaC02 - Pa02 
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compared to a mean AaD0 2 of 614 mm Hg in nonsurvivors, whereas an AaD0 2 of greater 
than 500 mm Hg before operation indicates a poor prognosis (92% mortality)"5 Collins et al 
confirmed more or less these observations a preoperative AaD0 2 greater than 560 mm Hg 
and a postoperative AaD0 2 greater than 600 mm Hg characterize those patients who certainly 
would die despite maximal conventional therapy ".Manthei et al reported that patients with an 
AaD0 2 greater than 500 mmHg both before and immediately after surgery did not survive "
8 
Bloss et al predicted outcome in dependence on pa02 change in response to postoperative 
tolazohne administration ' '9. An intravenous test dose of 2 mg/kg tolazoline was given, if 
postductal pa02 values were below 50 mmHg on maximal ventilatory therapy. He found that 
patients with a pa02 increase greater than 100 mmHg survived, whereas all patients with a 
pa02 increase less than 20 mmHg died. Fair "responders" with a pa02 increase between 20 
and 100 mmHg had an equivocal outcome. However in most studies concerning arterial 
bloodgas values and outcome the ventilatory circumstances were not mentioned (spontaneous 
respiration or mechanical ventilation) nor the sites at which the bloodgas samples were taken 
(pre- or postductally) Bohn et al connected paC02-values with a ventilation-index as a predic­
tor of outcome: "Bonn-boxes" (see figure 1) l2°. 
The ventilation index (VI) reflects the intensity of artificial ventilation in terms of ventilatory 
PaCO2=40 
A 
В 
80% 
0% 
100% 
50% 
С 
D 
Figure 1 Mortality risk for CDH , using bloodgas analyses and ventilator settings 
2 hours after surgical repair, according to Bohn 
VI = ventilatory index = MAP χ Fi02 
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rate and airway pressure and was defined as VI = ventilatory rate χ mean airway pressure. 
They found a (nearly) 100% survival in those infants, in whom normocapnia could be achie­
ved with a VI lesser than 1000 (Box B) 
Other authors distinguish "responders" and "nonresponders" for outcome-prediction, in which 
'•responders" and "nonresponders" are defined by the ability or the inability to achieve a best 
postductal pa02 (BPDP02) of 100 mmHg or more '2' '22 O'Rourke et al reported that the 
mortality rate was 100% in a group of patients in which the pa02 was consistently less than 
100 mmHg (13,3 kPa) on a Fi02 of 1 0, compared to a mortality rate of 23% in a group, in 
which at least one postductal pa02 value was greater than 100 mmHg (13,3 kPa) '21. In a study 
of Wilson et al it was shown that in patients with a BPDPa02 greater than 100 mmHg the 
survival was 91%, whereas the survival was only 7% when the BPDPa02 was less than 100 
mmHg m 
In a preliminary study Antunes et al speculated that the preoperative measurement of the 
functional residual capacity ( by helium dilution technique) is a good indicator of pulmonary 
hypoplasia, better than the oxygenation index, and as a consequence a better predictor of 
outcome in CDH'33. The measurement of preoperative pulmonary function tests (compliance 
and tidal volume) may be helpful to predict which infants will require ECMO3 
Tracy et al suggested that a postoperative tidal volume of more than 4 mL/kg may be critical 
for survival3. 
Other attempts have also been made to use anatomic parameters for predictive purposes '23 '32. 
Using chest X-ray studies Touloukian and Markowitz drafted a preoperative X-ray scoring 
system for prediction of outcome m . If the stomach was located intrathoracically in leftsided 
defects the survival had been reported to be worse 124-'26. A large defect requiring a prosthetic 
patch closure has been associated with a worse outcome 127 '2'. Right sided hernias appeared 
to have a poorer prognosis 82 n o '31 Nielsen et al reporting on factors affecting survival 
mentioned only one survivor out of six patients with right sided defects l3°. Tibboel et al 
observed a 100% mortality in patients with right sided defects '3I 
In other studies the time of diagnosis was considered to be of prognostic value 28 " 5 '27 l32. 
Young ascertained that there is an inverse relationship between the age at diagnosis and the 
mortality 28. If the clinical signs are so severe that a diagnosis of CDH is made within 24 
hours after birth, the mortality appeared to be more than 50% (61%). An antenatal diagnosis 
of CDH was felt to imply a poor prognosis " Adzick et al found only 19 survivors out of 94 
prenatally diagnosed cases (20%) despite optimal conventional therapy started immediately 
after birth The outcome for fetuses with prenatally detectable CDH and polyhydramnios is 
particularly dismal (89% mortality) '9. 
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2.1 Introduction 
Extracorporeal Membrane Oxygenation (ECMO) is the application of temporary, but prolong-
ed gas exchange outside the body by the use of extracorporeal circulation in patients with 
reversible life-threatening situations of cardiac and/or pulmonary failure'"4, (fig 1) 
It is a last-resort-therapy for those patients who do not respond to maximal medical manage-
ment including maximal mechanical ventilation and who are likely to die without ECMO in 
continuing conventional therapy. The use of this technique requires some type of anticoagula-
tion (usually heparinization) to prevent clot formation, but consequently bleeding is always a 
potential complication5,6. 
Under a grant of Governmental Healthcare Authorities Extracorporeal Membrane Oxygenati-
on was introduced into the University Hospital of Nijmegen for the treatment of respiratory 
failure in neonates - including infants with congenital diaphragmatic hemia - in 19917. 
The most accepted method of ECMO - certainly in those days - was venoarterial ECMO 
(VA-ECMO)M. Because veno-venous ECMO was still in the experimental stages of develop-
ment, VA-ECMO was adopted in our institution. In this introductory chapter general aspects 
of ECMO are briefly described according to our ECMO protocol, like ECMO-circuit, vascu-
lar access for ECMO, patient selection for ECMO, and complications of ECMO-therapy. 
2.2 Performance of ECMO-therapy 
2.2.1 Vascular access for ECMO 
Before initiation of ECMO-therapy the ECMO system has to be attached to the patient 
(fig. 2). For that purpose cannulas have to be placed in the patient for high-volume blood 
flow. 
In neonates the number of sites available for vascular access is limited8. 
Most frequently used is venoarterial bypass, for which cannulas are placed in the neck'"4,8. Via 
the right internal jugular vein blood is drained from the right atrium to the circuit. 
Through a cannula in the right common carotic artery the blood is returned to the systemic 
circulation. 
In our institution this procedure is performed in the Neonatal Intensive Care Unit. 
Both vessels are ligated at the cranial site permanently. The cannulas are connected to the 
circuit, ensuring that no air bubbles enter the circuit or the patient. 
To prevent bleeding from this operative site during bypass fibrin glue (Tissucol R) is installed 
into the wound before closure '. Cannula placement is confirmed by X-ray or more reliably by 
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ultrasound 10. The venous cannula should rest in the right atrium, and the tip of the arterial 
cannule shouls should be situated at the entrance to the aortic arch. 
Controversy exists regarding permanent carotid artery ligation. Debates on the issue of 
whether the carotid artery should be ligated or repaired if the patient is decannulated are not 
completely closed""15. Convincing arguments in support of carotid artery reconstruction have 
not been emerged yet. 
2.2.2 ECMO-circuit 
The ECMO system (circuit) consists basically of a blood pump, a membrane oxygenator, a 
heat exchanger, a tubing system and a servo-control module (fig 3). 
Figure 3 Stand-by ECMO cart : completely prepared for clinical application 
(i.e. being in store for a maximal period of 4 weeks) 
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Figure 4 The roller pump Figure 5 The membrane lung 
The blood pump is a roller pump pushing blood through the membrane lung (fig 4). The 
membrane lung accomplishes carbon dioxide removal from and oxygen delivery to the blood 
(fig 5). It has 2 compartments divided by a gas permeable membrane with ventilating gas on 
one side and blood on the other. The heat exchanger rewarms the blood by a countercurrent 
circulating circuit of warmed water (fig 6). 
The servo-control module consists of a small collapsible reservoir within the circuit (the 
bladderbox) with a sensitive microswitch resting on it (fig 7). If the reservoir collapses due to 
decreased volume of draining blood the roller pump is automatically turned off by the micros-
witch. 
A broad variety of control modules are placed along the circuit. Pressure monitors are situated 
before and after the membrane lung. Sensors have been applied to the blood path to measure 
flow, temperature, hemoglobin saturation. 
Before starting the ECMO procedure, the ECMO system is flushed with carbon dioxide that 
aids to remove air from the system and subsequently primed with cristalloid solutions, plasma 
and red blood cells. Acid-base balance and blood gases of the prime are adjusted appropriate-
ly4, l6"18. The prime volume of the ciruit is approximately 400 ml. 
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Figure 6 The heat exchanger Figure 7 The bladder box 
2.2.3 Daily Management of ECMO 
Oxygenation After priming of the circuit, insertion of the cannulas and after connection of the 
circuit to the cannulas pump flow is started. Generally bypass can be established approxima-
tely 2 hours after the decision to ECMO support. Blood flows by gravity to the bladderbox 
and finally back to the patient by the roller pump. The amount of blood-flow is based on the 
degree of support required. At the beginning of a run the pump flow is gradually turned up 
until 80% of the infants cardiac output goes through the ECMO circuit (160 to 180 
mL/kg/min, presuming 200 mL/kg/min as an average cardiac output) and/or good saturations 
(Sa02) are recorded1"17'9. 
ECMO patients remain intubated and on the ventilator to prevent alveolar collapse, but at low 
pressure, low rate and low fractional inspired oxygen settings. ( "rest"settings: Fi02 30%, rate 
16 breaths per minute , PIP 20 to 24 mbar, PEEP 4 mbar). 
Lung function of the infant is very poor the first 24 to 48 hours of ECMO. Typically the chest 
X-ray shows a pulmonary opacification ("white-out" of the lung)20. After 48 to 72 hours 
breath sounds improve, the chest X-ray shows increasing aeration and oxygenation is impro-
ving due to recovery of the lungs. Blood gases are monitored hourly. Patients oxygenation 
(measured by Pa02) is adjusted by increasing or decreasing bypass flow through the oxyge-
nator, whereas the PaC02 is adjusted by the flow and the mixture of gas (either oxygen or a 
mixture of oxygen and carbondioxide) flowing through the membrane lung. 
The extracorporeal flow is set to maintain arterial oxygen pressure between 10 to 13 kPa. As 
the infant's lung function improves, additional oxygenation is taking place and the systemic 
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Pa02 increases above the level of 13 kPa, allowing to decrease the flow through the extracor-
poreal circuit ("weaning"). This weaning process continues gradually (10 to 20 ml/min per 
hour) until an ECMO flow of 50 ml/min is achieved with adequate bloodgases of the child 
(continuing with "rest" settings of the ventilator). Once these "idling" flows are reached and 
patient's condition remains stable for 6 to 8 hours with bloodgases within the normal ranges, 
the patient is removed from bypass and decannulated. 
Heparinisation Systemic anticoagulation must be maintained during the ECMO-course to 
prevent clot formation56. Before cannulation a loading dose of 100 to 150 units of heparin per 
kg bodyweight is administered. This anticoagulation therapy is continued by a heparin main-
tenance dose of 20 to 50 units/kg/hour to the circuit. The heparin delivery is adjusted to 
maintain an activated clotting time (ACT) at 2 to 3 times baseline levels (220 to 250 seconds). 
The ACT is monitored every hour with an ACT-monitor (HemochronR). 
Figure 8 Bed-side anticoagulation monitoring 
During ECMO extensive monitoring and frequent therapeutic adjustments are necessary to 
optimize oxygenation, ventilation blood pressure, anticoagulation and fluid balance. 
Nutritional support is established by standard parenteral nutrition protocols. Prophylactic 
antibiotics (mostly ampicilline and gentamycin) are administered. 
During ECMO the infant is kept slightly sedated. A combination of fentanyl and midazolam 
is mostly used. 
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23 Patient selection for ECMO 
Because of the invasive nature of ECMO and the potential risks associated with the procedu-
re, controversy exists regarding patient selection for ECMO application2'21. 
Two questions have to be answered 
a Which patients can be treated and helped by ECMO treatment and, 
b. When should ECMO be instituted? 
From the experience with ECMO and based on known complications of ECMO several 
"general" entena have emerged for the application of ECMO2127 
Important considerations before the initiation of ECMO concern the reversibility of the 
disease or the respiratory failure and the quahty-of-life following survival with ECMO 
(Congenital) anomalies incompatible with quality life do not fit the neonate for ECMO 
therapy. 
After a penod of assisted ventilation lasting for 7 to 10 days the development of chronic lung 
disease may be presumed. Since ECMO is not able to reverse permanent pulmonary fibrosis, 
it is mostly not offered to a neonate, who has been ventilated for longer than 10 days 
The requirement of systemic anticoagulation sets restrictions to the application of ECMO in 
neonates with major bleeding disorders or with a significant intracranial hemorrhage281I. 
Because premature infants have significantly higher risks of intracranial hemorrhage, ECMO 
is recommended only for neonates weighing more than 2000 grams or being older than 34 
weeks gestational age31. 
The major underlying cause of respiratory failure in newborns is persistent pulmonary hyper-
tension (PPHN). PPHN is a reversible condition and an outstanding indication for ECMO 
treatment.Since ECMO provides good oxygenation it breaks the vicious cycle of PPHN, 
where hypoxia causes pulmonary vasoconstriction which causes right-to-left shunting, which 
continues the hypoxemia.PPHN is present in diseases such as meconium aspiration syndrome 
(MAS), congenital diphragmatic hernia (CDH), sepsis, perinatal asphyxia, and respiratory 
distress syndrome (RDS). 
It is generally accepted, that ECMO should be instituted, when all methods of conventional 
therapy have been exhausted and when the mortality risk is 80% or more with continuation of 
conventional therapy'42127. However, both conditions are not well-defined. 
Maximal conventional endeavours may vary from institution to institution Which treatment is 
included in maximal conventional therapy9 The optimal conventional therapy is changing 
with time. The formerly advocated hyperventilation has been abandoned21,2 ". Newer techni-
ques and therapies are now available such as high frequency ventilation , among which high 
frequency oscillation, nitric oxide, surfactant replacement therapy and liquid ventilation. 
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For the prediction of 80 to 100% mortality most institutions are using the alveolar-arterial 
oxygen difference (AaD02)24,26, the oxygen index (OI)23·34, or some other criterion, in which 
the oxygenation of the patient is registered as a function of ventilatory condition for a certain 
period of time''·23·27. Although these criteria seem to be very accurate and objective, these 
scoring systems do not work in all cases. So also more subjective criteria based on clinical 
judgment are added to the aforementioned criteria. All entry criteria are listed in table 1. Most 
centra have used historical controls to settle their criteria. 
Table 1 Criteria for ECMO treatment 
Gestational age > 34 weeks 
Birth weight > 2000 grams 
Reversible disease or cause of respiratory failure 
Mechanical ventilation < 10 days 
No major pathology incompatible with life 
No major cardiac lesion 
No coagulopathy or bleeding complications 
No (major) intracranial hemorrhage 
AaD02 > 610 mmHg for 8 hours* 
AaD02 > 605 mmHg for 4 hours and PIP > 38 mbar* 
Oxygen Index (OI) > 40 for 3 of 5 consecutive bloodgasanalyses** 
Acute deterioration with pH < 7.15 and/or pa02 < 5.3 kPa for 2 consecutive hours 
Unresponsiveness to maximal therapy with pH < 7.40 and p0 2 < 7.3 kPa for 3 hours 
Signs of barotrauma (presence of any four of the following): 
interstitial emphysema - pneumothorax 
- subcutaneous emphysema - pneumopericardium 
pneumoperitoneum - persistent air leak for 24 hours 
MAP>15cmH 20 
* AaDOj-Patm - PH20 - PaO; - PaC02, if Fi0 2 - 1.0 
* * OI = MAP χ FiOj χ 100/PaOj 
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Table 2 Complications 
Patient complications 
Bleeding complications 
intracranial (ICH) 
pulmonary or gastrointestinal 
cannule site or surgical site 
- disseminate intravasal coagulopathy (DIC) 
Neurological complications 
- brain death 
seizures 
- cerebral infarction 
Cardiovascular complications 
hypertension 
hypotension and renal failure 
myocardial stun 
cardiac arythmia 
Metabolic complications 
electrolyte disorders 
hematologic (anaemia, thrombocytopenia) 
renal 
Infectious complications 
Mechanical complications 
- Failure of devices 
oxygenator 
heat exchanger 
pump 
- Rupture or disconnections 
raceway 
tubing 
- connectors 
- Embolization 
air 
clots 
- Cannula problems 
- malposition 
kinking 
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2.4 Complications during ECMO 
Complications, problems or unexpected incidents during ECMO may arise in the patient or in 
the circuit and may be related to the primary disease, to the treatment on the whole or to 
technical aspects of the circuit in particular28 29 35 ** Complications are listed in table 2. 
Bleeding complications due to systemic anticoagulation belong to the most serious and the 
most often occurring complications28 3'35 3743. Intracranial bleeding is the most feared and is 
the most common cause of death Following surgical repair congenital diaphragmatic hernia 
patients can have significant bleeding requiring early removal from ECMO support. Other 
complications are related to embolization from the bypass circuit like clots, air or other kind 
of particles (for example aluminium)35 "2 41 ^ . Infection is another risk associated with such 
invasive procedure, but has not proved to be a major problem. Technical and mechanical 
complications within the circuit are usually managed by changing the component part of the 
circuit 
Table 3 Survival of neonatal ECMO patients by diagnosis according to ECMO 
Registry Report of the Extracorporeal Life Support Organization 
International Summary, January 1997 
Diagnosis 
Congenital Diaphragmatic Hernia 
Meconium Aspiration Syndrome 
Persistent Pulmonary Hypertension 
Respiratory Distress Syndrome 
Pneumonia/Sepsis 
Air Leak Syndrome 
Other 
Number 
2451 
4263 
1598 
1166 
1853 
49 
541 
Percent 
survived 
59 
94 
82 
84 
76 
69 
76 
Total 11921 81 
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2.5 Extracorporeal Life Support Organization (ELSO) 
In 1986, when the clinical application of ECMO was growing rapidly all over the world, 
existing ECMO centers decided to collaborate and to collect their experiences in a central 
database414?. 
This resulted in a worldwide patient registry, in which nearly all active ECMO centers are 
participating under the auspices of Extracorporeal Life Support Organization (ELSO). 
Table 4 Patient Complications associated with neonatal ECMO according to the 
ELSO-registry report 
International Summary, January 1997 
Patient Complication 
Intracranial hemorrhage 
byHUS 
by CT scan 
Brain death 
Seizures 
Other neurologic problems 
Gastrointestinal hemorrhage 
Surgical site bleeding 
Cannule site bleeding 
Hemolysis 
Other hemorrhagic problems 
Need for dialysis/hemofiltration 
Cardiac arytmia 
Systemic hypertension 
Number 
1563 
453 
140 
1543 
479 
253 
717 
665 
1568 
875 
1654 
476 
1450 
Percent reported* 
13 
4 
1 
13 
4 
2 
6 
6 
13 
7 
14 
4 
12 
Percent survived" 
50 
83 
0 
66 
70 
51 
52 
72 
73 
66 
59 
59 
78 
Infection 728 62 
percentage of the total number of reported neonatal cases 
percentage of the number reported with that complication 
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This registry, that has now been filed for approximately 12.000 neonatal ECMO patients, 
provides opportunities for studying patient selection criteria, complications, technical features 
of ECMO therapy and patient outcomes as well as for better understanding of diseases treated 
by ECMO and quality control. 
Cumulative reports are prepared quarterly and annually by this ELSO-registry'11. Overviews of 
the registry are sent to all participating centers. In this manner the ELSO-registry has pointed 
to standards for expected outcomes and complication rates, upon which an individual center 
can judge its results and can compare its experience to an international experience. 
The data of the Registry may be very helpful for technological improvement and adaptations 
in the current equipment, for health care providers and government authorities in reference to 
resource planning. 
Neonatal ECMO data summarizing survival rates by disease category are tabulated in table 3, 
whereas the patient and mechanical complications reported by participating centers are 
detailed in table 4 and 5. 
Table S Mechanical Complications associated with neonatal ECMO according to the 
ELSO-registry report 
International Summary, January 1997 
Complication Number Percent reported 
27 
11 
5 
2 
1 
1 
Clots in circuit 
Cannula problems 
Oxygenator failure 
Pump failure 
Tubing rupture 
Heat exchanger malfunction 
3243 
1252 
620 
199 
112 
129 
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3.1 Aim of the study 
This thesis was motivated by the ongoing and disappointing high mortality among neonates 
with Congenital Diaphragmatic Hernia In this patient group sufficient gasexchange cannot 
always be warranted even by optimal conventional ventilatory and pharmacological manage-
ment either the patient dies, or the patient survives at the cost of severe damage to the lungs 
For selected patients extracorporeal membrane oxygenation (ECMO) seems to represent a 
good alternative for relief of the respiratory insufficiency with an improvement of survival 
and with a reduction of persistent lungdestruction Wide experience in ECMO-treatment has 
been gained in the United States of America As appears from the Extracorporeal Life Sup-
port Organization (ELSO) registry ECMO was offered to more than 12000 neonates suffering 
from respiratory failure with a final survival rate of 81 % According to internationally accep-
ted criteria the survival rate of those neonates should have been approximately 0 to 20% by 
continuation of conventional therapy without the use of ECMO 
Preparatory to the definite introduction of ECMO in the Netherlands as approved by Health 
Care Authorities a study concerning the efficacy and the cost-effectiveness of ECMO was 
conducted This thesis reflects a part of the results of this study with regard to neonates with 
CDH who are judged irretrievable by conventional therapy 
The main question concerns the impact of clinical application of ECMO therapy on the 
management of neonates with Congenital Diaphragmatic Hernia 
3.2 Detailed objectives of the thesis 
1 CDH patients selected for ECMO treatment had to have an expected mortality chance of 80 
to 100 % if conventional treatment was continued The question is if it is possible anyway to 
assess the seventy of the disease and to predict the outcome for CDH patients Can mortality 
reliably be predicted either by radiological examination (Chapter 4) or by alveolar to arterial 
oxygen pressure gradients (Chapter 5)9 
2 Is ECMO therapy efficacious for CDH patients or in other words is it possible to improve 
the survival of CDH patients by the application of ECMO (Chapter 7)9 
3 ECMO is an aggressive and invasive, potentially life-saving therapy The questions are 
with which features (Chapter 6) and with which adverse consequences (Chapter 8 and 9) the 
clinical introduction of ECMO therapy is attended 
4 Beyond the effects at the short term - regarding survival and early complications- it might 
be wondered, what the effects at the long term are for CDH patients, who could be salvaged 
by ECMO (Chapter 10 and 11) 
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3.3 Main features of the thesis 
The studies presented in this thesis are all clinical, patient-linked studies. The questions 
concerning mortality prediction were answered by a retrospective study. For answering the 
major question regarding the efficacy of ECMO an open prospective study-design was used 
with historical controls. 
Starting ECMO as a project of developmental medicine with a grant of Governmental Health 
Care Authorities, it was decided to abandon a prospective randomized study. 
Because literature reports mentioned improved survival in favour of ECMO and because 
ECMO only should be applied in neonates, who were very likely to die without ECMO, a 
randomized study was estimated to be misplaced scientifically as well as ethically. 
The results of ECMO treatment were evaluated by comparing the survival of ECMO treated 
CDH patients with that of conventionally treated historical control patients with the same 
expected mortality and with the same in-and exclusion criteria. 
For evaluation of the short-and longterm effects and the outcome a registry form and a 
follow-up protocol were drafted before the introduction and clinical application of ECMO. 
All complications were registered. The psychomotonc and physical development was recor-
ded at one year of age, according to the previously appointed protocol. 
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Abstract 
Congenital diaphragmatic hernia (CDH) of the newborn constitutes an emergency. The 
overall mortality exceeds 50%. Touloukian and Markowitz described a preoperative X-ray 
scoring system for predicting outcome following repair of CDH. We reviewed the preoperati-
ve X-rays of 33 newborns with CDH according to this system All infants had to be operated 
within 24 h of age because of serious respiratory distress. Unlike Touloukian and Markowitz, 
we were not able to identify the survivors by this scoring system. A number of arguments are 
presented which may contribute to an explanation for this discrepancy. We conclude from our 
series and that of Touloukian and Markowitz that a preoperative pneumothorax and a di-
aphragmatic defect which cannot be closed primarily seem to constitute the only reliable 
unfavorable signs in emergency cases. 
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Introduction 
Congenital diaphragmatic hernia (CDH) constitutes a major surgical emergency in the new-
bom. Prompt diagnosis and appropriate treatment are essential for survival. Because of 
disturbed cardiopulmonary function, the overall neonatal mortality in CDH exceeds 50% \ If 
patients with the highest risk can be identified preoperatively, they may be submitted to more 
aggressive management. Such management may comprise ligation of the ductus Botalli ', 
prophylactic bilateral thoracic drainage, judicious postoperative artificial ventilation, and 
vasodilator therapy 5. Even extracorporeal circulation with a membrane oxygenator may be 
considered 2. 
Touloukian and Markowitz described a preoperative X-ray scoring system for risk assessment 
of newborns with CDH 6. They reviewed the X-rays of 34 newborns with CDH through the 
foramen of Bochdalek, obtained before 12 h of age. Seven factors were graded, including:( 1 ) 
side of diaphragmatic defect; (2) location of stomach in thorax or abdomen; (3) presence of a 
pneumothorax; (4) degree of mediastinal shift; (5) amount of visceral distention; and (6) 
relative volumes of aerated ipsilateral and (7) contralateral lung. There was no statistical 
difference in the degree of mediastinal shift or visceral distention in the surviving and non-
surviving group. The scores assigned to each of the fi ve remaining radiographic factors 
having a significant correlation with survival were summed to obtain a cumulative X-ray 
score (Table 1). Total scores ranged from 2 to 9. Twelve of 16 survivors (75%) scored 6 or 
less, whereas 16 of 18 non-survivors (89%) scored above 6. These results are highly signifi-
cant (P<0.005). Mortality was 100% in 4 infants with a preoperative pneumothorax and 90% 
in 10 infants with a right-sided hernia. 
Materials and methods 
We reviewed preoperative chest X-rays of 33 newborn infants who were operated because of 
CDH through the foramen of Bochdalek during the first 24 h of life. All children were opera-
ted between 1969 and 1985 in the University Hospital of Nijmegen. Patients whose preopera-
tive X-rays were not availabe were not included. All preoperative radiographs were reviewed 
by an unbiased observer who did not have knowledge of the clinical outcome. Only the final 
preoperative X-ray was used in calculating results. The criteria and grade assignments were 
identical to those described by Touloukian and Markowitz (Table 1). 
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Table 1 Preoperative X-ray scoring system 
as described by Touloukian and Markowitz 
Criteria Score 
Side of diaphragmatic defect 
left 
right 
right with liver 
Location of stomach 
abdomen 
thorax 
Pneumothorax (ipsilateral or contralateral) 
absent 
present 
Volume of aerated ipsilateral lung 
>25% 
<25% 
none 
Volume of aerated contralateral lung 
normal to 75% 
75 - 50% 
50 - 25% 
Results 
Twenty patients were male, 13 female. Twenty of 33 patients (61%) survived. The preoperati-
ve X-ray score of five factors ranged in our series from 5 to 7 (Table 2). Thirteen of 20 
survivors (65%) scored 6 or less, while 9 of 13 non-survivors(69%) scored more than 6. This 
difference between survivors and non-survivors was not statistically significant: X2=3.584 
(0.05<P<0.1). None of these five individual X-ray signs revealed significant differences 
between the two groups, nor were mediastinal shift and visceral distention associated with 
statistical differences between survivors and non-survivors. There were no cases with preope-
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rative pneumothorax in our series. We also reviewed length of gestation, birth weight, and 
preoperative blood pH of the newborns with CDH. Length of gestation and birth weight did 
not differ between survivors and non-survivors. The difference in blood gas analysis between 
survivors and non-survivors was nearly significant (0.05<P<0.10) by chi-square analysis 
X2=5.595 and df = 2). We were unable to close the diaphragmatic defect primarily in 8 cases 
so that some kind of a patch had to be used; none of the 8 patients survived. 
Table 2 Preoperative X-ray scores of our series 
The criteria and grade assignment are shown in table 1 
Total score Number of Number of 
survivors non-survivors 
2 
3 
4 
5 4 
6 9 4 
7 7 9 
8 
9 
Discussion 
At present, the overall mortality of CDH still exceeds 50%. If patients with the highest risk 
can be identified preoperatively, they may be submitted to more aggressive management. 
Touloukian and Markowitz described a preoperative X-ray scoring system and found a highly 
significant difference between survivors and non-survivors5. We did not find such a differen-
ce. Since we had no difficulties in carrying out the scoring system, we do not think that 
differences in interpretation may be the cause of of this discrepancy. A number of disparities 
between their series and ours may contribute to an explanation. 
First, the selection of patients in both series was different. In the series of Touloukian and 
Markowitz all first radiographs were taken before 12 h of age, so their group can include 
emergency cases as well as non-emergencies. 
Since the aim of a scoring system should not be to differentiate between emergency and non-
emergency, but rather to assess the risk of the emergency cases, we included only emergency 
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cases who had to be operated before 24 h of age. 
Secondly, in the series of Touloukian and Markowitz there were 10 cases (29%) with a nght-
sided hernia, while in our series there were only 4 (12,5%). These right-sided hernias are 
known to have a poor prognosis. 
Thirdly, we did not encounter a case with a preoperative pneumothorax, while Touloukian 
and Markowitz included 4 cases ( 12,5%), all of whom did not survive. Since this is not a 
normal feature of CDH, it reflects the necessity of forceful resuscitation for severe respiratory 
distress 
The Woolf test of homogeneity for the association between score over 6 and survival among 
the patients in both studies was calculated as X2=2.074 (df = 1 and 0.10 <P<0.20)". Since this 
test is not significant, the results of both studies are, statistically speaking, not different. 
In conclusion, we do not regard the X-ray scoring system of Touloukian and Markowitz to be 
as useful as they suggest It remains very difficult, if not impossible, to predict survival 
following repair of CDH The only reliable unfavorable signs in emergency cases seem to be 
a preoperative pneumothorax and a diaphragmatic defect which cannot be closed primarily. 
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Abstract 
In a retrospective review we analysed alveolar-arterial oxygen difference (AaD02) as an entry 
criterion for Extracorporeal Membrane Oxygenation (ECMO) in neonates with several forms 
of acute respiratory insufficiency. Although for meconium aspiration syndrome, respiratory 
distress syndrome, sepsis, and idiopathic pulmonary hypertension of the newborn we found 
values in accordance with the literature, patients with Congenital Diaphragmatic Hemia 
(CDH) met 80% mortality criteria with significant lower AaD02 values. Several patients died 
before ever reaching usual entry criteria for ECMO, because serious lung deterioration makes 
AaD02 values unreliable. Awaiting classical ECMO entry criteria for patients with CDH may 
at least partially explain the lower survival rate for ECMO in CDH. 
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Introduction 
Experience in the Unites States and in Europe has proved the beneficial effect of Extracorpo-
real Membrane Oxygenation (ECMO) on survival in neonates with acute temporary (cardio-) 
pulmonary insufficiency, refractory to maximal conventional treatment'. Awaiting long-term 
evaluation, ECMO is still considered as a therapy of last resort, requiring 80% mortality 
predictions. Raphaely and Downes used the alveolar-arterial oxygen difference (AaD02) to 
predict outcome in newborns with congenital diaphragmatic hernia (CDH)2. Subsequently 
several authors have used AaD02 to predict mortality in other cases of acute respiratory 
insufficiency. Critical AaD02 values linked to time have been calculated in several analyses 
3.4 
Despite overall good results of ECMO treatment in patients with several forms of acute 
temporary (cardiopulmonary failure, results in CDH are disappointing and the survival rates 
are significantly less than those in all other groups'. We hypothesized that these inferior 
results of ECMO in CDH, besides other reasons, could be explained by not using the right 
entry criteria. 
Materials and methods 
Calculating the 80% mortality risk for neonates of our group with acute respiratory distress, 
we analysed the files of 60 neonates with acute temporary (cardio-)respiratory insufficiency. 
This group consisted of 30 neonates treated in the neonatal intensive care unit between June 
1989 and February 1990 for meconium aspiration syndrome, respiratory distress syndrome, 
sepsis, and idiopathic persistent pulmonary hypertension (pediatric group) and of 30 neonates 
treated in the pediatric surgical intensive care unit for CDH between January 1985 and May 
1990(CDH-group). 
For all these patients we determined serial postductal AaD02s and calculated the AaD02/time 
span, that indicates the highest mortality with the best sensitivity and specificity. These 
calculations were done for the pediatric and CDH group separately. We used the method 
described by Beck et al in 19864. 
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Results 
In the pediatric group 11 of the 30 patients (37%) and in the CDH group 17 of the 30 patients 
(57%) died 
Table I shows the AaD02/time combination that predicts the highest mortality with the best 
sensitivity and specificity for both groups In both groups there was no significant difference 
between survivors and nonsurvivors concerning birthweight, gestational age, Apgar scores 
and other anomalies or complications The values for the pediatric group were in accordance 
with the literature In the CDH group most patients died before reaching classical ECMO 
entry criteria Using Beck's criterion (AaD02 > 610) sensitivity was only 47%, because 9 of 
the 17 deaths in the CDH group occurred before this criterion was met 
In our CDH group the best ECMO entry criterion seems to be an AaD02 > 520 mmHg for 8 
hours This includes nearly all nonsurvivors (sensitivity, 88%), and excludes most of the 
survivors (specificity, 85%) 
Table 1 Mortality risk in patient groups at published AaD02-time criteria 
Mort Sens Spec 
Pediatric group AaD02 > 520 for 8h 58% 100% 58% 
(n=30) AaDO2>600forl2h 89% 73% 95% 
AaDO2>610for8h 70% 64% 84% 
CDH-group 
(n-30) 
AaD02 > 520 for 8h 
AaDO2>600for 12h 
AaDO2>610for8h 
88% 
100% 
100% 
88% 85% 
41% 100% 
47% 100% 
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Discussion 
Mortality in CDH has remained virtually unchanged in spite of several important new deve-
lopments. The availability of ECMO has given new expectations. Nevertheless the results of 
ECMO in CDH are a little disappointing and survival rates are significantly less than in all 
other ECMO indications'. This higher mortality can have several causes. CDH patients have 
not only pulmonary hypertension like other ECMO candidates, but have pulmonary hypopla-
sia and require major surgical intervention. It has been argued that serious lung hypoplasia is 
frequently present and many patients are irretrievable because of insufficient respiratory 
surface. In such cases survival of CDH will not improve with ECMO treatment. 
Predictors of mortality in CDH are unreliable and the pulmonary hypoplasia cannot be 
measured in emergency circumstances. Several ECMO centers have tried to exclude patients 
with serious lung hypoplasia by asking for extra entry criteria, for instance a honeymoon 
period or at least one preductal or postductal Pa02 of 80 to 100 mm Hg. Selection of patients 
with severe bilateral lung hypoplasia by these criteria is impractical because several other 
factors (barotrauma, fluid overload, preductal shunting) may play a role in the patients' 
deterioration. The use of a preductal or postductal Pa02 > 80 or 100 mm Hg will improve the 
results but will exclude several babies from the benefit of ECMO5. 
In a retrospective review of ECMO deaths in CDH patients from the ELSO Central Registry 
data, Price et al showed that only 17% died of lung hypoplasia and 83% of the patients had a 
cause of death that was potentially reversible6. On the other hand the presence of hypoplasia 
makes the lungs more vulnerable to the deleterious effects of maximal conventional treat-
ment, so that early ECMO could be more beneficial. 
Our study showed that ECMO entry criteria may be different in CDH. It was proved that at 
least 53% (but probably even 100%) of the CDH patients would be selected too late for 
ECMO by adhering to the usual entry criteria (Table 1). In the calculation of AaD02 it is 
assumed that the PAC02 equals PaC02 (Table 2). 
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Table 2 Calculation of alveolar-arterial oxygen gradient 
AaD0 2 
PA02 
PAC0 2 
So: AaDO, 
PA0 2 - Pa0 2 
Pbaro - P H 2 0 - PAC0 2 (if F i0 2 = 1,0) 
PaC0 2 , if there is a good lung function 
Pbaro - P H 2 0 - PaC0 2 - Pa0 2 (if F i 0 2 = 1,0) 
ΡΑθ2 
Pa02 
Pbaro 
PH20 
FiO, 
alveolar oxygen tension 
arterial oxygen tension 
athmospheric pressure 
partial water vapor pressure 
respiratory oxygen fraction 
p02/pC02 (mm Hg) 
100 
90 
80 
70 
60 
50 
40 
30 
20 
ECMO group NIJMEGEN 
A - a D 0 2 (mm Hg) 
A-aD02 PHYSIOLOGIC 
в 
A-aD02 CLINICAL 
p02 
+ 
650 
640 
630 
620 
610 
600 
590 
580 
570 
560 
550 
-4 -3 -2 
Time (h) prior to ECMO 
-1 
Figure 1 The clinical calculated AaD02 drops below the ECMO entry criterion because 
the PaC02 increases while the clinical condition is getting worse. If physiolo­
gical PACO 2 is substituted for actual PaC02, the patient is eligible for ECMO. 
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In normal lung function this is a reasonable assumption, but this may not be correct in hy-
poplastic and damaged lungs, where PAC02 can drop below physiological values, while the 
PaC02 increases. High PaC02 values have an adverse effect on the AaD02 calculations. 
The use of "classical calculated AaD02" may be misleading in CDH and may suggest impro-
vement whereas in fact the baby is deteriorating (Fig 1). Therefore, we suggest that it would 
be better to calculate a physiological PAC02 (40 mmHg) than to use the actual PaCO, value. 
We recalculated AaD02s for patients dying from CDH by substituting physiological PAC02 
for actual PaC02. In table 3 we compare "classical AaD02" with "physiological corrected 
AaD02" of these patients. Whereas according to "classical AaD02" 9 patients died before 
reaching ECMO entry criteria, if "physiological corrected AaD02" is used all 17 patients 
became eligible for ECMO. 
Table 3 AaD02 during 8 hours "classically calculated" and "physiologically cor-
rected" in 17 patients with CDH, who died 
classical corrected arterial 
No AaD02-8h. AaD02-8 h. PaC02 (mmHg) 
8 600-640 620-635 <60 
6 560-600 610-650 53-105 
3 500-560 620-635 100-125 
In conclusion it can be said that adhering to usual ECMO entry criteria may adversely influ-
ence outcome of patients with CDH and it should be realized that serious disturbance of lung 
function may make AaD02 values unreliable. Awaiting "classical ECMO entry criteria" for 
patients with CDH may at least partially explain the lower survival rate for ECMO in CDH. 
Therefore, we advise starting ECMO earlier in neonates with CDH, ie, at lower AaD02/ time 
levels or to use a "physiologically corrected AaD02" time combination as an entry criterion 
for ECMO. 
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Abstract 
In high-risk patients with congenital diaphragmatic hemia (CDH), we conducted a strategy of 
delayed repair following preoperative stabilization, including ECMO if necessary From 
January 1991 to July 1992, preoperative ECMO treatment was delivered to 6 out of 14 high-
risk patients with CDH In this study, we report our experience with this policy of preoperati-
ve stabilization in six ECMO-treated patients in whom the diaphragmatic defect was repaired 
on ECMO In all patients bleeding complications occurred Three of the six ECMO-treated 
patients died, in two cases due to recurrent persistent pulmonary hypertension Overall 
mortality was 43% 
Conceptual aspects of our approach are discussed Since the goals of our policy were not 
achieved, adjustments and renovations of the management protocol are discussed 
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Introduction 
Mortality in newborn infants with congenital diaphragmatic hernia (CDH) who are sympto­
matic immediately after birth is still unsatisfactory despite all new developments in treatment 
Death can be due to severe pulmonary hypoplasia, to moderate pulmonary hypoplasia associ­
ated with persistent pulmonary hypertension (PPHN), or to recurrent PPHN after surgical 
repair In order to prevent respiratory and hemodynamic deterioration caused by PPHN 
postoperatively, several centers adopted a management protocol of preoperative stabilization 
and delayed repair of the diaphragmatic defect. 
When extracorporeal membrane oxygenation (ECMO) routinely became available in our 
institution, we incorporated it in our management protocol to stabilize patients preoperatively 
if necessary. The aim of this study is to report our experience with delayed repair of CDH 
during ECMO treatment and to discuss some undecided questions in our strategy concerning 
CDH patients. 
Materials and methods 
Since ECMO became available in our institution (January 1991), we have used the following 
management strategy in high-risk CDH patients. Conventional treatment was initiated, 
consisting of (1) immediate endotracheal intubation and mechanical ventilation; (2) antibio­
tics; (3) nasogastric suction, (4) paralysis by pancuronium bromide, and (5) if necessary 
pharmacologic treatment with tolazohne, dopamine/dobutamine, or prostaglandin. After 
stabilization, the diaphragmatic defect was repaired. If necessary, ECMO was initiated 
postoperatively. Patients who were refractory to this maximal conventional support were 
preoperatively placed on veno-artenal ECMO. ECMO entry criteria for these patients are 
summarized in Table 1. 
The methodology of veno-artenal ECMO has previously been described by Bartlett et al'. 
Heparin was continuously administered into the ECMO circuit to maintain the activated 
clotting times (ACTs) at 180-200 seconds. Platelets were infused to maintain counts more 
than 80 χ 109/1. Once the hemodynamics and the patient's general condition had stabilized, the 
infant was weaned from ECMO to idling. As soon as weaning to idle was possible, surgical 
repair of the diaphragm was performed on ECMO in the Intensive Care Unit. 
During and directly after surgery the ECMO flow was maintained at a high level during the 
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Table 1. ECMO entry criteria for CDH 
1. AaD02 > 600 mm Hg for 8 h 
2. PIP > 38 cm H20 and AaD02 > 605 mm Hg for 4 h 
3. ΟΙ > 40 for 3 h 
4. Acute deterioration 
(pH < 7.15 and/or pa02 < 40 mmHg for 2 h) 
5. Failure to respond to maximal conventional treatment (pa02 < 55 mmHg for 3 h) 
6. Signs of barotrauma (four of the following) 
interstitial emphysema - subcutaneous emphysema 
- pneumothorax - persistent air leak > 24 h 
- pneumopericardium - MAP > 15 cm H20 
7. At least once a preductal pa02 > 80 mmHg 
AaD02= Alveolar-arterial oxygen differences O.I.» oxygenation index 
PIP - peak inspiratory pressure MAP- mean airway pressure 
first 24 to 36 hours, on the one hand to prevent a recurrent PPHN due to worsened thoracic 
compliance following repair9, on the other hand allowing low ACTs to cope with bleeding 
complications. After this period of high ECMO flow the infant was weaned again to idle and 
finally decannulated. Conventional treatment was continued. 
Results 
From January 1991 to July 1992 we treated 14 neonates with high-risk CDH who were 
symptomatic at birth. Two infants died within 2 hours after birth despite immediate intubation 
and resuscitation. Six infants were operated upon after preoperative stabilization. One of these 
six patients died in the operating room and the remaining five could finally be weaned from 
the ventilator, but one of them required ECMO postoperatively because of recurrent PPHN. In 
six patients preoperative stabilization required ECMO treatment and these six patients under­
went surgical repair of the CDH during ECMO. 
The patient characteristics and clinical course of this latter group are depicted in table 2. 
Table 2 Characteristics of CDH patients treated by ECMO 
Results Non-survivors Survivors 
Patients No la lb 
Gestational age (weeks) 
Hemia side (L,R) 
Age at cannulation (h) 
ECMO time prior surgery (h) 
Patch repair 
ECMO time after surgery (h) 
Total time on ECMO (h) 
Extubation (days after ECMO) 
Complications: 
. hemorrhagic 
. red blood cells (mL) 
. platelets (mL) 
. culture proven sepsis 
. recurrent PPHN 
Survival 
Death after decannulation (days) 
40 
L 
48 
82 
+ 
36 
118 
-
+ 
662 
526 
+ 
+ 
40 
L 
191 
-
-
-
87 
-
-
272 
390 
-
+ 
no 
15 
41 
L 
24 
102 
+ 
60 
162 
-
+ 
798 
935 
-
+ 
no 
10 
36 
L 
26 
116 
+ 
101 
217 
-
+ 
1215 
886 
-
-
no 
0 
41 
L 
18 
87 
+ 
54 
141 
43 
+ 
455 
457 
-
-
yes 
41 
L 
10 
108 
+ 
73 
181 
10 
+ 
800 
1250 
-
-
yes 
38 
R 
25 
143 
+ 
92 
235 
22 
+ 
900 
467 
-
-
yes 
* 1 b designates second course of ECMO in the same patient 
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ECMO therapy was instituted 10 to 48 hours after birth (mean 25 hours). The duration of 
bypass ranged from 141 to 235 hours (mean 190 hours). Failure to wean from bypass because 
of severe pulmonary hypoplasia was not observed. Surgical repair was performed at age 118 
to 168 hours after birth (mean 134 hours), after 82 to 143 hours on bypass (mean 109 hours) 
respectively. In all 6 patients the diaphragmatic defect was repaired with a Gore-texR prosthe-
sis through an abdominal approach. In 1 patient the abdominal wall had to be closed with a 
Gore-texR patch. A chest tube was placed in all cases. 
In all patients bleeding complications occurred at the surgical site, requiring 455 to 1215 ml 
of red blood cells (mean 850 ml) and 457 to 1250 ml of platelets (mean 818 ml). Therapy with 
ECMO was discontinued in one patient because of uncontrollable bleeding, but clinical 
deterioration forced us to return on bypass and recannulation 24 hours after decannulation. 
Postoperative ECMO bypass lasted for 36 to 147 hours (mean 85 hours). 
Of the six infants, in whom ECMO was started after conventional therapy failed, three died 
(50%). Deaths were related to multi-organ failure in one patient and to recurrent PPHN in two 
patients, 10 and 15 days after decanulation. The overall mortality in the entire group was 43% 
(6 out of 14). 
Discussion 
Mortality remains high in neonates with high-risk CDH despite all new developments in 
treatment. The availability of ECMO has raised new expectations. Nevertheless, the results of 
ECMO treatment for CDH are somewhat disappointing and survival rates are significantly 
less for CDH than for all other neonatal ECMO indications (63% vs. 90%)13. 
Patients with high-risk CDH have not only pulmonary hypertension, like other ECMO treated 
infants, but concomitantly have pulmonary hypoplasia and require a major surgical interventi-
on as well. Some patients have such severe lung hypoplasia, that they cannot survive, even 
with ECMO therapy. ECMO therapy should be avoided in these infants. It is thus important to 
determine the degree of hypoplasia prior to ECMO. However a reliable criterion or measuring 
method for adequate lung parenchyma is not available at this moment, whereas several other 
factors, such as barotrauma, fluid overload and preductal right-to-left shunting may contribute 
to hypoxemia as well6. Some centers added the presence of a "honeymoon" or the ability to 
ever attain a pre- or postductal Pa02 of 80 or 100 mm Hg, to the existing ECMO entry criteria 
for CDH patients'2. That may improve results, since the existence of sufficient lung capacity 
has been proved but will exclude babies from the potential benefits of ECMO. On the other 
hand hypoplastic lungs are more prone to the deleterious effects of maximal conventional 
therapy7. Therefore, the poorer outcome of CDH patients can also be related to long-overdue 
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ECMO treatment Many infants die from chronic lung disease (resembling bronchopulmonary 
dysplasia) after successful weaning from ECMO because they have been exposed too long to 
elevated airway pressures and oxygen concentrations before ECMO was started7 A former 
study from our institution showed that ECMO entry criteria have to be adjusted and ECMO 
has to be initiated earlier in CDH patients" 
In our series all patients could be weaned from bypass and no death was due to lung hypopla-
sia, so it seems, that hypoplasia was not a major problem in our group of ECMO-treated CDH 
patients. This probably has to do with the selection requirement of - at least once - a Pa02 of 
80 mm Hg. In an ELSO survey concerning ECMO, CDH and death pulmonary hypoplasia 
was the predominate cause of death in only 17% of the evaluated patients, whereas 83% of 
the infants had a cause of death that was potentially reversible8. Among those, PPHN was a 
major cause of death in ECMO-treated CDH patients (25%)8 
In order to cope with the problem of PPHN, the strategy of delayed repair and preoperative 
stabilization was drafted in the management of CDH-patients3 "16 Up to now, this concept has 
not led to a significant decrease in mortality, but has also not affected overall mortality This 
approach enables not only selection of patients, but also enables electively scheduled CDH 
repair. In 1988 we adopted this policy of delayed repair for CDH patients, and when ECMO 
became available at our institution, we incorporated ECMO into our strategy of preoperative 
stabilization. 
If preoperative stabilization requires ECMO, we have to deal with the question of the best 
time to repair the diaphragmatic defect. There are two alternatives for surgical intervention 
during or following ECMO support. If we operate during ECMO, recurrent PPHN - elicited 
by the surgical procedure and the consequently diminished thoracic compliance9 - can be 
controlled by ECMO, but a high nsk at hemorrhagic complications is introduced. If we 
operate following ECMO, we can preclude bleeding complications due to heparinization, but 
the ability to influence recurrent PPHN has been restricted. We decided to repair the defect on 
ECMO late in the ECMO course, when the patient had been shown to be weanable from 
ECMO. In this concept, PPHN as a result of the surgical procedure could be precluded or 
faced by ECMO support and in case of hemorrhagic complications, ECMO could be 
withdrawn within 1 or 2 days. During surgery we avoided major dissections and incidental 
procedures (eg. Ladd's procedure or appendectomy) because of heparinization. For the same 
reason, we used running sutures and prosthetic patches, which are also advantageous for the 
compliance 2. By running high ECMO flows during and directly following surgical repair we 
try to not only prevent PPHN, but at the same time to preclude bleeding , since high ECMO 
flows allow low ACTs. 
Despite all these measures, all our patients had significant bleeding at the surgical site, 
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requiring an average amount of 850 ml RBC and 818 ml platelets. In addition, we still en-
countered PPHN, even some time after ECMO discontinuation. Ultimately two infants died 
from PPHN, 10 and 15 days following decannulation. 
Therefore, neither bleeding complications nor recurrent PPHN were prevented by this appro-
ach. In view of this experience, our strategy must be adjusted. One option is to prevent 
hemorrhagic complications, whether by the use of aprotinin5 or aminocaproic acid", the use 
of a Cameda-hepann bounded circuit after surgical repair10 or to abandon systemic heparini-
zation entirely and at the same time renew the ECMO circuit14 following surgery. 
The other option is to postpone diaphragmatic repair after completion of ECMO support and 
decannulation16. If PPHN occurs following surgical repair and is again refractory to the 
conventional therapy, we have to consider reinitiating ECMO. However, ECMO is not a 
therapy for pulmonary hypoplasia, so does it make sense to return to ECMO at all7 And if so, 
how much time may pass after which a second ECMO course will still be meaningful9 If 
ECMO support is instituted a second time, we have to recannulate the infant. How many days 
following decannulation are we able to recannulate? How much risk of tromboembolic 
complications do we encounter9 Moreover, has the patient to meet the same entry entena? Do 
the same exclusion criteria apply to the second course? 
So far, we have carried out a second ECMO course in one patient. Because of uncontrollable 
bleeding the first ECMO-run was discontinued 36 hours after surgical repair of the 
diaphragm. Clinical deterioration due to PPHN forced us to reintroduce ECMO support. 
Meanwhile the bleeding had stopped At recannulation we removed clots from the internal 
jugular vein by a Fogarty catheter. After rehepannization bleeding did not recur again. 
Ultimately, this patient died from PPHN 15 days following the second decannulation. In 
retrospect, was it a good decision to go on ECMO for a second course? 
The best approach will await more experience. 
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Abstract 
The benefit of extracorporeal membrane oxygenation (ECMO) in cases of high-risk congeni-
tal diaphragmatic hemia (CDH) was studied by comparing pre-ECMO (1987-1990) and post-
ECMO (1991-1994) 3-month survival statistics. Fifty-five CDH patients who presented in 
respiratory distress within 6 hours after birth, were referred - 18 in the pre-ECMO era and 37 
in the ECMO era. 
During the entire study period (December 1987 through July 1994) the patients were treated 
by the same protocol of preoperative stabilization and delayed surgery; the only difference 
was the addition of ECMO beginning in January 1991. The patients were stratified based on 
the response to conventional treatment: 1, no response (irretrievable); 2, stable; 3, unstable. 
The 3-month survival for the unstable neonates (who could not be stabilized by conventional 
therapy) improved from 0% (0 of 9) in the pre-ECMO era to 61% (11 of 18) in the ECMO era 
(p = 0,004). This highly significant difference shows that ECMO is a very valuable addition 
to the management of high risk CDH patients whose conditions remain unstable despite 
maximal conventional therapy. 
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Introduction 
Despite advances in neonatal care, including prenatal diagnosis, neonatal transport, intensive 
care treatment, anaesthesiology and surgery, the mortality rate among infants with congenital 
diaphragmatic hernia (CDH), treated by conventional ventilatory management and pharmaco-
logical support, remains high. The reported mortality rate for high-risk patients who have 
symptoms within 6 hours after birth ranges from 29% to 80% ' 9 Extracorporeal Membrane 
Oxygenation (ECMO) was introduced as a therapy for newborns with respiratory failure 
unresponsive to maximal conventional treatment and may be used to support neonates who 
have respiratory distress caused by CDH.ltM2 
A number of investigators have reported success in treating CDH with ECMO.2 413 '6 Howe-
ver, others have not seen improvement with use of ECMO '7 '8 
According to the Extracorporeal Life Support Organization (ELSO) registry, the survival rate 
for CDH patients, treated by ECMO, is 58%.'9 This suggests that ECMO has no significant 
impact on the survival of newborns with high risk-CDH. 
In the present report we evaluate the role of ECMO in the management of CDH at our institu-
tion. 
Materials and Methods 
All patients with CDH who were symptomatic within 6 hours after birth and who were 
referred between December 1987 and July 1994 were included in the study. All patients were 
treated by a protocol of delayed surgery after preoperative stabilization.5 8 
When ECMO became available in our institution (in January 1991), it was incorporated into 
this protocol for CDH, whether preoperatively or postoperatively. ECMO was offered after 
conventional ventilatory and medical management had failed, if the patient fulfilled the entry 
criteria for ECMO, if there were no contraindications for ECMO and if parental consent was 
obtained. No infant in this study was excluded from ECMO support on the basis of failure to 
achieve a minimum Pa02 before the institution of ECMO. 
Venoarterial ECMO was used as previously described by Bartlett et al. '2 If ECMO was 
required for preoperative stabilization, the diaphragmatic defect was repaired during ECMO, 
at the end of the ECMO run, if the patient could be weaned from ECMO-support.20 ECMO 
was discontinued, when respiratory failure resolved (gas exchange requiring PIP of less than 
30, ventilator rates of less than 40 and Fi02 of less than 0,50) or when a complication arose 
that required cessation of ECMO (such severe bleeding complications rendering a contraindi-
cation to continued hepannization) Survival is defined as "alive at the age of 3 months". 
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Survival statistics were compared for two time periods 
(1) December 1987 through December 1990, when ECMO was not available and all children 
were treated with conventional ventilatory support and pharmacological management 
(the pre-ECMO era, n=18) and 
(2) January 1991 through July 1994, when ECMO was available and was used, if conventio-
nal treatment failed (the ECMO era, n=37). 
The children were classified into the three groups described below. 
"Irretrievable" Patients. These patients were (1) newborns with severe respiratory distress, 
noted immediately after birth, in whom a reasonable or normal gas exchange was never 
reached, despite endotracheal intubation and artificial ventilation and who died within 2 hours 
after birth, before ECMO could be initiated (2) newborns who died before or during transpor-
tation (pre-ECMO era n=l ,ECMO era n=7) or (3) newborns with severe congenital anomaly 
(especially chromosomal), for whom not all therapeutic modalities were offered (pre-ECMO 
eran=l). 
Conventionally stabilized Patients These were newborns with high-risk CDH, who recove-
red well by (maximal) conventional treatment and who underwent surgical repair of their 
diaphragmatic defect after conventional stabilization. They never met ECMO-entry criteria 
before repair of their diaphragmatic defect (pre-ECMO era n=7, ECMO era n=12). 
Unstable Patients. These were newborns with high-risk CDH, and who could not be 
stabilized by maximal conventional treatment and who met one or more ECMO-entry entena 
(pre-ECMO era n=9, ECMO era n=18). The patients in this category were subdivided into 
those who did (a) or did not (b) receive ECMO support. 
We made this stratification because we wanted to evaluate the effect of ECMO on survival. 
The irretrievable patients were in such distress that ECMO could not be initiated before death 
or before severe brain damage had occurred. In these circumstances any therapy, which ever 
applied, is doomed for failure. The availability of ECMO equipment had no effect on survi-
val, neither in this group nor in the group of conventionally stabilized patients. Because no 
patient in the latter category met the ECMO-entry entena and nearly all patients survived, 
ECMO is not a therapeutic option for this group. Thus, only in the unstable patients could the 
effect of the availability of ECMO equipment be measured. 
For compansons of survival rates, the two-sided Fisher's Exact test was used. 
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Results 
Fifty-five newborns with high-risk CDH were evaluated, - 18 in the pre-ECMO era (Fig. 1 ) 
and 37 in the ECMO era (Fig.2). 
One patient in the pre-ECMO era was categorized as "irretrievable" because of a chromoso­
mal anomaly. One neonate in the first period and seven in the latter period were irretrievable; 
they died of severe respiratory distress shortly after birth, before ECMO could be or could 
have been initiated. In this category, the average transcutaneous oxygen saturation was 64%, 
the average Pa02 4,5 kilo-Pascals (kPa) (34 mm Hg), the average PaC02 10,9 kPa (82 mm 
Hg) and the average pH was 6,89. 
In the pre-ECMO period, preoperative stabilization could be achieved by conventional 
treatment (CT) in seven patients (Fig. 1). In these patients the diaphragmatic defect could be 
repaired, and six survived. 
Figure 1. Progress of 18 High Risk CDH patients in the pre-ECMO era 
(december 1987 through december 1990) 
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Figure 2. Progress of 37 High Risk CDH-patients in the ECMO era 
(January 1991 through July 1994) 
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Nine patients could not be stabilized conventionally; none of them had surgical repair, and 
none survived. These patients would have qualified for ECMO support had it been available. 
Since ECMO became available at our institution, preoperative stabilization by conventional 
therapy could be achieved in 12 patients (Fig. 2). All 12 had repair of their diaphragmatic 
defect, and 10 survived, although postoperative ECMO support was required for one of them. 
Eighteen cases were refractory to conventional management and were considered for ECMO-
treatment. In two of the patients, ECMO therapy was not instituted; in one patient ECMO 
treatment was refused by the parents, and in the very first patient, who was an ECMO candi­
date, we thought it was better to repair the diaphragmatic defect before initiation of ECMO, 
during preparation of the ECMO-circuit. Both patients died. Thus, in 16 patients ECMO was 
used for preoperative stabilization. In one patient the ECMO treatment was discontinued 
Table 1 Demographic data for both time periods: 
pre ECMO era (Dec 87 through Dec 90) and ECMO era (Jan 91 through July 94). 
male female ratio 
gestational age (wk) 
average 
range 
birth weight (g) 
average 
range 
Apgar (average & range) 
1 min 
5 min 
side 
left right 
Irretrievable 
pre-ECMO 
0 2 
42,0 
(42-42) 
2850 
(2300-3400) 
1,5(1-2) 
2,5(1-4) 
2 0 
ECMO era 
4 3 
38,7 
(36-42) 
2740 
(1500-3460) 
1,8(1-4) 
3,8 (2-6) 
5 2 
Conventionally stable 
pre-ECMO 
3 4 
38,5 
(34-41) 
2780 
(1480-3500) 
7,4 (4-9) 
6,0 (4-9) 
5 2 
ECMO era 
5 7 
38,0 
(34-42) 
2660 
(1760-3740) 
5,0 (3-9) 
6,7(4-10) 
10 2 
pre-ECMO 
5 4 
40,3 
(38-42) 
3160 
(2450-3930) 
4,5(1-9) 
4,8(1-8) 
8 1 
Jnstable 
ECMO era 
10 8 
39,8 
(34-42) 
3410 
(2560-4175) 
3,2 (0-6) 
4,8 (0-8) 
16 2 
84 Chapter 7 
because of severe cerebral bleeding and the patient died without having repair of the di-
aphragmatic defect. The other 15 patients could be weaned from ECMO, and all had repair of 
their diaphragmatic defect during ECMO, late in the ECMO run. Eleven survived. The four 
deaths after ECMO were related to multiorgan failure (n=l), severe lunghypoplasia (n=l), or 
recurrent persistent pulmonary hypertension (n=2) The demographic data of the different 
patient groups, for the two time periods, are reported in Table 1. 
The overall survival was 33% in the pre-ECMO era and 57% in the ECMO era. Excluding the 
irretrievable patients in both periods the survival rate was 38% in the first period and 70% in 
the second period (Fisher's Exact test, p=0,08). The survival rate among infants who could be 
stabilized conventionally was 86% in the pre ECMO era and 83% m the ECMO era (Fisher's 
Exact test, p>0,50). The survival rate for the conventionally not-stabilized patients was 0% in 
the first period and 61% in the latter period (Fisher's Exact test, p=0,004). 
Ultimately, 11 of the 16 unstable patients who were supported by ECMO survived (69%), 
whereas no unstable patient survived without ECMO support (Fisher's Exact test, p=0,0006). 
Discussion 
In this report we present our experience with 48 severely afflicted infants with CDH, who 
were treated according to a protocol of preoperative stabilization and delayed surgery 5 9 This 
protocol was unchanged during the entire period of the study. 
The only difference in management was the addition of ECMO for (pre- or postoperative) 
stabilization since January 1991. This offers the opportunity to evaluate the role of ECMO in 
the treatment of high-risk CDH, by dividing the patients into two groups with respect to 
ECMO availability (pre-ECMO and ECMO era). 
The overall survival rate for high-risk CDH patients increased from 33% in the pre- ECMO 
era to 57% in the ECMO era. This means improvement, but the difference is not significant 
statistically. For this reason, and because infants with CDH have gained less advantage by 
ECMO than have infants with respiratory distress from other causes ", the benefits of ECMO 
support for high-risk CDH patients remain controversial.2 4I3 '8 However, to assess the 
impact of ECMO we must compare identical populations with respect to demographic data as 
well as seventy of disease, because differences in the composition of the groups can influence 
the outcome. 
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Over the past decades many attempts have been made to grade the seriousness of the disease 
and to establish criteria by which survival could be predicted or by which patients could be 
considered for a certain kind of (aggressive) therapy. 
Parameters used, are the interval from birth until the appearance of symptoms, the occurrence 
of a "honeymoon period" 2', and bloodgas analysis with and without linkage with ventilator 
settings and time, eg, AaD02, oxygenation index, ventilation index linked with PaC02 922 28 
Nevertheless, all entena appear to be unreliable, there is no single, simple objective criterion 
by which the clinical course and outcome can be predicted and by which the two interrelated 
pathophysiological mechanisms (lunghypoplasia and pulmonary hypertension) can be unrave-
led.4 I4"1628 " In the literature there is agreement that neonates who are m respiratory distress 
within 6 hours after birth constitute a high-risk group. We divided this high-risk group in 
three subgroups, based on the clinical course at the time (maximal) conventional treatment 
was applied. 
Some patients are considered to be irretrievable because they are unable to attain satisfory 
oxygenation despite maximal conventional therapy immediately begun after birth. These 
patients have not even the ability to meet standard ECMO criteria because of lack of time. 
They die before ECMO can be initiated. Most investigators report only a few such cases, but 
these compnse 19% of the CDH patients referred to our institution in the ECMO era. This 
group reflects the impact of the availability of ECMO on referral patterns, but this group has 
a negative influence on the overall survival rate, which can lead to misinterpretation of the 
efficacy of ECMO treatment in CDH patients. The amount of functional lung tissue in these 
infants is inadequate for survival. Since January 1991, 14 infants were transferred, pre- or 
postnatally, specifically for ECMO. Two could be treated conventionally, nine received 
ECMO support and three died before ECMO could be initiated. 
In other patients, respiratory distress can be alleviated by immediate applied conventional 
therapy. Some such patients can be stabilized by conventional ventilatory management and 
never meet ECMO-entry entena. Others cannot be stabilized conventionally and meet stand-
ard ECMO entena. Only in this latter group of patients can a reliable judgment be made of 
the benefit of ECMO for CDH. 
In both periods the conventionally stabilized patients and the unstable patients were compara-
ble with respect to gestational age, birth weight, gender distribution, Apgar scores and side of 
the defect (Table 1 ). As might be expected, the survival rate of category II patients was 
virtually the same in both time periods - 86% in the pre-ECMO era and 83% in the ECMO 
era. However, the survival rate for unstable patients is significantly better in the ECMO era 
than it was beforehand (61% versus 0%). Because the groups are comparable for both time 
periods, and because the only difference in treatment is the addition of ECMO in the latter 
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period, the better survival rate can be attributed completely to ECMO therapy. 
All children who survived after stabilization with ECMO, represent an increase in survivalra-
te. All unstable children, who met ECMO entry criteria died without ECMO support. 
The fact that all children who met ECMO criteria died without ECMO support is in accordan-
ce with the aim of ECMO as a treatment of last resort, ie, only applied in critically ill infants, 
whose projected mortality rate was more than 80% 
From the experience with high-risk CDH patients treated in our institution by a protocol of 
delayed surgery after preoperative stabilization, with and without ECMO, we draw the 
following conclusions-
(1) The overall mortality of high risk CDH patients is still high. 
(2) Some infants have such severe lung hypoplasia that they were unable to attain sufficient 
gas exchange to bridge the time until initiation of ECMO. 
(3) Use of ECMO support is an improvement m our therapy protocol for cases that cannot 
be stabilized by conventional treatment, the survival rate associated with ECMO (61%) 
is significantly better than that without ECMO (0%). 
(4) ECMO availability changed the referral pattern, increasingly sicker patients are seen, 
who previously would not have survived. 
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Abstract 
Extracorporeal membrane oxygenation (ECMO) was incorporated in a strategy of delayed 
repair of congenital diaphragmatic hemia (CDH) and was used for preoperative stabilization 
in patients who were unresponsive to maximal conventional treatment. If ECMO was requi­
red for preoperative stabilization the diaphragmatic defect was repaired while the patient was 
on ECMO In the early experience with this approach all patients suffered from bleeding 
complications. Therefore, we adopted the use of antifibnnolytic therapy with tranexamic acid 
(TEA) during and immediately after CDH repair on ECMO. 
The efficacy of TEA was studied in an unbhnded study using historical controls by compa­
ring the postoperative blood loss and the transfusion requirements of red blood cells (RBC) in 
patient groups treated without (n=9) and with TEA (n=10) Patients who received TEA had 
significantly less bleeding at the surgical site than patients not receiving TEA (57 ν 390 mL, 
p=0.005) and had significantly lower RBC transfusion requirements than patients not recei­
ving TEA ( 1.13 ν 2 95 mL/kg/h, p=0 03). In the very first two patients of the TEA group we 
encountered fairly severe thrombotic complications. TEA may have contributed to those 
complications. Based on the authors' experience they conclude 
(1) TEA is effective in reducing postoperative blood loss, hemorrhagic complications and 
RBC transfusion requirements associated with CDH repair on ECMO. 
(2) TEA may be responsible for thrombotic complications. 
(3) The appropriate, empirically established, dosage and administration pattern of TEA for 
CDH repair during ECMO seem to be one bolus of 4 mg/kg TEA intravenously 30 minu­
tes before the anticipated CDH repair and a continuous infusion of 1 mg/kg/h TEA during 
the 24 hours after CDH repair. 
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Introduction 
Since extracorporeal membrane oxygenation (ECMO) became available in our institution in 
January 1991, ECMO was incorporated in a protocol of preoperative stabilization and delay-
ed repair for congenital diaphragmatic hemia (CDH).1 If ECMO was necessary for preopera-
tive stabilization, surgical repair of the diaphragmatic defect was performed while the patient 
was on ECMO at the end of the ECMO-run.2 
In the early experiences with this approach significant postoperative bleeding complications 
were encountered at the surgical site.2 In all first six patients - who form part of this study -
bleeding complications occurred, requiring 455 to 1215 mL red blood cells (RBC; mean 850 
mL). Four of the 6 patients were forcefully weaned from ECMO because of the hemorrhage, 
and three of these four died of recurrent pulmonary hypertension. 
Wilson et al. were the first who described the effect of an antifibrinolytic agent on hemorrha-
gic complications during ECMO.3 They administered e-aminocaproic acid (EACA) to 42 
patients who were considered to be at high risk for bleeding complications (such as anticipa-
ted surgical procedures, preexisting intracranial hemorrhage [ICH] or profound hypoxia), 
starting just before or after cannulation until decannulation. Compared with 68 patients not 
receiving EACA, the patients who received EACA had significantly less bleeding while on 
ECMO and required fewer blood transfusions. This difference was most significant in the 
congenital diaphragmatic hemia and cardiac subgroups. The incidence of ICH in the neonatal 
subgroup was also significantly reduced in the EACA group. These investigators advocated 
the use of EACA for all patients who were thought to be at risk for hemorrhagic complicati-
ons on ECMO. 
Therefore we adopted the use of an antifibrinolytic agent as advocated by Wilson et al.3 Since 
January 1993 we administered tranexamic acid (TEA) during and after CDH repair on 
ECMO. In this report our experience with hemorrhagic and thrombotic complications in CDH 
repair during ECMO is presented, and the effect of TEA is evaluated. 
Materials and Methods 
Since January 1991, 20 high-risk CDH patients needed ECMO support for preoperative 
stabilization in our institution. In all patients veno-arterial ECMO was used as described by 
Bartlett et al.4 During the ECMO run heparin was titrated to maintain the activated clotting 
time (ACT) at levels of 200 to 220 seconds with ECMO flow rates higher than 250 mUmin. 
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ACTs were monitored at the bedside using the Hemochron (International Technidyne Corpo­
ration, Edison, NJ). At lower ECMO flow rates higher ACT levels were maintained (for 
example ACT levels of 240 to 250 seconds at ECMO flows of 50 to 200 mL/min). ACT goals 
were not different in any one of the groups. Thrombocytes were administered to maintain 
their count above the level of 80 χ 109/L pre-CDH repair and above 100 χ 109/L during and 
after CDH repair. The ACT was monitored every hour, and the platelet counts were determi­
ned every 8 hours. RBC's were routinely transfused to maintain the hematocrit greater than 
40% and the hemoglobin-concentration above 8.0 mmol/L. CDH repair was performed at the 
end of the ECMO run if the patient was weanable from ECMO and the ECMO flow could be 
decreased to 50 mL/min. 
During surgery we avoided major dissections and incidental procedures, and we used running 
sutures to close the defect. If the defect was too large for primary closure a prosthetic patch 
(Gore-tex soft tissue patch) was used. Fibrin-glue was spred on the suture line at the end of 
the repair. During and directly after surgical repair we tried to preclude major bleeding 
complications by running high ECMO flows, which allow relatively low ACTs (aim, 180 to 
200 seconds). This strategy was the same during the whole study period. The surgical proce­
dure has been founded on a long-lasting experience, did not undergo a fundamental change 
and was performed by the most experienced surgeon in the first group and by several surge­
ons in the second group. 
Nineteen patients underwent elective repair while on ECMO; in one patient ECMO was 
stopped because of a severe intracranial hemorrhage at day 1 of ECMO, and she died. 
The patients were divided into 2 groups. Group 1 consisted of 9 patients who underwent 
repair without the use of TEA (1991 to 1992) and group 2 contained 10 patients who received 
TEA (1993 to 1995). 
Except for the addition of TEA the ECMO-protocol was identical for both groups. 
TEA administration happened in different ways. In the first patient TEA was given intermit­
tently by intravenous infusion, 15 mg/kg every 8 hours, during the first 48 postoperative 
hours. In all other patients TEA was administered by an intravenous loading bolus just before 
surgery (10 mg/kg in patients 2 and 3, and 4 mg/kg in the ensuing patients), followed by a 
continuous intravenous infusion of 2 mg/kg/h TEA over 48 hours in the second patient and of 
1 mg/kg/h TEA over 24 hours in the third and ensuing patients. 
For all patients the total blood loss was recorded. Total blood loss was defined as the perope­
rative blood loss from the surgical site and the postoperative bleeding from the chest tube. 
The blood losses were calculated in reference to the body weight and the postoperatieve 
ECMO time (ie milliliters blood per kg body weight and per postoperative ECMO hour). The 
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transfusion requirements of red blood cells were assessed for the whole ECMO run as well as 
in relation to the weight of the patients, the duration of the ECMO run and the moment of 
CDH repair. The incidence of reexploration for bleeding and the thrombotic complications 
were noted in addition to the incidence of forced discontinuation of ECMO because of 
bleeding. 
For statistical analysis of the differences in both groups the two-sided Wilcoxon's rank sum 
test and the two-sided Fisher's Exact test were used. Ρ values of less than 0 05 were conside­
red significant. 
Results 
Both groups were comparable with respect to birthweight, age at institution of ECMO, side 
of the defect, patch repair, and the time of CDH repair during ECMO (Table 1 ) Only for 
the duration of the ECMO run there was a significant difference between both groups Seven 
of the nine group 1 patients (78%) and 9 of the 10 group 2 patients (90%) had a left-sided 
defect. Patch repair was accomplished in 16 patients 8 of group 1 (89%) and 8 of group 2 
(80%). 
Table 1 Demographic data 
birth-weight (g) 
age at ECMO (h) 
duration of ECMO (h) 
time of CDH repair (ECMO h) 
group 1 
(n-9) 
3200 
(2880,3660) 
25 
(18,27) 
181 
(150,217) 
108 
(87,143) 
group 2 
(n-10) 
3050 
(2700,4050) 
18 
(16,28) 
130 
(110,167) 
92 
(67,110) 
Wilcoxon 
ρ - value 
0.96 
0.68 
0.02 
0 15 
Note The median values are stated with the 25% and 75% percentiles for all variables 
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Hemorrhagic complications led to a forced discontinuation of ECMO support in five of the 
nine patients of group 1 - in one patient even after heparinization had been stopped. Four of 
the five patients who were removed earlier from ECMO because of bleeding died of rebound 
pulmonary hypertension. One patient in each group required an abdominal reexploration 
because of hemorrhage. There were four patients with thrombotic complications (two in each 
group). The thrombotic patient complications consisted of an upper cavai vein thrombosis 
centered around a central venous line placed immediately after ECMO, at the time of decan-
nulation, via the internal jugular vein. These complications seemed to be more severe in the 
first two patients of group 2. A chylothorax developed in both patients, which lasted for 
several weeks despite special MCT formulas and even complete discontinuation of enteral 
feeding. In one patient of group 1 the obstructed venous return may have led to a hydrocepha­
lus. In addition, in two cases of group 2 there were clots in the circuit. The survival rate for 
group 2 (100%) was significantly higher than for group 1 (56%) (Fisher's Exact test, p<0.05). 
Wilcoxon 
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Figure 1 Box-plots of intra- and postoperative blood loss after CDH repair on ECMO in 
both groups (group I without the use of TEA, group ¡I with TEA). They illustrate the distribu-
tion of data. The bottom and the top of the box indicate the first and third quartile, the line in 
between indicates the median, and the dotted lines represent the extreme values (range), (a) 
total volume (mL) and (b) volume per kg body weight per postoperative ECMO time 
(mhlkgih) 
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The median total intra- and postoperative blood loss was significantly different: 390 mL in 
group 1 versus 57 mL in group 2 (Wilcoxon's rank sum, ρ = 0.005; Fig la). The median intra-
and postoperative blood loss in reference to the postoperative ECMO time and the body 
weight was significantly less in group 2: 2.26 mL/kg/h in group 1 versus 0.49 mL/kg/hr in 
group 2 (Wilcoxon's rank sum, ρ = 0.02; Fig. lb).The median transfusion requirement of 
RBC during an ECMO run in group 1 was significantly more than in group 2: 838 mL versus 
442 mL (Wilcoxon's rank sum, ρ = 0.003; Fig. 2a). In respect to the preoperative transfusion 
requirement of RBC there is no difference between both groups: median amount of 0.83 
mL/kg/h (group 1) versus 0.96 mL/kg/h (group 2; Wilcoxon's rank sum, ρ = 0.3). The diffe­
rence in intra- and postoperative requirements of RBC between both groups is statistically 
significant: median of 2.96 mL/kg/h in group 1 versus 1.13 mL/kg/h in group 2 (Wilcoxon's 
rank sum, ρ = 0.03; Fig. 2b). 
U ilcoKon 
ρ = 0 003 
ml/kg/hr 
U ikoxon 
Ρ = 0 0 3 
group 1 group II group I group 11 
Figure 2 Box-plots of transfusion requirements ofRBCs in CDH patients, treated without 
(group I) and with TEA (group II). They illustrate the distribution of data. The bottom and the 
top of the box indicate the first and third quartile, the line in between indicates the median 
and the dotted lines represent the extreme values (range), (a) total volume during the whole 
ECMO run. (b) volume per kg bodyweight per postoperative ECMO hour (mL/kg/h) 
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Discussion 
Hemorrhage is the major complication in neonates during ECMO. Among all Extracorporeal 
Life Support Organization (ELSO) registry patients treated by ECMO hemorrhagic complica­
tions occurred in 21%5. In CDH patients treated by ECMO the overall incidence of bleeding 
complications appears to be 43% (209 of 483) including a 24% (117 of 483) incidence of 
operative site bleeding6. Repair of the hemia defect while on ECMO may increase the risk of 
bleeding complications up to 58 to 60%67. Our initial experience - reflected in group 1 of this 
study - is consistent with these reported rates: six of the first 10 CDH patients treated by 
ECMO had severe hemorrhage (intracranial 1 ; surgical site 5). 
Hemorrhagic complications are a hallmark of poor outcome7. A statistically significant 
difference in bleeding complications has been found between surviving and nonsurviving 
CDH patients who needed ECMO support6 7. The reported incidence of fatal hemorrhage is 
4% to 5%68. However, this rate is probably higher because any hemorrhagic complication 
may force the patient to be removed from ECMO earlier, and the immediate cause of death 
would be classified as pulmonary failure rather than hemorrhagic6. We only can confirm this 
experience because all patients who died in this series had major hemorrhagic complications. 
So far we repair CDH on ECMO late in the ECMO course when the patient had been shown 
to be weanable from ECMO. In this concept, a recurrence of persistent pulmonary hypertensi­
on of the newborn (PPHN), elicited by the surgical procedure and the consequently diminis­
hed thoracic compliance, can be controlled by ECMO, whereas ECMO could be withdrawn 
soon in case of hemorrhagic complications. 
Adhering to our strategy, in which the benefits of perioperative ECMO support have to be 
outweighed by the risks of hemorrhagic complications, it seemed to be important to diminish 
the chance of those complications. Initially it was thought that bleeding complications during 
ECMO were caused by the anticoagulation. Undoubtedly heparinization is an important, but 
certainly not the only, factor for the occurrence of hemorrhage. It is known from the cardio­
pulmonary bypass (СРВ) surgery, that fibrinolysis is a cause of postoperative bleeding and 
that the fibrinolytic activity increased immediately after СРВ had begun and remained 
elevated throughout the period of extracorporeal circulation (ECC)9. So, the increased fibri­
nolytic activity seems to be caused by ECC itself9. Fibrinolysis is believed to play a role in 
the increased hemorrhagic tendency in patients who require extracorporeal life support 
(ECLS)asweH'0". 
The increased fibrinolysis during ECC and ECLS is possibly caused by an imbalance be­
tween tissue plasminogen activator (TPA) and plasminogen activator inhibitor (PAI), two of 
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the major components regulating fibrinolysis (Fig 3)" . McVeen et al found a marked elevati 
on of both PAI activity and TPA antigen in pre-ECMO infants experiencing respiratory 
distress10. 
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Epsilonaminocaproic Acid (EACA) and tranexamic acid (TEA) inhibit fibrinolysis by binding to 
plasminogen and plasmin. Urokinase and TPA accelerate the formation of plasmin from plasminogen. 
Figure 3 Schematic diagram of the fibrinolytic system 
After institution of ECLS there is a rapid reduction of PAI activity within 24 hours, whereas 
TPA levels appear to remain more elevated and decline more gradually during ECMO 
treatment10. This imbalance may cause an increased risk for hemorrhage. Therefore, antifibri-
nolytic therapy represents a pharmacological modality to reduce hemorrhagic complications 
on ECMO. 
Drugs used to inhibit fibrinolysis during and after СРВ surgery are epsilon-aminocaproic acid 
(EACA), tranexamic acid (TEA) and aprotinine1213. EACA and TEA inhibit fibrinolysis by 
binding to the lysine binding sites of plasminogen and plasmin, which are the binding sites 
for fibrin. In this manner they blocked the fibrin breakdown by plasmin. The affinity of TEA 
for plasminogen is much stronger than EACA, so that TEA is 6 to 10 times as potent as 
EACA13. Moreover TEA also competitively inhibits the activation of enterokinase. EACA has 
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been adopted for use in neonatal ECLS patients by Wilson et al1 Because EACA was not 
registered in the Netherlands, we choose TEA instead of EACA Because the optimal dosage 
of TEA for neonates on ECMO is not known, we tried to determine the dosage and the means 
of administration on the basis of the report of Horrow et al about TEA11 The recommended 
dosage by the manufacturer and the dosage of EACA used by Wilson (taking into considerati­
on the greater efficacy of TEA) gave us guidelines for the dosing scheme 1 n 
Patients who received TEA penoperatively had significantly less blood loss while on ECMO 
than the patients who did not receive TEA (Wilcoxon's rank sum, ρ = 0 005) Similarly the 
transfusion requirements of RBC were significantly less in the TEA-treated group (Wil­
coxon's rank sum, ρ = 0 003) No patients in the TEA-treated group had to be withdrawn 
early from ECMO support because of major bleeding The survival rate for group 2 was much 
higher (100% vs 56%) The improved survival in group 2 may be attributed to the decreased 
occurrence of severe hemorrhages 
Those data may reflect the possibility that antifibnnolytic therapy has played a role in the 
diminution of bleeding complications and the improved survival However, these results may 
be attributed as well to the increased experience of the whole ECMO team 
Because this is an unblinded study with historical controls, it is more difficult to unravel the 
influence of the gained experience on the one hand and the influence of TEA on the other 
hand on the improved results It can be supposed that less blood loss and less RBC require­
ment can be explained by a better and more well-balanced anticoagulation management in the 
second group as a result of learning over time 
To investigate the effect of the learning curve, the RBC requirements were studied in all other 
ECMO patients (CDH excepted) in the same time frames as group 1 and 2 CDH patients were 
treated In the first episode (1991 to 1992) the median RBC requirement during ECMO was 
0 66 mL/kg/h of ECMO versus 0 75 mUkg/h in the second episode (1993 to 1995, p=0 27) 
This observation does not suggest a big alteration in ECMO handling caused by the learning 
curve 
With respect to the operative technique there was no fundamental change in the surgical 
approach with the advent of ECMO This technique has been rooted in a more than 20-year 
surgical experience with CDH repair So it is hard to believe that a learning curve or a big 
alteration in the operative procedure is responsible for the bleeding complications in the early 
part of this study (Group 1 CDH patients) 
Although the validity of this study may be a point of debate because of the use of historical 
controls, the following points can be made 
(1) The preoperative RBC requirements in CDH-patiens on ECMO in both episodes 
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(0.83 mL/kg/h in group 1 and 0.96 mL/kg/h in group 2) were comparable to the RBC 
requirements in all other indications in both episodes (0.66 mL/kg/h and 0 75 
mL/kg/h respectively). 
(2) The postoperative RBC requirements after CDH repair on ECMO in the second 
episode (group 2, 1 13 mL/kg/h) were comparable to the RBC requirements in the 
pre-CDH repair episodes (0 83 to 0 96 mL/kg/h) and in all other ECMO indications 
(0.66 to 0.75 mL/kg/h). 
(3) The postoperative RBC requirements after CDH repair on ECMO in the first period 
(group 1 without the use of TEA, 2.96 mL/kg/h) differed significantly from the 
requirements in the second period (group 2 with the use of TEA, 1.13 mL/kg/h, 
p=0.03). 
(4) The surgical procedure was well established over years and did not change with the 
introduction of ECMO or during the study period 
Therefore it may be concluded that TEA is effective in controlling bleeding complications 
and in reducing RBC transfusion requirements. 
Although thrombotic complications are to be expected by the use of TEA, the reports concer­
ning antifibnnolytic therapy during and after СРВ surgery did not show an increase in those 
complications12 '3. In this study rather severe thrombotic complications were encountered in 
the first two patients treated with TEA. Right atrial and superior cavai vein (SCV) thrombosis 
developed with an SCV syndrome and a long-lasting chylothorax. It was unclear whether 
these complications of central venous line thrombosis several days after ECMO were caused 
by TEA because we experienced the similar complications previously in two patients of 
group 1 who did not receive TEA. In addition those complications have been reported as well 
after ECMO without the use of antifibnnolytic therapy'4 '5, and thrombosis around an indwel­
ling central venous line is a fairly known complication in neonates16. However, meeting these 
problems and noting fatal thrombotic complications by the use of antifibnnolytic therapy17, 
we decided to adapt the dosage and the administration of TEA. Since that alteration, neither 
severe hemorrhages nor severe thrombotic complications were observed. 
This study demonstrates that TEA is effective in reducing postoperative blood loss and 
hemorrhagic complications associated with CDH repair on ECMO. It also reflects the possi­
bility that TEA may be responsible for severe thrombotic complications. Empirically, based 
on our experience, the appropriate dosage and administration pattern of TEA for CDH repair 
dunng ECMO seem to be one bolus of 4 mg/kg TEA intravenously 30 minutes before the 
anticipated CDH repair and a continuous infusion of 1 mg/kg/h TEA during 24 hours after 
CDH repair. 
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Abstract 
Extracorporeal membrane oxygenation (ECMO) is a lifesaving treatment for neonates who 
have severe respiratory failure that does not respond to maximal conventional therapy. A 
consequence of venoarterial ECMO is the sacrifice of the right common carotid artery. 
Evaluation of the impact of a single carotid artery in babies treated with ECMO concerns 
mostly long-term neurodevelopmental outcome. The authors encountered a peculiar problem 
caused by a single carotid artery in a post-ECMO patient during the surgical correction of 
aortic coarctation with hypoplastic distal aortic arch. For patients with a confirmed cardiac 
malformation that necessitates future surgical repair and for whom ECMO support is requi-
red, reconstruction of the right common carotid artery should be considered. Venovenous 
ECMO is an alternative solution if this approach is not contraindicated because of the pa-
tient's clinical condition. Patients with congenital diaphragmatic hemia have a higher inci-
dence of cardiac malformations; therefore, careful cardiological attention is required. Anoma-
lies masked by pulmonary hypertension also must be considered. 
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Introduction 
The treatment of congenital diaphragmatic hernia (CDH) in neonates has received new 
perspectives by the application of extracorporeal membrane oxygenation (ECMO)'. With 
venoarterial ECMO, cannulation and ligation of the right common carotid artery are inevita-
ble. In many ECMO centers, efforts are made to save the carotid artery either by its recon-
struction after ECMO or through avoiding arterial cannulation and initiating venovenous 
(VV) access if possible The early complications and late sequelae of a single carotid artery 
are studied intensively in most ECMO centers, however, these studies are focused primarily 
on cerebral circulation and long-term neurodevelopmental outcome21. 
We report on a baby with CDH treated with venoarterial ECMO. The patient's clinical course 
was complicated by the development of an aortic coarctation, diagnosed after decannulation. 
Surgical correction of the associated hypoplastic distal aortic arch was incomplete because of 
the ligated right common carotid artery and the impossibility of clamping the remaining left 
carotid artery 
Case report 
A 3.500-g white boy was bom by spontaneous vaginal delivery after 40 weeks of uneventful 
gestation. The neonate had severe respiratory distress and was transferred to our clinic. The 
Apgar scores were 4 and 6 at 1 and 5 minutes, respectively. A chest radiograph showed a left-
sided diaphragmatic hemia. Intensive artificial ventilation and pharmacological support with 
vasoactive drugs did not result in satisfactory gas exchange. The initial cardiac evaluation 
showed a wide patent ductus arteriosus with a bidirectional flow, but no structural anomalies 
were evident (Fig 1). 
ECMO via venoarterial access was initiated. Six days later, surgical repair of the diaphragma-
tic defect was performed while the patient was on ECMO. The postoperative course was 
complicated by hemorrhages at the surgical site, hypotension, poor diuresis, distension of the 
abdomen, and poor venous return to the extracorporeal circuit. An increase in fluid intake, 
transfusions of blood products, pharmacological support with vasoactive drugs, and surgical 
decompression of the abdomen, widened by a Goretex patch (W.L. Gore and Associates, Ine, 
Flagstaff, AZ), did not result in improved circulation Subsequently, as the parameters of gas 
exchange became satisfactory, the patient was weaned from ECMO. After decannulation, the 
hypotension continued to persist. Total anuria developed, and gas exchange worsened. 
Echographic examination of the abdomen showed an empty bladder, without compression of 
но 
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the kidneys or the inferior cavai vein. Echocardiographic examination showed a paraductal 
aortic coarctation and a small patent ductus arteriosus with a bidirectional shunt (Fig 2). 
Fig I Echocardiographic image of the aorta before iniation ofECMO 
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Fig 2 Echocardiographic image of the aorta after decannulation 
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Prostaglandin therapy resulted in rapid improvement of the patient's clinical condition. Four 
days later, extended resection of the isthmic coarctation was performed, followed by end-to-
end anastomosis at the inferior side of the aortic arch. The ductus arteriosus was closed; 
however, a more proximal anastomosis on the proximal aortic arch was not possible because 
the single left carotid artery could not be clamped. An evaluation performed immediately 
after the surgery showed a residual gradient of approximately 20 mm Hg between the right 
upper extremity and the umbilical artery. 
The patient was extubated 21 days after decannulation, and 17 days later was transferred to 
the referring hospital. Cardiological examinations performed 2 months and 1 year later did 
not show residual or recurrent aortic arch stenosis (Fig 3). The patient's current clinical 
condition is satisfactory, but his psychomotor development is retarded because of cerebral 
atrophy and ventriculomegaly, probably caused by asphyxia and cerebral anoxia before 
ECMO was begun. 
Fig 3 Echocardiographic image of the aorta after repair of the coarctation and the hy-
poplastic distal aortic arch 
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Discussion 
Despite the growing importance of ECMO in the treatment of CDH and other severe neonatal 
respiratory failure, well-documented reports proving the deletenous consequences of the 
cannulation and ligation of the great vessels in the neck are still scarce. The possibility of 
sudden cerebral ischemia caused by an anomalous circle of Willis, which results in insuffi-
cient blood supply to the right hemisphere at the moment of cannulation of the right carotid 
artery, has been a concern4. Most studies of late complications of ECMO concern the possibi-
lity of sequelae related to psychomotor development5 
We encountered a technical difficulty, which arose a few days after decannulation, during the 
surgical repair of an aortic coarctation with hypoplastic distal aortic arch, and was related to 
the absence of the second carotid artery. Similarly, as a late sequela of venoarterial ECMO, 
the same technical problem theoretically can occur during the surgical repair of traumatic 
injuries of the left carotid artery In cases of advanced atherosclerosis, the collateral vessels 
are believed to be sufficient for ensuring adequate blood supply to the brain. 
Before ECMO, only a patent ductus arteriosus, without coarctation, was demonstrated in our 
patient Closure of the ductus arteriosus led to paraductal coarctation because of fibrotic 
changes and traction on the aortic wall; this was confirmed by the presence of a fibrotic ring 
at the site of the opening of the ductus into the aorta, and this ring is frequently associated 
with a hypoplastic distal aortic arch. 
Awareness of the presence of any cardiac malformation in CDH patients is essential before 
initiating ECMO. The possibility that anomalies can become evident through functional 
circulatory changes in the course of pulmonary hypertension during an ECMO procedure 
must be considered. 
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Abstract 
After successful ECMO treatment for CDH patients recurrent hernia was noted more fre-
quently. This observation gave rise to a retrospective study in which we attempted to identify 
risk factors for a recurrence. The medical records of 66 surviving children bom with congeni-
tal diaphragmatic hernia were reviewed. Fifty-seven patients had a left sided defect and 9 
paitents a right sided defect. The diaphragmatic defect was repaired by primary suture in 54 
patients and by a prosthetic patch closure in 12 patients. Conventional mechanical ventilation 
with pharmacological support sufficed in 55 patients, whereas 11 patients required ECMO 
support The defects were divided into 3 groups according to the dimensions of the defect 
(small, moderate or large) Nine patients (14%) developed a recurrent hernia on the average 
of 4.0 months ( range 0 2-69) after the initial repair Recurrences occurred ( 1 ) in 5 patients 
with a left sided defect (9%) and in 4 patients with a right sided defect (44%), (2) in 4 pa-
tients with a primary repair (7%) and in 5 patients with a prosthetic patch repair (42%), (3) in 
5 patients who were treated conventionally (9%) and in 4 patients who required ECMO 
support (36%) and (4) in 5 patients with a small or moderate defect (8%) and in all 4 patients 
with a large defect (100%). In conclusion, large patch-repaired right sided defects in patients 
who required ECMO stabilization are risk factors for the development of a recurrent hemia. 
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Introduction 
Congenital diaphragmatic hernia (CDH) is one of the unsolved problems in paediatric surge­
ry. Despite all kinds of innovations, including extracorporeal membrane oxygenation (EC-
MO) the mortality is still high Besides the complicated pathophysiology there are still 
surgical problems, especially in children with large defects Little is known about the ideal 
reconstruction of large defects, the best prosthetic material for patching, the fate of prosthetic 
patches, the late sequelae of large defects and the risk factors for a recurrence of a hernia 
This study evaluates which factors are involved in the recurrences 
Patients and methods 
From 1980 to 1994 116 neonates with a congenital posterolateral diaphragmatic defect were 
referred to the Department of Paediatric Surgery of the University Hospital of Nijmegen The 
charts of these infants were reviewed retrospectively Forty-five patients died in the neonatal 
period. Since January 1991 ECMO has been used for severely affected neonates Seventy-one 
patients (61%) survived the initial treatment 60 patients, who were treated conventionally 
and 11 patients who received ECMO support. Two survivors of these 71 patients were 
mentally retardated and died of pneumonia at the age of 5 and 11 months respectively and 3 
patients were lost to follow up, leaving 66 patients for this study. Data collected included 
demographics, side and dimensions of the primary defect, presence of a hernial sac, the 
technique used to close the defect (e.g. primary suture or patch repair), the condition during 
follow up visits, the incidence of a recurrence and the time between the surgical correction 
and the recurrence. In general the diaphragmatic defect was repaired by primary closure using 
interrupted non-absorbable sutures. In those cases, in which primary closure was impossible a 
prosthetic patch was used (Lyo-dura η = 3 and Gore-Tex η = 9). The repair was accomplished 
through a transabdominal approach in all patients except one 
Patients were divided in three groups according to the dimensions of the defect small (less 
than 1/4 absence of hemidiaphragm), middle (1/4 to 3/4 absence) and large (more than 3/4 
absence). 
A chest x-ray was made routinely at the age of 3 and 12 months and at other times if necessa­
ry. A recurrent hernia was diagnosed by chest x-ray and / or upper gastrointestinal contrast 
study. 
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The clinical features between the successfully repaired group and the group with a recurrent 
hemia were compared using the Fisher's Exact test or the Wilcoxon two sample test. A ρ 
value of <.05 was considered statistically significant. To investigate the possible confounding 
of different factors logistic regression analyses were applied. The relation between recurrence 
of the hemia and the separate factors can be expressed with the oddsratio. An oddsratio of 
less than 1 means that the absence of the factor involved gives a higher risk for recurrence. 
An oddsratio of more than 1 means that the presence of the factor gives a higher risk for 
recurrence. The statistical analyses were performed using the statistical software package 
SASR, version 6, Sas Institute Inc. 
Results 
Fifty-seven of the 66 studied children (86%) had a left sided hemia (Table 1). Eleven patients 
received ECMO perioperatively. Twelve ( 18%) had defects which were too large for primary 
closure and required a prosthetic patch. Nine patients developed a recurrent hemia at an 
average of 4.0 months (range 0.2 - 6.9) following initial surgical repair. Except for one 
patient, in whom the recurrence was found on a routine chest x-ray, all patients with a recur­
rence presented with dyspnoea (n = 5) and / or feeding problems (n = 6). All but one recur­
rences were reoperated. Six recurrent defects were closed primarily and in one patient a patch 
was used. In one other patient a second patch was placed. Two patients developed a second 
recurrent hemia. 
There were no statistical differences between the successfully repaired group and the group of 
recurrent hemia concerning gender, gestational age and birth weight (Table 1 ). Statistically 
significant differences between the successfully repaired group and the group with a recurrent 
hemia were found for right sided defects, ECMO treatment, the necessity of using a patch and 
the size of the defect. 
The distribution of the patients by size of the defect, side of the defect, type of surgical repair, 
ECMO treatment and the incidence of a recurrent hemia are listed in Table 2. 
Table 1 Clinical features of neonates with CDH after successful repair and recurrent hernia 
Gender 
Male 
Female 
Gestational age (wk)' 
Birth weight (kg)' 
Location defect 
left 
right 
Treatment 
conventional 
ECMO 
Technique to close the defect 
primary 
patch 
Dimensions defect 
small 
middle 
large 
Presence of hernial sac 
no 
yes 
Total 
repair 
(n-66) 
37 
29 
39.1 ±2.5 
3.1 ±0.7 
57 
9 
55 
11 
54 
12 
17 
45 
4 
50 
16 
Successful 
repair 
(n-57) 
32 
25 
39.1 ±2.5 
3.1 ±0.7 
52 
5 
50 
7 
50 
7 
16 
41 
0 
42 
15 
Recurrent 
hernia 
(n-9) 
5 
4 
39.1 ±2.4 
3.0 ±0.7 
5 
4 
5 
4 
4 
5 
1 
4 
4 
8 
1 
Ρ Value 
NS* 
N S " 
N S " 
<.05 
<.05* 
<.01 
<.001* 
NS' 
Mean ± SD Abbreviation: NS, not significant 
Fisher's Exact test, Wilcoxon two sample test 
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Table 2 Distribution of patients by size of the defect, location, surgical 
repair, ECMO treatment and the incidence of a recurrent hernia 
left sided right sided 
primary patch primary patch 
size number CT ECMO CT ECMO CT ECMO CT ECMO 
small 17(1) 16 0 0 0 1 (1) 0 0 0 
middle 45(4) 30(1) 1 1 6(1) 5(2) 1 1 0 
large 4(4) 0 1 1(1) 2 (2) 0 0 0 1(1) 
total 66(9) 46(1) І 2 Ш 8~(3J 6(3) Ï І ï~(ïj 
Noie: number of recurrent hernias between brackets, CT - conventional treatment 
Logistic regression analyses were performed for the whole group and after removal of the 4 
patients with large defects to find possible predisposing factors for the relapse of a hemia. 
These 4 patients were omitted because they all had recurrences and therefore strongly influ-
ence the results concerning the variables correlated with the size of the defect. The oddsratios 
showed that the right sided defects, the use of a patch and in lesser extent the ECMO treat-
ment are the main factors for a relapse of a hemia (Table 3a and 3b). 
A strong correlation was found between the use of a patch and the size of the defect, as could 
be expected by the conducted management strategy. A hernial sac was found in 16 patients 
(24%) during their first operation. The finding of a hernial sac during the initial operation 
appears to lower the risk for a relapse of a hemia. 
Discussion 
A recurrent hemia is one of the complications following successful initial treatment for 
congenital diaphragmatic hemia. In the literature there are only a few communications 
concerning rehemiation before 1990, suggesting that rehemiation was not a major problem in 
those days. However, it is very likely that this problem was secondary to the issue of survival 
for CDH. Nevertheless, in 1981 Cohen and Reid described 13 recurrences among 58 survi-
vors (22% recurrence rate).4 Because of the limited attention paid to this subject little is 
known about the incidence and the risk factors for the occurrence of a rehemiation. 
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We found 9 relapses in 66 reviewed CDH survivors (14% recurrence rate). This overall 
recurrence rate seems not to differ unfavourably compared to the recurrence rates reported in 
literature (Table 4). In this study significant differences between the "successful group" and 
the "recurrence group" were found for the following variables: 1) the presence of a right sided 
diaphragmatic defect (44% recurrence rate); 2) ECMO treatment (36% recurrence rate); 3) 
the dimensions of the defect; 4) and the unfeasibility for primary closure of the diaphragmatic 
defect (42% recurrence rate, Table 1 ). 
Table 3 Oddsratios (OR) for a recurrent hernia 
Table 3a Oddsratios and corrected oddsratios for patch (ORp), 
location and of the defect (ORI) 
OR ORp OR] 
Patch 8.9' 12.8' 8.0 8. Γ 8.6* 
Location1 8.3* 12.7* 9.5* 7.5' 10.6* 
ECMO 5.7' 1.2 6.6* 
Size* 3.1 1.4 2.4 
Hernial sac 0.4 0.4 0.2 
Table 3b Oddsratios and corrected oddsratios for location of the defect 
(ORI) for patients with small and middle size defects 
OR ORI 
Location1 15.6* 16.1* 16.1* 15.7* 18.1* 
Patch 1.8 2.1 
ECMO 1.8 2.1 
Size* 1.6 0.9 
Hernial sac 0.7 0.4 
An oddsratio of > 1 is considered as an increased risk for rehemiation 
*P< 0.05 ' Right versus left Large and middle versus small Middle versus small 
Table 4 Recurrences of CDH, reported in literature linked up with conventional treatment (CT) and or ECMO-treatment and in 
respect of the way of closing the diaphragmatic defect (direct suture, patch or muscle plasty) 
authors 
Cohen/Reid(1981)" 
Bax/Collins(1984)3 
Koot(1993)7 
Wischermann (1995)18 
Ehren (1992)5 
Atkinson (1992)2 
Lally (1992)9 
ν Meurs (1993)16 
West(1992)17 
this study (1996) 
numbers of 
survivors 
58 
8 
40 
45 
52 
5 
18 
18 
58 
66 
overall 
recurrence rate 
22% 
13% 
13% 
4% 
12% 
80% 
50% 
22% 
15% 
14% 
kind of 
therapy 
CT 
CT 
CT 
CT 
CT/ECMO" 
ECMO 
ECMO 
ECMO 
CT (43) 
ECMO (15) 
CT (55) 
ECMO (11) 
recurrence 
rate 
22% 
13% 
13% 
4% 
12% 
80% 
50% 
22% 
9% 
33% 
9% 
36% 
direct 
suture 
58 
16 
NT 
NT 
NT 
14 
NT 
NT 
52 
2 
recurrence 
rate 
22% 
0 
14% 
8% 
0 
kind of prosthetic recurrence 
material 
8* 
2 4 1 
NT 
NT 
5« 
NT 
4 n 
NT 
NT 
3 1 
9 s 
rate 
13% 
21% 
80% 
50% 
33% 
44% 
not split up NT- not traceable, which kind of repair was used and/or how many times with which results 
Teflon, Prolene, Marlex and Lyodura; · Lyodura; § Gore-tex; n not mentioned which kind of prosthetic material 
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These variables are not independent factors in the relapses of CDH although the oddsratios 
indicate that the right sided location, the size of the defect and / or use of a patch and in lesser 
extent the ECMO treatment are the main factors in the development of a recurrent hernia 
(Table 3a and 3b). 
We have no explanation for the higher incidence of recurrences at the right side, just as the 
reason for the increased mortality in right sided defects has not yet been elucidated. These 
defects constitute probably a distinct entity different from the left sided hernias Perhaps the 
impaired visual field due to the position of the liver makes it more difficult to close the 
defect. A transthoracic approach to right sided defects may enable a better view and contribu-
te to a more satisfying closure of the hernia.6 '8 
The increased incidence of relapses following ECMO treatment has been reported also by 
other authors, ranging from 22% to 80% (Table 4) Therefore it seems that ECMO is an 
important factor in the relapse of a hernia. Nevertheless ECMO, the size of the defect and the 
use of a patch are strongly correlated with each other. When we correct for the use of a patch 
by logistic regression analysis, it appears that the factor ECMO is less important in the 
development of a recurrence. 
It is difficult to unravel the precise influence of each individual factor considering the strong 
coherence of the different factors and the limited numbers of patients. 
In our institution CDH is repaired by direct suturing of the edges of the diaphragmatic defect. 
When the edges of the defect can not be approximated, the defect is regarded as being large 
and generally a prosthetic patch closure has been accomplished. Until the ECMO era the 
mortality among large-patch-repaired CDH patients was high with the exception of the series 
of Bax and Collins and presumably Koot et al. as well who used patch materials very gene-
rously to close the defect in order to create a diaphragmatic dome.3 7 Since the use of ECMO 
the survival for CDH, especially in cases of large patch-repaired defects, has been improved 
(Table 5). It is obvious, that there is an increase of relapses concomitantly with the increased 
survival for patch-repaired CDH patients (Table 4). This is also emphasized by the fact that in 
our study 3 of the 4 recurrences in the ECMO treated group had large defects. 
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Table 5 Survival for patch repaired-defects before and after the introduction of ECMO 
treatment 
author 
Atkinson (1991)1 
West (1992)'7 
vd Staak (1996)13 
before ECMO era 
number of 
patch repair 
6 
16 
14 
number of 
survivors 
0 ( 0%) 
2(13%) 
2(14%) 
ECMO era 
number of 
patch repair 
6 
13 
29 
number of 
survivors 
5 (83%) 
11 (85%) 
24 (83%) 
It has been suggested, that recurrences depend on the kind of material used especially on the 
use of Lyodura.7 However, recurrences were seen also after the use of Gore-Tex and other 
prosthetic materials.2 Therefore it seems preferable to reconstruct the hemidiaphragm from 
living vascularized tissue if there is almost total agenesis of the hemidiaphragm so long as 
there is a minimal amount of native diaphragmatic tissue present for the attachment of a 
prosthetic patch."1216 However, an extensive dissection - e.g. for a reverse latissimus dorsi 
flap or an abdominal wall muscle flap - is a less feasible strategy, in cases where ECMO has 
been used, because of the potential risk of severe bleeding complications. Thus in that situati-
on some type of prosthetic material has to be used. 
As yet the question of which kind of foreign material should be employed for patching 
remains unanswered, not only in consideration of recurrences, but in view of the fate of the 
patch with growth as well.3,8'415 At this moment it can be questioned, if Lyodura still is an 
option; there is doubt, whether Lyodura can transmit BSE. 
Atkinson and Poon, who used Gore-Tex (expanded polytetrafluoroethylene), reported 
reoperations at 18 months of age and explained a rehemiation by an impaired patch expansi-
on.2 In the present study recurrences were only noted before the age of 7 months, and not later 
on, indicating that an impaired incorporation of the patch in the first months is more a pro-
blem than the restricted size of the patch, which gradually becomes too small as the infants 
chest grows in the cross-sectional area. Probably, Touloukians observations, that persisting 
marginal skeletal muscle may reconstitute a portion of the diaphragmatic defect, might 
explain why recurrences seldom occur after a longer time (more than one year following the 
initial treatment).14 
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The risk of a relapse of a hemia seems to be lower when an hernial sac is found during the 
initial operation. The presence of a hernial sac was found in 24% of the patients during their 
first operation. Generally when this sac is not used for the closure of the defect it is excised to 
avoid its occupying space necessary for the lung. This sac could play a role in the recurrence 
because in four of nine patients a hernial sac was identified during the repair of their recurrent 
hemia. One can wonder whether this sac has been missed during the initial operation or 
develops later through a weak part in the reconstructed diaphragm. 
In this study 3 recurrent hemias occurred in the group with middle size defects which were 
initially closed by primary suture. It can be questioned if the application of a patch in those 
defects causes less tension on the sutures and therefore results in less recurrences. Bax and 
Collins suggested that every defect should be closed by a patch in order to create a dome. In 
that way a dome would improve diaphragm function and keep the functional capacity small to 
avoid or lessen overstretching of the lungs.3 However as pointed out above a recurrence 
probably develops because of lack of biological union between the patch and the diaphragm 
tissue and if so, the use of a patch should be minimized. Furthermore tension could contribute 
to the growth of persisting precursor tissue and therefore recreates a firm "new" diaphragm.14 
To get an answer to the question of which procedure is preferable for closing middle size 
defects and to gain a better insight into the development of biological union between prosthe-
tic materials and diaphragm tissue and into the possible influence of tension on this union, 
experimental studies should be undertaken. 
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Abstract 
Purpose: Increasingly more children with CDH are surviving due to ECMO. Beyond the 
issue of survival arise the concerns of the morbidity, the outcome and the quality of life for 
these patients. The outcome and early morbidity of these survivors have been studied and 
compared with the outcome and early morbidity of CDH survivors who received conventional 
treatment in the same period (January 1991 through December 1996). 
Methods. Twentythree survivors out of 29 ECMO treated CDH infants were enrolled in a 
routine ECMO evaluation program, whereas 15 of 17 survivors who recovered on conventio-
nal treatment (CT) could be followed retrospectively. The evaluation was divided into 4 parts: 
(1) medical and surgical complications, (2) respiratory condition, (3) growth and nutritional 
condition and (4) neurological and developmental outcome. 
Results: Much more complications were noted in the ECMO group than in the CT group 
during the first admission. Chronic lung disease upon discharge and chronic respiratory 
illness at 1 year of age were encountered in respectively 61% and 60% of the ECMO survi-
vors and in 20% and 36% of the CT survivors. The weight of many CDH survivors was below 
the 10th percentile: upon discharge and at one year of age respectively in 87% and 73% of the 
ECMO group and in 47% and 45% of the CT group. Nutritional disorders (such as need for 
tubefeeding, gastroesophageal reflux and swallowing problems) were noted in 57% of the 
ECMO survivors upon discharge and remained in 27% of them throughout the first year of 
life. 
Neurological abnormalities at one year of age were met in 20% of the ECMO survivors and in 
36% of the CT survivors. In the ECMO group the motor development was normal in only 
33% of the children whereas the cognitive development was normal in 67% of the children. 
The average mental development score for the ECMO group fell within the normal range: 99 
(range 55 to 125). The average motor development score fell more than one standard deviati-
on below the norm: 0.73 (range 0.55 to 1.0). The delay in gross motor performance was 
chiefly related to respiratory restrictions which these infants still have at that age. 
Conclusions: (1) the morbidity in high-risk CDH patients surviving due to ECMO is substan-
tial and more than in these patients surviving with conventional treatment. However the 
outlook for these children remains encouraging with a reasonably low incidence of definite 
disabilities, and (2) taking into account the known mortality and the severe disability (impair-
ment) at one year of age there is little doubt about the benefit of ECMO compared to conven-
tional therapy for these high-risk CDH infants. 
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Introduction 
Term or near-term newborns with a high likelihood of dying from reversible respiratory 
failure could be salvaged by extracorporeal membrane oxygenation (ECMO)1 ' 
This potentially lifesaving therapy is a highly invasive procedure with a temporary or perma 
nent ligation of the right internal jugular vein and/or carotid artery and it requires systemic 
heparinization2 This technique is applied in critically ill neonates, who suffer from hypoxia, 
acidosis, hypotension, hypo- or hypercarbia prior to ECMO therapy 
All these conditions may affect cerebral blood flow and oxygenation and may cause central 
nervous system damage due to hemorrhage or infarction1 β 
From the Extracorporeal Life Support Organization (ELSO) registry it is well known, that 
infants with CDH fare worst9 1 0 CDH patients have longer ECMO runs, longer periods of 
mechanical ventilation and longer hospital stays than other ECMO-treated infants10 In 
addition they require operative treatment, have a more unstable course and they have pulmo 
nary hypoplasia The overall survival rate for ECMO treated CDH patients is only 59% which 
is lower than for other ECMO indications Even than this survival rate with ECMO therapy is 
better than with conventional treatment " n In consequence there is concern, that improved 
survival with this technique might be offset by an increased risk of neurodevelopmental 
morbidity and long term disability 
Therefore it is important to evaluate the outcome of ECMO treated CDH survivors This 
study describes the early morbidity and outcome m this population, compared with those of 
CDH survivors who received conventional treatment 
Patients and methods 
From January 1991 through December 1996 sixty patients with CDH who were antenatally 
diagnosed or who were symptomatic within 6 hours after birth, were referred to the Pediatric 
Surgical Center Nijmegen These patients were classified into the 3 categories as described 
below 
"Irretrievable ' patients These patients were ( 1 ) inborn neonates with severe respiratory 
distress, dying within 2 hours after birth before ECMO could be initiated, (2) newborns who 
died before or during transportation, (3) newborns with associated anomalies to whom not all 
therapeutic modalities were offered, or (4) newborns fulfilling ECMO entry criteria whose 
parents refused ECMO therapy They all died (n= 12) 
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Conventionally treated patients These were newborns who recovered well on (maximal) 
conventional treatment (n=19). Seventeen of whom survived (89%). Fifteen of these survivors 
were followed retrospectively. Two were lost to follow-up; they were transferred to the 
referral hospitals while intubated and on the ventilator. 
ECMO treated patients These were newborns who could not be stabilized by maximal 
conventional treatment and who received ECMO therapy (n=29). Twentythree of these 
patients survived (79%). These survivors were enrolled in a routine ECMO-evaluation 
program that was drawn up before the beginning of the ECMO program in our institution. 
In this preliminary study the outcome was evaluated upon discharge and at the age of 1 year. 
During the first year two late deaths were noted in the ECMO treated survivors. Nine patients 
have not yet reached the age of one year (4 conventionally treated and 5 ECMO-treated 
patients), whereas three patients were lost to follow-up (2 conventionally treated and 1 
ECMO-treated). Thus 26 patients could be evaluated at the age of one year: 15 ECMO treated 
and 11 conventionally treated (CT) patients. 
The evaluation has been divided into four parts: 
1. Medical and surgical complications 
2. Respiratory condition 
3. Growth and nutritional condition 
4 Neurological and developmental evaluation 
Complications 
Medical and surgical complications were listed, including all hospitalizations and surgical 
procedures. 
Respiratory condition 
The pulmonary condition was assigned as "'normal", as "'chronic lung disease" (CLD) if 
supplemental oxygen was required for more than 28 days after birth, and as "chronic reactive 
airway disease" (CRAD) if recurrent episodes with tachypnea and dyspnea associated with 
wheezing occurred for which bronchodilators and/or corticoids were necessary. 
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Growth and nutritional condition 
At the fixed checkpoints weight and nutritional disorders were noted. By nutritional disorders 
or feeding problems we understand swallowing difficulties, food refusal and repetitive 
vomiting, the presence of gastroesophageal reflux and the need for tubefeeding The weights 
were plotted against age and compared to those of similar age groups and gender (percentile 
curve). 
Neurological evaluation 
In the ECMO group a routine screening was performed before discharge consisting of a 
physical examination by the pediatrician, a head ultrasonography (HUS), a cerebral computer 
tomography (CT), a brainstem auditory evoked response (BAER), an electroencephalography 
(EEG) and an ophthalmological consultation 
At one year of age all children were examined by a pediatrician. Neurological abnormalities 
were defined as muscle tone abnormalities and abnormal tendon reflexes, chronic seizure 
disorder, blindness or deafness (interfering with normal function) Motor skills and cognitive 
or developmental skills were measured by a physical therapist and by a psychologist The 
Mental Developmental Index (MDI) from the Bayley scales of Infant Development and the 
Motor Quotient (MQ) according to Hoskins and Squires'4 were used for the developmental 
evaluation. The MQ was defined as the present motor age divided by the actual calendar age. 
The outcome was classified as '"normal" if the score of a test was within one standard deviati-
on (SD) of the test mean of the age group and no abnormalities were detected on 
physical/neurologic examination. A score of more than one but less than two SD's below the 
test mean were defined as "suspect" Outcome was assessed as "delayed", if the score was 
more than 2 SD's below the test mean or if neurologic abnormalities were identified. 
Statistics 
Because of the small number of patients only descriptive statistic are used 
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Results 
Outcome upon discharge 
The average hospital stay lasted for 80 days (range 42 to 177 days) in the ECMO group 
compared to 41 days (range 15 to 114 days) in the control group The longer hospitalizations 
were related to complications, chronic lung disease (CLD) and feeding problems The morbi-
dity upon discharge for both groups is reported in table 1 
Table 1 Morbidity upon discharge 
Complications 
patients with complications 
number of complications 
Respiratory 
CLD 
CRAD 
Oxygen at home 
Nutritional 
disorders 
GER 
Weight < PIO 
Neurological 
abnormal 
ECMO group 
(n-23) 
15 (65%) 
24 
14 (61%) 
6 (26%) 
3 (13%) 
13 (57%) 
9 (39%) 
20 (87%) 
2 (9%) 
CT group 
(n-15) 
3 (20%) 
3 
3 (20%) 
3 (20%) 
0 
6 (40%) 
2 (13%) 
7 (47%) 
2 (13%) 
Complications Twentyfour complications were observed in 15 patients of the ECMO group 
during the first admission (table 2) In the ECMO group 2 patients with a bowel obstruction 
received a temporary enterostomy after bowel resection because of intestinal ischemia In the 
CT group 3 complications were noted consisting of a chylothorax in 2 patients and a small 
bowel obstruction in 1 patient Large diaphragmatic defects which could not be closed by 
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primary suture were present in 20 patients (87%) of the ECMO group and in 5 patients (33%) 
of the CT group. CDH repair in these patients was accomplished with a polytetrafluoroethyle-
ne (PTFE-Goretex) patch. In 6 patients of the ECMO group the abdominal wall could not be 
closed by primary suture after CDH repair closure was accomplished with a PTFE patch. All 
6 patients underwent reoperations for removal of the patch; in 4 of them because of septic 
complications. 
Table 2 Complications encountered in 23 ECMO CDH patients. 
Superior Vena Cava Syndrome 4 
Chylothorax 2 
Coarctatio Aortae 1 
Hydrocephalus 1 
Persistent PDA 2 
Postoperative hemorrhage 5 
Small bowel obstruction 4 
Recurrent hemia 4 
Abdominal wall patch 6 
Note: More than one complication may be present in one patient 
Respiratory condition In the ECMO group more respiratory problems were encountered than 
in the conventional group. Fourteen neonates (61%) of the ECMO group required supplemen-
tal oxygen for longer than 28 days (CLD) compared to 3 (20%) in the CT group. Nevertheless 
17 ECMO survivors were able to leave the hospital without any kind of respiratory therapy. 
Nutritional condition More feeding problems were encountered in ECMO CDH survivors 
than in the CT CDH survivors such as the need for tubefeeding and the need for antireflux 
medication. At the time of discharge in 87% of the ECMO CDH survivors the weight was 
below the 10th percentile (corrected for age and gender), whereas 47 % of the CT group 
survivors was below the 10th percentile. 
Neurological status Two patients in each group had definite neurological abnormalities 
closely related to substantial (postanoxic) cortical atrophy. One of these patients in the ECMO 
group who was profoundly impaired died at the age of 11 months. 
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Outcome at one year of age 
The morbidity at one year of age is summarized for both groups in table 3. 
Table 3 Morbidity at 1 year of age 
ECMO-group CT-group 
( n - 1 5 ) ( n - 1 1 ) 
Complications 
hydrocephalus 
recurrences 
small bowel obstruction 
Musculoskeletal 
chest wall deformity 
scoliosis 
Respiratory 
CRAD 
oxygen at home 
Nutritional 
remaining on tubefeeding 
GER-medications 
Growth 
weight below PIO 
median weight (gramms) 
range 
Neurological/developmental 
abnormal 
hearing loss 
1 (7%) 
4 (27%) 
0 
8 (53%) 
1 (7%) 
9 (60%) 
3 (20%) 
4 (27%) 
4 (27%) 
0 
0 
3 (27%) 
4 (36%) 
2(18%) 
4 (36%) 
0 
0 
3 (27%) 
11 (73%) 5 (45%) 
7650 9500 
6900-10500 5500-11200 
2(13%) 
1 (7%) 
3 (27%) 
1 (9%) 
Complications In the first year of life a hydrochephalus was diagnosed in one survivor of 
the ECMO group. A recurrent diaphragmatic hernia was noted in 4 ECMO survivors of whom 
3 underwent a reoperation. In addition to the usual procedures such as cannulation, decannu-
lation and CDH repair in total 35 surgical procedures had to be performed in 16 patients of 
the ECMO group because of medical and surgical complications (table 4). In the CT group 
Congenital Diaphragmatic Hernia Outcome and early morbidity 139 
only 4 procedures, in addition to the usual CDH repair, were performed in 4 patients because 
of a small bowel obstruction. 
Musculoskeletal defomities Chest wall deformity is significant feature after CDH repair in the 
ECMO group as well as in the control group. 
Table 4 Additional Surgery - Reoperations in the first year 
ECMO-group CT-group 
Hemorrhage at the surgical site 6 
Cannula problems (bleeding, clots, dislodgement) 4 
Small bowel obstruction 4 
Closure enterostomy 2 
Removal of abdominal wall patch 6 
Recurrent diaphragmatic hemia 3 
Nissen fundoplication 5 
Ventriculoperitoneal drain 1 
Peritoneal Dialysis 1 
Coarctatio aortae repair and reexplorations 
because of anuria 3 
Note : More than one complication may be present in 1 patient 
Respiratory condition At one year of age the ECMO survivors continue to have more pulmo-
nary problems. Nine children of the ECMO group (60%) displayed breathing difficulties with 
tachypnea and costostemal retractions at physical examination and were receiving airway 
medications. Three of them required supplemental oxygen at home. 
Growth and nutrition In the ECMO group more feeding problems remained than in the CT 
group. One patient had an extreme food refusal. Gastroesophageal reflux (GER) was encoun-
tered in both groups. However a Nissen fundoplication was performed in four patients of the 
ECMO group and in none of the CT group during the first year of life. Eleven children (71 %) 
of the ECMO group demonstrated a failure to thrive. 
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Neurological evaluation No patient had evidence of spasticity or cerebral palsy. The neurolo-
gical development can be specified as delayed in two survivors of the ECMO group and in 
three patients of the CT group, namely not achieving the expected developmental milestones 
on time with abnormal findings on neurological examination. The neurocognitive outcome of 
ECMO CDH survivors has been assessed more exactly thant in the CT CDH survivors 
because of the nature of the follov. -up study (table 5) Generally the motor skills lagged 
behind the cognitive skills 
Table 5 
Motor 
normal 
suspect* 
delayed** 
Neu rode velopmen tal outcome at 1 
motor quotient by MDI - score 
Cognitive 
normal 
5 
4 
1 
10 (67%) 
Cognitive 
suspect 
1 
2 
3 (20%) 
year of age for ECMO 
Cognitive 
delayed 
2 
2(13%) 
survivors : 
5 (33%) 
5 (33%) 
5 (33%) 
15(100%) 
suspect 1 SD - 2 SD below mean 
** delayed > 2 SD below mean 
Only one ECMO survivor had a motor quotient equal to or greater than 1 0. The mean MDI 
score for this population fell within the normal range 99 (range 55 to 125) The mean MQ 
score fell more than 1 SD below the norm 0.73 (range 0.55 to 1.0). 
Discussion 
ECMO has been shown to improve survival for neonates with persistent pulmonary hyperten-
sion (PPHN) from diverse causes '2 '° n. Beyond the issue of survival questions arise the 
concerns of the morbidity, the outcome and the quality of life among the survivors of ECMO. 
Most reports have focused on the neurodevelopmental outcome in the entire population that 
survived ECMO without regard to the original underlying disease and without adressing 
morbidity from causes other than neurodevelopmental impairmentl4"17. In other reports 
concerning the outcome of neonates with severe respiratory failure treated with or without 
ECMO patients with congenital diaphragmatic hernia were even excluded from follow-up 
studies '8 ". Therefore, the purpose of this study is to describe all sequelae encountered in the 
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early follow-up of CDH patients, surviving after ECMO-treatment. The outcome of this group 
of neonates was compared with a group of contemporarily treated CDH patients, surviving 
without ECMO support The study of this latter group had a retrospective nature. Therefore 
the data of this group may not be so detailed as that the ECMO group, in which a prospective 
standardized follow-up was performed The morbidity encountered in the ECMO group is 
much more than in the CT group, especially, more complications and more additional surgical 
procedures were observed. 
Respiratory outcome 
Considering the presence of pulmonary hypoplasia, the intensity of pre-ECMO artificial 
ventilation, the duration of post ECMO artificial ventilation and the disturbed pulmonary 
mechanics - in part due to the (almost) complete absence of the hemidiaphragm in many 
survivors - the presence of chronic lung disease and signs of chronic reactive airway disease 
amounting to 60% of the population is as to be expected 
Up to now little is known about the pulmonary function and respiratory illness in CDH-
ECMO-survivors. Extensive studies of respiratory function in children surviving with CDH in 
the era before ECMO have been published 20 21. Although spirometrie data and ventilation-
perfusion (V/Q) radionuclide scans show signs of restrictive lungfunction and V/Q mismatch 
with particularly a great reduction in perfusion these survivors live generally a normal life and 
exhibit normal physical activity without subjective complaints These data may however not 
be applied to this group of patients with pronounced pulmonary hypoplasia, who would not 
have survived without ECMO. Lund et al in their article about hidden morbidity in high-nsk-
CDH-survivors report on the "significant disabilities in addition to the chronic lung problems 
that they may also have", but don't mention the pulmonary sequelae themselves 24 The results 
at discharge in the present report are comparable to the data reported by Van Meurs in a group 
of 18 CDH-ECMO-survivors 2S. In that series 12 meet the criterion for chronic lung disease 
(67%) (receiving oxygen therapy at 28 days of age), 4 were discharged with oxygen at home 
(18%) and 5 were receiving bronchodilators or diuretics at the time of discharge (23%). 
The incidence of CLD upon discharge and chronic respiratory illness at one year of age in 
CDH-ECMO survivors reported in the present senes (60%) is in accordance with other 
studies2528. 
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Nutritional conditions 
The - by many authors - noted growth failure in the CDH-ECMO population has been 
connected with chronic respiratory problems because of the higher energy expenditure for 
breathing and because of the poorer sucking and/or swallowing ability 24"29. 
However, nutritional disorders encountered in 57% of the ECMO group may also contribute 
to a poor weight gain of these children. Some infants experience an extreme food refusal. In 
one patient this food refusal lasted for 5 years. Managing these problems may be difficult 
according to our experience. Nutritional and respiratory problems appear to be strongly 
correlated. In a number of patients GER, food refusal, foregut dysmotility, swallowing 
difficulties, poor sucking ability and/or restricted pulmonary function are hardly distinguisha-
ble from each other. GER is one of the main problems seen in association with the increasing 
survival of severe high risk CDH infants; both for CT treated infants and for ECMO treated 
infants 25 3\ The reported incidence ranges from 39 to 89% in ECMO CDH survivors and up 
to 62% in the CT CDH survivors. Foregut dysmotility with food refusal and swallowing 
difficulties is particularly observed in ECMO CDH survivors 24"32. The cause of the disturbed 
motility in the esophagus remains unknown. It is not unimaginable that pressure on the 
esophagus by herniated viscera and acute kinking of the esophagus by an intrathoracically 
located stomach may interfere with the blood supply and the prenatal development of the 
esophagus with resulting impaired motility 2930'16. Several factors predisposing to GER may 
be present in these children such as the disturbed anatomy of the gastroesophageal junction 
and the raised abdominal pressure after CDH repair 14 ". In any case in patients with large 
defects with complete or partial absence of the perihiatal diaphragm it is hard to expect that a 
normal functioning lower esophageal sphincter (LES) is present29,I32M. 
On the basis of their observations Stolar et al drew attention to the functional and the anato-
mic abnormalities of the esophagus and the lower esophageal sphincter2W0. They observed a 
megaesophagus accompanied by poor esophageal motility in association with GER and 
polyhydramnios. They supposed that esophageal dilatation seen on postnatal chest X-rays was 
caused by prenatal kinking of the esophagus leading to polyhydramnios prenatally, and 
swallowing disorders postnatally. Nagaya et al postulated that infants with severe pulmonary 
hypoplasia have GER because of deviation of the esophagus to the affected side with shorte-
ning of the intra abdominal esophagus and the subsequent creation of a hiatal hernia as lung 
expansion occurs 32. 
Whatever the cause of GER it is clear that GER is present in a large number of CDH ECMO 
survivors and that GER may be responsible for significant morbidity in this population. 
Recurrent bronchitis and aspiration pneumonia are wellknown complications of GER whereas 
bronchospasm may occur as a vagal nerve reflex during acidification of the esophagus 37 38. 
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Because such pulmonary complications due to GER may be potentially disastrous in this 
already compromised group of patients an aggressive management of GER might be advoca-
ted in order to avoid these complications Although nutritional disorders may be present as a 
source of morbidity for a long time, it seems that these will resolve with time 
Neurodevelopmental outcome 
This study displayed neurological abnormalities in about 20% of the survivors, consisting of 
hearing loss, hydrocephalus, and seizure disorders. One patient who was severely impaired, 
died before one year of age. None of the survivors had cerebral palsy, spasticity or mental 
retardation. Mild to moderate developmental delays were demonstrated in 67% of the survi-
vors at one year of age. Usually these delays were characterized by a delay in motor skills 
with normal cognitive development This delay in motor skills is probably related to the 
pulmonary condition and to a poor endurance. Only one patient showed a motor development 
in conformity with calendar age, whereas the neurocognitive outcome was within normal 
ranges for 67% of the survivors 
The interpretation of these findings is difficult for several reasons. Firstly it is not clear 
whether an unfavourable outcome is attributable to the duration of pretreatment hypoxemia, 
to the pre-ECMO therapy (such as hyperventilation and alkalization), to the ECMO-treatment 
itself, to the long hospitalization and the morbidity during the first hospital stay or to the 
underlying disease or remaining disabilities 2 8 394°, Furthermore, it is difficult to compare the 
results concerning the neurodevelopmental outcome in ECMO CDH survivors with other 
groups of patients. These ECMO-CDH-survivors can neither be compared to other CDH 
patients surviving without ECMO nor to other infants, surviving ECMO. Comparison of the 
results of the present study with those of other published studies is difficult, because differen-
ces in outcome may relate to differences in survival. It seems plausible that neurodevelop-
mental outcome is better as survival is lower in a certain group. Thus far, studies reporting on 
ECMO-survivors contain often a small amount of CDH patients and limited data on CDH-
ECMO-survivors themselves are available 14"17. Even less information is available on the 
neurodevelopmental outcome of those infants with high-risk CDH who are treated without 
ECMO4'. Davenport reported on the outcome of 23 CDH survivors who had been managed 
by delayed surgery after a period of stabilization. He observed major disabilities in 2 patients 
(9%) and minor disabilities in 2 further patients (9%), he noted a mean developmental quo-
tient (DQ) of 108 in this group with no developmental delay (defined as DQ < 70) In a study 
focused on the outcome of ECMO-treated CDH-patients the neurodevelopment of children 
with CDH had been reported to be similar to that of all other ECMO-survivors 25 In other 
studies it was apparent that the CDH-population as a whole fared significantly worse 26_2e'12 
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Developmental delays have been reported to be present in 46% to 58% of ECMO-CDH-
survivors, with severe delays or impairment in 13% to 23% l4-1624-2842. 
The results of the present study concur remarkably closely with the reported results of CDH-
ECMO-survivors in the literature major neurodevelopmental disabilities were noted in 13% 
ot the survivors, the cognitive development is normal in at least 67% of the survivors, where-
as 67% of the survivors have a motor delay at 1 year of age 26 28 42 
Nobuhara et al, Bembaum et al and d'Agostino et al who reported motor delays in their CDH-
populations connect this motor delay with the presence of hypotonicity in more than 75% of 
the survivors at 1 year of age 26 28 This decreased muscle tone affects the lower extremities 
more than the upper extremities 27. 
In the present study the gross motor performance was significantly poorer than the fine motor 
performance and the motor development in prone position was more delayed than in supine 
position. Probably this delay in gross motor performance has to attribute to the respiratory 
restriction that most infants yet have at this stage. So, a different motordevelopmental route 
was noted However at this moment it is unknown what that means for the later motor outco-
me (which does not necessarily mean to be worse). 
Concluding, (1) the present study shows that the extent and the degree of morbidity in a high 
risk CDH population surviving due to ECMO are substantial. It seems to be the pnce for the 
gain of a higher survival rate. Notwithstanding all kinds of adverse factors, the outlook for 
these children remains encouraging with a reasonably low incidence of definite disabilities. 
(2) Taking into account the known mortality and severe disability at 1 year of age, there is 
little doubt about the benefit of ECMO compared to "conventional" therapy. Even for infants 
with congenital diaphragmatic hernia. (3) With increasing experience in the management of 
these CDH-infants it may be expected that morbidity decreases. 
Therefore, long-term follow-up in specialized centers with a well-cooperating multidisciphna-
ry team - familiar with the variety of problems encountered - remains essential for improve-
ment in the quality of life for these children and for good support of the parents. 
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12.1 Introduction 
This thesis addresses the impact of the clinical application of ECMO on the management of 
neonates with Congenital Diaphragmatic Hemia (CDH). An unacceptably high mortality 
among neonates with CDH despite all new developments in management of CDH patients 
together with the ongoing reports regarding the successful clinical application of ECMO in 
these patients stimulated a study for the efficacy of ECMO support in the therapeutical 
armoury for neonates with CDH. 
The most important objectives of the studies presented in this thesis were: 
1. Is it possible to predict the outcome of CDH patients? 
2. Is ECMO therapy efficacious for CDH patients? 
3. With which hazards and adverse sequelae is this aggressive, invasive and potentially life 
saving therapy attended? 
4. What is the morbidity, the neurodevelopmental outcome and the quality of life of the 
CDH patients who could be salvaged by ECMO? 
12.2 Results of the study 
1. Risk assessment and outcome prediction Reviewing preoperative chest radiographs of 
newborns with CDH according to a previously described scoring system we were not able to 
identify survivors and nonsurvivors. For outcome prediction this X-ray scoring system is not 
of great value (Chapter 4). Analyzing alveolar to arterial oxygen pressure gradients (AaD02) 
linked to time as an entry criterion for ECMO it was proved that AaD02/time criteria as 
formulated in the literature could be deceptive for infants with CDH. High paC02 values are 
affecting the sensitivity of AaD02 as entry criterion, so that 53% of the infants who ultimately 
died should not have become eligible for ECMO support. All CDH patients should have died 
before ever reaching "classically" formulated AaD02 entry criteria for ECMO. AaD02 values 
may be unreliable for outcome prediction and for ECMO-selection in CDH patients.. (Chapter 
5) 
2. Efficacy of ECMO in CDH patients The benefit of ECMO in cases of high-risk CDH was 
studied by comparing pre-ECMO ( 1987 to 1990) and post-ECMO (1991 to 1994) 3-month 
survival statistics. The 3-month survival rate for unstable neonates (who could not be stabili-
zed by conventional therapy) improved from 0% in the pre-ECMO era to 61 % in the ECMO-
era (p=0.004). This highly significant difference showed that ECMO is a very valuable 
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addition to the management of high-risk CDH patients whose conditions remain unstable 
despite maximal conventional therapy (chapter 7) 
3 Consequences and hazards attending the clinical introduction of ECMO-therapy In the 
early experience with ECMO in CDH patients significant bleeding complications were 
encountered at the surgical site (Chapter 6) This complication could successfully be faced by 
the use of tranexamic acid (Chapter 8) An unexpected complication occurred in a patient 
with CDH treated with venoarterial ECMO In this patient the clinical course was complica-
ted by the development of an aortic coarctation diagnosed after decannulation and sacrifice of 
the right common carotid artery Limits to surgical correction of the hypoplastic distal aortic 
arch were set, because the single left carotid artery could not be clamped (Chapter 9) 
4 The outlook and neurodevelopmental outcome After successful ECMO treatment for CDH 
recurrent hernia was noted more frequently This increase of relapses was attributed to the 
improved survival of patients with large patch-repaired defects by using ECMO (Chapter 10) 
Ultimately it was shown that the higher survival achieved by ECMO was obtained at the cost 
of more morbidity and was attended by pulmonary, gastrointestinal and neurological seque-
lae However, no patient had evidence of severe neurological impairment at 1 year of age The 
neurodevelopmental evaluation at 1 year of age was characterized by a mild or moderate 
delay in motor skills with normal cognitive development (Chapter 11 ) 
12 J General discussion; the state of the art 
In only a few decades the interpretation of congenital diaphragmatic hernia as a purely 
anatomical defect has turned to a complex pathophysiological problem '2 In the early days of 
paediatnc surgery surgical repair of CDH seemed to be a straight forward therapeutic soluti-
on Ladd and Gross advocated surgical treatment immediately after birth or as soon as possi-
ble, before respiratory problems occurred ' Early repair should determine the outcome and 
the poor results were related to delay in surgery However, despite an aggressive attitude the 
survival rates decreased rather than increased 3 5 In 1969 Young showed that there was an 
inverse relationship between the age of admission and mortality 5 Earlier diagnosis combined 
with successful resuscitation and rapid transport to surgical centers resulted in more neonates 
being admitted and undergoing surgery, who did not have any chance of survival before 
because of the extent of pulmonary hypoplasia 4 
The high mortality associated with CDH has been shown to be caused by pulmonary hypopla 
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sia and by persistent pulmonary hypertension ^1'. The persistent pulmonary hypertension has 
been considered as the major abnormality in CDH, responsible for the majority of the deaths 
associated with CDH '° ". However, the pulmonary hypoplasia as a cause of death cannot be 
ruled out and there exist no tests or objective criteria by which the extent of pulmonary 
hypoplasia can be established. At this moment we are not able to distinguish infants, who 
have hypoplasia incompatible with life from infants who have a potentially reversible pulmo-
nary hypertension, despite the various criteria which have been proposed to predict the 
outcome of neonates with CDH '2 22 Nevertheless these criteria may be helpful for risk 
assessment and may be used for the development of therapeutic strategies. 
Monitoring ventilatory parameters it was observed that the clinical condition of the infants 
was deteriorating rather than improving by reduction of the hernia23 24. Based on the observed 
postoperative deterioration, a strategy of delayed surgery after a preoperative period of 
ventilatory and hemodynamical stabilization has been introduced 23 26. However, until now 
there have been no strict criteria to dictate at which point surgical repair should be performed 
nor how long surgery should be delayed 27 28. Until now it has not been clear what is happe-
ning during the period of stabilization, although Moffitt et al have tried to study this w. Most 
authors could not show an improved survival with the strategy of delayed surgery nor for that 
matter a decreased survival24"26 2810. This approach has however gained increasing application 
in the past decade and has become the standard procedure 3'36 Anyhow, the preoperative 
period of stabilization provides the opportunity to optimize the clinical condition and to avoid 
risk factors for the development of a recurrent pulmonary hypertension. Coping with pulmo-
nary hypertension remains an important assignment in CDH patients because PPHN is one of 
the determining factors of outcome. In the eighties various vasodilators have been advocated 
and used to diminish the pulmonary vascular tone, if PPHN is present37 41. However a specific 
pulmonary vasodilator was not available and most agents had no or only a temporary effect39. 
At that time the introduction of ECMO provided new opportunities to overcome episodes of 
persistent pulmonary hypertension 42 43. Many centers around the world have used ECMO in 
patients with PPHN with encouraging results, i.e., improved survival rates ^53. However, the 
benefit of ECMO is less evident in CDH-patients 54"59 According to the ELSO registry the 
survival rate of CDH patients treated by ECMO lagged behind that of other patient groups 
receiving ECMO such as those suffering from meconium aspiration syndrome (59% vs. 94%) 
46
. This lower survival rate stresses again the complexity of the pathology in CDH. Although 
ECMO is a good therapy for neonates with a PPHN, it is no therapy for newborns with a 
serious pulmonary hypoplasia, who have no chance of survival after discontinuation of 
ECMO therapy Maturation of the lungs may not be expected to occur during the limited 
period of ECMO therapy. Therefore several centers have tried to exclude these newborns 
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from ECMO treatment by asking for extra entry criteria, for instance a honeymoon period or 
at least one preductal or postductal Pa02 of 80 to 100 mmHg (10,7 to 13,3 kPa)6 0 6 1 Although 
fulfilling one or both extra criteria is a fairly good predictor of a favourable outcome, not-
fulfilling of one of these criteria does not necessitate an unfavourable outcome, as the effects 
of pulmonary hypoplasia cannot be distinguished from the effects of therapeutic efforts such 
as barotrauma (causing lung injury) and/or hyperhydration 6 2 6 λ. As a consequence the applica­
tion of ECMO has been advocated in all CDH patients for whom conventional treatment does 
not suffice 62. However, the increased survival - by applying ECMO in all CDH patients 
without using extra entry criteria - has to be weighed against the number of patients, in which 
ECMO treatment was not helpful, because those patients have no chance of survival In these 
cases ECMO causes unreliable expectations and needless efforts with a waste of scant resour­
ces. The benefit of the approach without the use of extra entry criteria (i.e. honeymoon or 
Pa02 of 80 to 100 mmHg) seems to be very limited 5 9 6 4. Despite the fact, that over the years 
already more than 12000 neonates have been treated by ECMO, there is still much controver­
sy regarding its usefulness and clinical application, especially for infants with a primary 
diagnosis of CDH 65 70. The debates about the value of ECMO are often confused by varying 
interpretation of selection criteria and estimates of applied maximal conventional treatment. 
Because of reluctancy to withhold ECMO therapy with a good survival chance (more than 
62%) from children, who were very certain to die without ECMO, the idea of a randomized 
controlled study was rejected at the beginning of the ECMO program in our institution 7I. 
Recently the UK Collaborative ECMO Trial Group has however published the results of a 
randomized trial of neonatal ECMO throughout the United Kingdom M. The clinical effective­
ness of ECMO was demonstrated with a reduced risk of death or severe disability in all 
categories of patients. That trial group was not able to give such a pronounced opinion upon 
the role of ECMO in the management of infants with CDH because of the limited numbers of 
CDH patients who were enrolled into the study. The results of the present study with 21 
survivors at the age of 1 year out of 29 ECMO treated CDH patients (72% survival rate at 1 
year of age) compare favourably to the reported results concerning CDH in the UK study with 
only 4 survivors of 18 ECMO allocated CDH patients (22% survival rate) and put the effecti­
veness of ECMO (for CDH on the short term)beyond doubt. 
From the UK study as well as from the present study it may be concluded, that at this moment 
for CDH-infants who met entena for ECMO eligibility (1) continuation of conventional 
treatment is doomed to failure and (2) ECMO is the best therapy available. 
So far ECMO has been reserved as rescue therapy for infants who cannot be stabilized by 
alternative therapies. Despite the use of ECMO as a last resort therapy - when the alternative 
therapies are failing - no other new therapy has met such criticism as ECMO65 67 68 7'. 
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In fact there are few therapeutic modalities for which all aspects of the treatment - selection, 
clinical application and performance, follow-up and outcome studies, registration and data 
collection - are so well-documented and have been so strictly laid down by protocol as is the 
case for ECMO Perhaps these factors are just the basis of the good success of ECMO to a 
great extent n The ELSO and Bartlett may take credit for these aspects of ECMO therapy to 
themselves. 
Since deferred surgery has become the widely accepted approach to the management of CDH, 
ECMO support has been incorporated as part of the preoperative stabilization 24"16 " 7 6 . If 
ECMO is used for stabilization prior to surgery, the question arises when the diaphragmatic 
defect should be repaired during or after weaning from ECMO support before or after 
decannulation71ΑΊΊ 81. The timing of surgical repair before decannulation has the advantage 
that the ECMO circuit acts as a safety net, if recurrent pulmonary hypertension occurs after 
surgery The disadvantage of repair on ECMO - before decannulation - is the increased risk 
of bleeding complications 7 4 8 0 82. In our institution we decided to repair the defect on ECMO, 
late in the ECMO course when the patient had shown to be weanable from ECMO80. In this 
concept PPHN - elicited by the surgical procedure - could be precluded or faced by ECMO 
support and in case of hemorrhagic complications ECMO could be withdrawn within 24 to 48 
hours. By running high ECMO flows during and directly after surgical repair we cannot only 
prevent PPHN but at the same time we can probably reduce bleeding complications because 
high ECMO flows allow a lower level of anticoagulation therapy. During surgery major 
dissections and incidental procedures have been avoided because of the hepannization. 
Inspite of these measures significant bleedingcomphcations were encountered at the surgical 
site 80. Adhering to our strategy and noting reports in the literature concerning the use of 
antifibnnolytic agents for reduction of hemorrhagic complications on ECMO we started with 
the application of tranexamic acid (TEA) during and after CDH repair82 M TEA administrati­
on has been proven to be effective for this purpose, but it must be borne in mind that throm­
botic complications may occur with the use of antifibnnolytic therapy 8 4 8 5 
With regard to the operative repair of the diaphragmatic defect the fundamentals remain the 
same with or without the use of ECMO. However, two remarkable features were observed in 
the group of infants who required ECMO for preoperative stabilization these concern the 
extent of the diaphragmatic defect and the closure of the abdomen. In only 3 out of 28 ( 11 %) 
ECMO stabilized infants the diaphragmatic defect could be closed by a primary repair. In all 
other cases (89%) the defect was too large to reapproximate the edges without undue tension, 
closure was accomplished by synthetic polytetrafluoroethylene (PTFE-Goretex) patch repair. 
Continuing surgery the scaphoid and mostly undersized abdominal cavity can make primary 
closure of the abdomen difficult or impossible Closure that create undue tension can compii-
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cate the postoperative ventilatory management, can cause a decreased perfusion of the lower 
extremities and kidneys with a decreased urine output and can compromise the surgical repair 
resulting in recurrent hernias of the diaphragm and wound dehiscences. For these reasons a 
PTFE (Goretex) patch repair of the abdominal wall had to be accomplished in 11 of the 28 
(39%) ECMO stabilized patients In general there is sufficient room in the abdominal cavity 
within a few weeks enabling the removal of the abdominal wall patch and the subsequent 
closure of the laparotomy wound The question relating to the fate of the PTFE diaphragmatic 
patch with growth remains unanswered for the present8б9192 
In recent years several new therapeutic methods have been used in the management of CDH. 
Surfactant deficiency in CDH has been documented in human studies as well as in the fetal 
lamb model of CDH 91 ^ Two alternative approaches may be tried to correct this deficiency 
(1). Surfactant replacement therapy has been used by the administration of exogenous bovine 
surfactant96 98 In the fetal lamb model improvement in lung compliance and gas exchange as 
well as reduced pulmonary vascular resistance have been demonstrated by exogenous surfac­
tant therapy " m (2). Another approach is offered by the prenatal administration of glucocor­
ticoids, by which the endogenous surfactant production may be enhanced and by which lung 
maturation may be accelerated "" "". 
Inhaled Nitric Oxide (NO) has been shown to reduce pulmonary hypertension without syste­
mic hypotension and to increase pulmonary blood flow 104"106. Although the response to NO in 
newborns may be very dramatic, not all infants respond. The experience in newborn infants 
with CDH is still small and the results have been inconsistent 
Until recently hyperventilation has been the standard approach to the treatment of PPHN 
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. Barotrauma appears now to be one of the most frequently encountered causes of death and 
morbidity 35 36 ' '°. Hyperventilation can not only cause lung damage, but the concomitant 
hypocarbia may have inadvertent effects on cerebral circulation, resulting in brain damage'52 
'
54
. Therefore efforts have to be addressed to avoid ventilation-induced injuries. Wung et al 
advocated a pressure limited ventilation ignoring hyercabia (now commonly known as 
"permissive hypercapnia ventilation") ,09. Survival rates were reported to be improved with a 
strategy in which the use of hyperventilation has been abandoned and in which a preductal 
saturation of greater than 90% has been maintained 15 ' " " 2. In order to avoid barotrauma it 
has become more accustomed to increase ventilatory rates rather than to increase airway 
pressure designated as high frequency positive pressure ventilation (HFPPV) ' n "\ Currently 
the greatest HFPPV experience in neonates has been gained with high frequency oscilatory 
ventilation (HFOV) In randomized studies HFOV has appeared to be beneficial compared to 
conventional ventilation in newborns with respiratory failure | И No randomized trial has 
158 Chapter 12 
been done yet in CDH concerning the use of HFOV. Some studies are claiming the efficacy 
of HFOV for preoperative stabilization in CDH patients with improving survival " 6 " 7 
However, one of the mainstays for the use of HFOV is the hyperventilation-produced alkalo­
sis. Therefore it can be questioned whether HFOV application has great prospects with the 
increasing awareness of the adverse effects of that approach Otherwise the reported results 
with the employment of HFOV in CDH patients are disappointing ' ' "" '8 ' ", ma recent report 
the survival rate for infants treated by HFOV rescue therapy was only 11 % ,6. So the place of 
HFOV in the treatment of CDH is still uncertain The same observation can be applied to 
intratracheal pulmonary ventilation (ITPV) 12° '22 Partial liquid ventilation has presumably 
more possibilities to overcome respiratory insufficiency and to avoid lung damage " 7 '23 After 
beneficial findings in experimental animal studies partial liquid ventilation (PLV) with 
perflurocarbon has been attempted for severe respiratory failure in neonates with CDH while 
on ECMO l24"127 More experience with these new therapeutic modalities is required before 
the clinical usefulness of each of these methods can be elucidated. Because the results of the 
clinical application of these new therapies are still uncertain, trials studying the value of these 
new therapies should be restricted to those institutions in which ECMO facilities are availa­
ble. In case of failure ECMO support can always be provided as a rescue treatment. 
All the aforementioned therapies concern the postnatal management of the lung and pulmona­
ry vascular abnormalities. So far pulmonary hypoplasia was accepted as a given fact for 
which condition no therapy was availabe. However, several authors were able to demonstrate 
an improvement in lung growth, expansion and maturation after repairing the defect in utero 
in fetal lamb studies 1 2 8 , 2 5. These observations offered new perspectives for the treatment of 
CDH by fetal surgery n o ' " Repair of CDH in human fetuses was attempted by Harrison et al 
but only moderate results in terms of survival were reported '34. Fetal repair of CDH is techni­
cally very difficult A less invasive fetal procedure consisted of tracheal ligation, by which the 
effects of pulmonary hypoplasia in the Iamb model could be prevented and corrected l 3 5 '37. 
Fetal tracheal ligation may be accomplished by endoscopic surgery Π8l4° 
Follow up studies of CDH patients treated with conventional therapy in the past did not 
suggest much morbidity among the survivors '4' l44. Even the pulmonary sequelae in these 
patients turned out to be better than was expected and were not interfering with acitivities of 
daily life On the contrary preliminary follow-up studies of CDH patients treated with ECMO 
suggest more morbidity, namely gastroesophageal reflux, feeding problems, hearing loss, 
neurological impairment, chest wall deformities and scoliosis among these survivors ' 4 5 , 4 9 . In 
spite of ECMO therapy up to 60% of the infants appears to have chronic pulmonary disease 
due to pulmonary hypoplasia and/or pulmonary injury (barotrauma). ECMO support has 
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resulted in a higher survival rate especially in children with large defects in whom a prosthe-
tic replacement is required 87 8815° '5' However in this group of patients a higher rate of 
recurrent hernias has been encountered 88 Thus it seems that an increasing morbidity rate is 
the price for a decreasing mortality rate Together with more morbidity other kinds of compli-
cations and problems are met which were not seen before More morbidity and more compii 
cations may be responsible for a declining quality of life That in its tum may put forward 
questions about the benefit of an improved survival Concomitantly that raises the dilemma 
whether ECMO support as a rescue therapy should be applied earlier and in every infant with 
a CDH, or whether ECMO support should be withheld from certain infants 
12.4 Conclusion 
At present we believe that 
(1) ECMO as rescue therapy is a valuable addition to our treatment arsenal for CDH pa-
tients, 
(2) The morbidity and the adverse sequelae occurring in consequence of survival with 
ECMO don't outweighed the increased survival itself, gained by ECMO, 
(3) ECMO has only to be offered to strictly selected patients 
Studying ECMO and CDH it becomes clear that 
1 Several clinical problems associated with CDH have not yet been elucidated 
2 The management of both strongly interrelated pathophysiological mechanisms of CDH 
(pulmonary hypoplasia and elevated pulmonary vascular resistance) is difficult despite 
the great variety of therapeutic options 
3 Consequently the best therapeutic approach for CDH patients with a poorer prognosis 
has yet to be evolved 
4 PPHN in newborns with CDH is a more complex problem than PPHN in newborns with 
other underlying conditions 
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This thesis deals with the clinical aspects of congenital diaphragmatic hemia (CDH) and the 
application of extracorporeal membrane oxygenation (ECMO) in the management of neonates 
with CDH By congenital diaphragmatic hernia is meant the posterolateral diaphragmatic 
defect, also designated as the hernia of Bochdalek. It entails a developmental defect in which 
the usual closing proces of the diaphragm has been arrested or disturbed before birth Because 
there is no (complete) separation between the thoracic and abdominal cavities the abdominal 
viscera migrate unhindered into the thorax This condition (CDH) remains a critical problem 
in neonatal surgery because respiratory failure occurring immediately after birth is responsi-
ble for the death of 40 to 60% of the newborns with this anomaly. Initially it was thought that 
the respiratory distress was caused by the protruded intestines by which the lungs were 
compressed and were unable to inflate themselves The solution of the problem seem to be 
straight forward the allevation of the pulmonary embarassment by removal of the intestines 
from the thoracic cavity and an ensuing surgical repair of the diaphragmatic defect 
However the underlying pathophysiological condition turned out to be more complex than a 
purely mechanical problem on the basis of a simple anatomical defect. The pathophysiology 
is not yet fully understood but currently it is generally assumed that pulmonary hypoplasia 
and pulmonary hypertension are the main pathophysiological phenomena responsible for the 
respiratory distress and the high mortality in CDH patients. 
Although the term hypoplasia is not well defined, by pulmonary hypoplasia is meant an 
underdevelopment of the lungs. This underdevelopment concerns not only a reduced lung 
weight in reference to the body weight, but also a defective development of each of the 
functional systems within the lungs- conducting airways, gas exchange surfaces, air-blood 
interfaces, surfactant system, antioxidant defense system and last but not least pulmonary 
vasculature. The underdevelopment of the pulmonary vascular bed consisting of a reduced 
number of arterial vessels and concomitantly of an increased muscle mass in the vessel wall, 
form the morphological basis for the pulmonary hypertension. In this condition of persistent 
pulmonary hypertension of the newborn (PPHN) diverse factors (among which hypoxia and 
acidosis) have an effect on the anatomically abnormal pulmonary vasculature, that reacts with 
vasoconstriction and consequently with a rise in the pulmonary vascular resistance As a 
result of the increased pulmonary resistance the pulmonary blood flow shunts from right-to-
left to the systemic circulation. That induces a gradually increasing oxygenation problem for 
the infant and leads ultimately to death. Management strategies were adapted according to 
what was known of the pathophysiology. These aspects of CDH are discussed in Chapter 1. 
Generally pulmonary hypoplasia was considered as a given condition for which condition no 
therapy was available. Infants who have a severe pulmonary hypoplasia can never be adequa-
tely oxygenated and die shortly after birth regardless of the kind of treatment Therefore 
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therapeutic protocols focused on the manipulation of the pulmonary hypertension. Therapeu-
tic efforts were adressed to avoid risk factors and conditions which might trigger increasing 
pulmonary vascular resistance such as hypoxemia, acidemia, alveolar hypoxia and increased 
transpulmonary pressures. If pulmonary hypertension developed in spite of all these measures 
several vasodilators were administered in an attempt to reduce pulmonary vascular resistance 
and concomitantly to reduce nght-to-left shunting. Emergency surgery was replaced by 
deferred surgery after a period of cardiorespiratory stabilization. 
The introduction of extracorporeal membrane oxygenation (ECMO) provided new opportuni-
ties to reverse pulmonary hypertension for those infants in whom all conventional therapies 
had failed Clinical aspects of ECMO therapy are discussed in Chapter 2 ECMO is the 
process of temporary but prolonged gas exchange (especially oxygenation) outside the body 
across a semipermiable membrane (membrane oxygenator=artificial lung) by the use of 
extracorporeal circulation For the ECMO application infants have to be connected to the 
ECMO circuit. Using veno-artenal (VA) ECMO cannulas are placed into the right common 
carotid artery and the right internal jugular vein. As a consequence cerebral circulation 
through both vessels is interrupted temporary or permanently. During ECMO support blood is 
drained from the right atrium to the circuit and returns into the systemic circulation after 
oxygenation in the membrane oxygenator. Therefore systemic anticoagulation has to be 
maintained during the whole course of ECMO in order to prevent clot formation as a result of 
the contact of blood with foreign surfaces. The use of systemic hepannization however, 
exposes the already compromised infants to the risk of bleeding complications, particularly 
intracranial hemorrhage. 
The high mortality among neonates with CDH despite all advances in the management of 
these infants together with ongoing reports on the succesful clinical application of ECMO was 
the motivation behind to this study of which the objectives are described in Chapter 3. 
Because of the invasive nature of ECMO and the potential risks associated with ECMO, 
ECMO treatment must be confined to those infants who are thought to have a high risk of 
death on continuing with conventional treatment and a low risk of complications upon initiati-
on of ECMO. However, selection of the "appropriate" patients for an "appropriate" therapy 
may be difficult, especially for a complicated and nskful procedure such as ECMO Through 
the years several investigators have attempted to identify high risk CDH infants for whom a 
more agressive therapy has to be instituted In Chapter 4 we tried retrospectively to identify 
patients with a high-risk of death by means of a previously described X-ray scoring system of 
Summary 173 
preoperative chest radiographs. Reviewing preoperative chest radiographs of 33 newborns 
who were operated because of CDH within 24 hours after birth we were not able to identify 
survivors and non-survivors according to that scoring system. 
In Chapter 5 we studied retrospectively the alveolar to arterial oxygen difference (AaD02) 
linked to time as an entry criterion for ECMO in 60 neonates with respiratory failure 30 
neonates who were treated for meconium aspiration syndrome, respiratory distress syndrome, 
sepsis or idiopathic PPHN (pediatric group) and 30 neonates who had a CDH. It was proven 
that the AaD02 time criteria as formulated in the literature were reliable for the infants of the 
pediatric group but not for neonates with CDH. Fourtyseven percent of the CDH infants died 
before reaching formulated ECMO entry entena. Thus, 53% of the CDH patients would be 
selected too late for ECMO, when we adhere to the published AaD02 time criteria AaD02 
time entena may therefore be unreliable as an entry criterion for ECMO in neonates with 
CDH. 
In Chapter 6 we describe the early experiences with ECMO in CDH patients in our instituti-
on. These CDH patients were treated by a strategy of delayed surgery after a period of preo-
perative stabilization, in which ECMO was incorporated if necessary. All patients who 
required ECMO for preoperative stabilization and who underwent diaphragmatic repair while 
on ECMO had bleeding complications. Conceptual adjustments of this approach are discus-
sed, because bleeding complications had an adverse effect to the outcome of these CDH 
patients. 
In Chapter 7 the benefit of ECMO in cases of high-risk CDH was studied by comparing pre-
ECMO (1987 through 1990) and post-ECMO (January 1991 through July 1994) three months 
survival statistics. Dunng the entire study period (December 1987 through July 1994) all 
patients who presented in respiratory distress within 6 hours after birth were treated by the 
same protocol of preoperative stabilization and delayed surgery, the only difference was the 
addition of ECMO beginning in January 1991. The patients ( 18 in the pre-ECMO era and 37 
in the ECMO era) were stratified based on the response to conventional treatment (1) irretrie-
vable, (2) stable and (3) unstable. The 3 months survival rate for the unstable neonates (who 
could not be stabilized by conventional therapy) improved from 0% (0 of 9) in the pre ECMO 
era to 61 % ( 11 of 18) in the ECMO era (p=0.004). Based on this highly significant difference 
it was concluded that ECMO is a very valuable addition to the management of high-risk CDH 
patients. 
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Because all patients who required ECMO support for preoperative stabilization and in whom 
the diaphragmatic defect was repaired while on ECMO suffered from bleeding complications 
we introduced the use of antifibnnolytic therapy with tranexamic acid (TEA) into the treat-
ment protocol In Chapter 8 the efficacy of TEA was studied in an unblinded study using 
historical controls by comparing the postoperative blood loss and the transfusion requirements 
of red blood cells (RBC) in patient groups treated without (n=9) and with TEA (n=10) 
Patients who received TEA had significantly less bleeding at the surgical site (59 versus 390 
ml, p=0 005) and had significantly lower RBC transfusion requirements than patients not 
receiving TEA (1.13 versus 2 95 ml/kg/h, p=0.03). It was concluded that TEA is effective in 
reducing hemorrhagic complications and RBC transfusion requirements associated with CDH 
repair on ECMO and that the higher survival rate in the TEA treated group might be attribu-
ted to the decreased occurrence of severe hemorrhages 
In Chapter 9 an unexpected complication is described occurring in a patient with CDH after 
decannulation from venoarterial (VA) ECMO. This patient developed an aortic coarctation. 
Because of the sacrifice of the right common carotid artery due to VA-ECMO treatment the 
single left carotid artery could not be clamped during the surgical correction of the aortic 
coarctation This fact limited the surgical resection of the aortic coarctation and the hypoplas-
tic distal aortic arch. 
After successful ECMO treatment for CDH patients recurrent hernia was noted more fre-
quently. This observation gave rise to a retrospective study in which we attempted to identify 
risk factors for a recurrence. The results of this study are described in Chapter 10. The 
medical records of 66 CDH survivors were reviewed. Fiftyseven patients had a left sided 
defect and 9 paitents a right sided defect. The diaphragmatic defect was repaired by primary 
suture in 54 patients and by a prosthetic patch closure in 12 patients. Conventional mechani-
cal ventilation with pharmacological support sufficed in 55 patients, whereas 11 patients 
required ECMO support The defects were divided into 3 groups according to the dimensions 
of the defect (small, moderate or large). Nine patients (14%) developed a recurrent hernia on 
the average of 4.0 months after the initial repair. Recurrences occurred· (1) in 5 patients with 
a left sided defect (9%) and in 4 patients with a right sided defect (44%), (2) in 4 patients with 
a primary repair (7%) and in 5 patients with a prosthetic patch repair (42%), (3) in 5 patients 
who were treated conventionally (9%) and in 4 patients who required ECMO support (36%) 
and (4) in 5 patients with a small or moderate defect (8%) and in all 4 patients with a large 
defect (100%). So, large patch-repaired right sided defects in patients who required ECMO 
stabilization are at risk for the development of a recurrence. 
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Beyond the issue of survival arise the concerns of the morbidity, the outcome and the quality 
of life for the patients who are surviving due to ECMO support. The outcome and early 
morbidity of these survivors are described in Chapter 11 and are compared with the outcome 
and early morbidity of CDH survivors who received conventional treatment in the same 
period (January 1991 through December 1996). Twentythree survivors out of 29 ECMO 
treated CDH infants were enrolled in a routine ECMO evaluation program, whereas 15 of 17 
survivors who recovered on conventional treatment (CT) could be followed retrospectively 
The evaluation was divided into 4 parts. (1) medical and surgical complications, (2) respirato-
ry condition, (3) growth and nutritional status and (4) neurological and developmental outco-
me. Much more complications were noted in the ECMO group than in the CT group during 
the first admission. Chronic lung disease upon discharge and chronic respiratory illness at 1 
year of age were encountered in respectively 61 % and 60% of the ECMO survivors and in 
20% and 36% of the CT survivors. The weight of many CDH survivors was below the 10th 
percentile upon discharge and at one year of age respectively in 87% and 73% of the ECMO 
group and in 47% and 45% of the CT group Nutritional disorders (such as need for tubefee-
ding, gastroesophageal reflux and swallowing problems) were noted in 57% of the ECMO 
survivors upon discharge and remained in 27% of them throughout the first year of life. 
Neurological abnormalities at one year of age were met in 20% of the ECMO survivors and in 
36% of the CT survivors. In the ECMO group the motor development was normal in only 
33% of the children whereas the cognitive development was normal in 67% of the children. 
The average mental development score for the ECMO group fell within the normal range 99 
(range 55 to 125). The average motor development score fell more than one standard deviati-
on below the norm: 0.73 (range 0.55 to 1.0). The delay in gross motor performance was 
related to respiratory restrictions which these infants still have at that age. In conclusion ( 1 ) 
the morbidity in high-nsk CDH patients surviving due to ECMO is substantial and more than 
in these patients surviving with conventional treatment. However the outlook for these 
children remains encouraging with a reasonably low incidence of definite disabilities, and (2) 
taking into account the known mortality and the severe disability (impairment) at one year of 
age there is little doubt about the benefit of ECMO compared to conventional therapy for 
these high-risk CDH infants. 
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Conclusions 
1. ECMO as rescue therapy is a valuable addition to our treatment arsenal for CDH pa-
tients. 
2. The morbidity and the adverse sequalae occurring in consequence of survival with 
ECMO don't outweigh the increased survival itself gained by ECMO. 
3. Several clinical problems associated with CDH have not yet been elucidated. Conse-
quently the best therapeutic approach for CDH patients with a poor prognosis has yet to 
be evolved. 
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Congenitale hernia diafragmatica (CHD) is een aangeboren afwijking van het middenrif, die 
bij ongeveer 1 op 3000 à 4000 pasgeborenen voorkomt. Bij een CHD is er sprake van een 
storing in het gebruikelijke sluitingsproces van het middenrif tijdens de foetale ontwikkeling, 
waardoor geen (volledige) scheiding plaatsvindt tussen borst- en buikholte. Als gevolg 
daarvan kunnen de buikorganen zich nestelen in de borstholte. Ondanks de vele verbeteringen 
die zich hebben voorgedaan in de behandeling en zorg van pasgeborenen sterft nog steeds 40 
tot 60% van de kinderen die geboren worden met een middenrifdefect als gevolg van ernstige 
ademhalingsmoeilijkheden. Aanvankelijk is gedacht dat de ademhalingsmoeilijkheden na de 
geboorte veroorzaakt werden door druk van de darmen op de longen. De darmen vullen zich 
na de geboorte met lucht en als gevolg daarvan kunnen de longen zich niet ontplooien. De 
oplossing van het probleem leek derhalve simpel en puur chirurgisch. De darmen moesten 
teruggehaald worden uit de borstholte en het middenrif moest gesloten worden. In de loop der 
jaren is echter duidelijk geworden dat de pathofysiologie bij een CHD veel ingewikkelder is 
dan een puur mechanisch probleem op basis van een simpel sluitingsdefect. Waarschijnlijk is 
het sluitingsdefect slechts van ondergeschikt belang. Twee andere belangrijkere pathofysiolo-
gische processen lijken de prognose te bepalen van de kinderen met een CHD: de aanwezig-
heid van een longhypoplasie en het optreden van een pulmonale hypertensie. Onder longhy-
poplasie verstaan we een algemene onderontwikkeling van de long tijdens de zwangerschap. 
De longen zijn daardoor in aanleg te klein, het aantal vertakkingen van de luchtwegen en van 
de bloedvaten in de longen is sterk verminderd en ook het aantal longblaasjes, waar de 
gaswisseling plaatsvindt, is afgenomen. Bovendien hebben de bloedvaten in de longen bij 
CHD-kinderen een afwijkende structuur: de spierlaag in de wand van de bloedvaten is sterk 
verdikt, terwijl de kleinere bloedvaatjes, die normaal een elastische bekleding hebben, ook 
omgeven worden door spierweefsel. Als gevolg van deze abnormale structuur hebben de 
longvaten een verhoogde neiging zich samen te trekken (vasoconstrictie), waardoor de 
bloedstroom door het longvaatbed wordt belemmerd. Dit kan leiden tot een verhoogde 
bloeddruk in het longvaatbed (pulmonale hypertensie). Als gevolg van de pulmonale hyper-
tensie kan er een shunting optreden van het bloed vanuit de longcirculatie naar de systemische 
circulatie. De longdoorbloeding zal daardoor afnemen, zodat ook de gaswisseling in de 
longen zal afnemen. Er ontstaat een geleidelijk in emst toenemend zuurstofgebrek, waardoor 
het kind uiteindelijk komt te overlijden. In de loop der jaren is de behandeling van kinderen 
met een CHD aangepast aan de veranderende inzichten in de pathofysiologie. Algemeen werd 
aangenomen dat aan de gestoorde foetale ontwikkeling van de long niets gedaan kon worden: 
de longhypoplasie was een gegeven feit. Een ernstige longhypoplasie was onverenigbaar met 
het leven en ondanks alle therapeutische inspanningen zouden deze kinderen toch overlijden. 
De aandacht in de behandeling werd derhalve meer gericht op het voorkómen en bestrijden 
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van de pulmonale hypertensie. Factoren die aanleiding zouden kunnen geven tot het optreden 
van een pulmonale hypertensie zouden vermeden moeten worden. Het idee van een spoedope-
ratie werd verlaten. Het sluiten van het defect in het middenrif werd uitgesteld tot een later 
tijdstip, nadat de toestand van het kind was gestabiliseerd. Indien er toch een pulmonale 
hypertensie optrad werd getracht de opgetreden vasoconstrictie te bestrijden langs farmacolo-
gische weg Vele vaatverwijders zijn geprobeerd, maar uiteindelijk werkte geen van deze 
vaatverwijders specifiek op de longvaten en hadden deze vaatverwijders in het algemeen 
slechts een tijdelijk effect De pathofysiologische aspecten en de daaraan gekoppelde inzich-
ten in de behandeling van kinderen met een CHD worden besproken in hoofdstuk 1. 
De invoering van extracorporele membraanoxygenatie (ECMO) bood in de tachtiger jaren 
nieuwe perspectieven voor het bestrijden van een ernstige pulmonale hypertensie. Tijdens 
ECMO vindt er gedurende langere tijd gaswissehng plaats buiten het lichaam in een kunst-
long (de membraanoxygenator), waarvoor gebruik wordt gemaakt van een bloedsomloop 
buiten het lichaam (extracorporele circulatie). Voor de toepassing van ECMO moeten kinde-
ren aangesloten worden op het ECMO-circuit. Bij de tot op heden meest toegepaste veno-
arteriele (VA) ECMO methode worden daartoe slangen (canules) ingebracht in de rechter 
halsader (vena jugularis interna) en rechter halsslagader (arteria carotis communis). Geduren-
de de ECMO-behandeling wordt het bloed via de canule in de halsader afgevoerd naar het 
ECMO-circuit en nadat er gaswissehng heeft plaatsgevonden in de kunstlong keert het bloed 
weer terug in het lichaam via de canule in de halsslagader. Als gevolg van het inbrengen van 
deze canules in de halsader en halsslagader is de bloedstroom naar de hersenen via de rechter 
hals tijdelijk of permanent onderbroken. Omdat gedurende de ECMO-behandeling het bloed 
in contact komt met vreemd hchaams materiaal moet systematische antistolhngs behandeling 
worden ingesteld, teneinde stolselvorming van het bloed te voorkomen. Het gebruik van 
antistolhngstherapie (heparinisatie) kan echter leiden tot ernstige bloedings complicaties, met 
name hersenbloedingen. In hoofdstuk 2 worden de principes van ECMO-behandeling be-
schreven. 
De hoge sterfte onder pasgeborenen met een CHD en de berichten in de literatuur omtrent de 
gunstige behandeling van ECMO bij zuigelingen in geval van een pulmonale hypertensie 
vormden de aanleiding voor deze studie (hoofdstuk 3). 
Gezien het invasieve karakter van een ECMO-behandeling en gezien de potentiële risico's van 
een ECMO-behandeling is een nauwkeurige selectie van patiënten die in aanmerking komen 
voor een ECMO-behandeling van groot belang. ECMO-behandelmg zou slechts toegepast 
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moeten worden bij die kinderen, die vrijwel zeker zouden overlijden bij het voortzetten van 
de conventionele behandeling. Anderzijds moeten die kinderen, die ook zonder ECMO-
behandeling zouden overleven, uitgesloten worden van een ECMO-behandeling. 
Vele onderzoekers hebben in de afgelopen decennia gezocht naar parameters, op grond 
waarvan men de prognose voor kinderen met een CHD kon bepalen en op grond waarvan men 
de emst van de aandoening kon vastleggen. In hoofdstuk 4 wordt een studie beschreven 
waarin getracht wordt de prognose van zuigelingen met een CHD te bepalen aan de hand van 
röntgenfoto's volgens een eerder in de literatuur beschreven scoringssysteem. Hiertoe werden 
pre-operatieve röntgenfoto's bekeken van 33 pasgeborenen, die binnen 24 uur na de geboorte 
werden geopereerd wegens een CHD. Op grond van dit röntgenologische scoringssysteem 
waren wij niet in staat een scheiding aan te brengen tussen kinderen die niet zouden overleven 
en kinderen die wel zouden overleven. 
In hoofdstuk S is nagegaan of de alvéolaire arteriole zuurstofgradiënt (AaD02) gekoppeld aan 
de tijd bruikbaar was als toegangscriterium voor ECMO-behandeling. Bloedgasanalyses van 
60 pasgeborenen met ademhalingsmoeilijkheden werden uitgezet in de tijd: 30 pasgeborenen 
die behandeld waren voor een meconiumaspiratie syndroom, een respiratory distress syn-
droom, sepsis of idiopathische pulmonale hypertensie (pediatrische groep) en 30 pasgebore-
nen met een CHD. Uit dit onderzoek kwam naar voren dat de AaD02 gekoppeld aan de tijd 
als toegangscriterium voor ECMO betrouwbaar was voor alle pasgeborenen in de pediatrische 
groep. Voor kinderen met een CHD bleek dit toegangscriterium ontoereikend: 47% van de 
pasgeborenen met een CHD stierf alvorens het vastgestelde ECMO-toegangscriterium werd 
bereikt. Dientengevolge zou 53% van de pasgeborenen met een CHD te Iaat geselecteerd 
worden voor een ECMO-behandeling. 
In hoofdstuk 6 worden onze eerste ervaringen met ECMO in het kader van de behandeling 
van pasgeborenen met een hernia diafragmatica beschreven.. Het behandelingsplan voor deze 
kinderen bestond uit een uitgestelde operatieve sluiting van het middenrifdefect na een 
periode van preoperatieve stabilisatie. Voor stabilisatie werd zonodig gebruik gemaakt van 
ECMO. Indien ECMO nodig was voor preoperatieve stabilisatie dan werd het diafragmade-
fect gesloten gedurende de ECMO-behandeling. Bij alle kinderen, die preoperatief slechts 
gestabiliseerd konden worden dankzij ECMO en bij wie het middenrifdefect werd gesloten 
tijdens de ECMO-behandeling, traden ernstige bloedingscomplicaties op. Onder die kinderen, 
welke bloedingscomplicaties hadden was de sterfte hoog (60%). Het leek derhalve wenselijk 
ons behandelingsprotocol aan te passen. 
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In hoofdstuk 7 wordt de waarde van de ECMO-behandeling voor kinderen met een CHD 
nagegaan. Gekeken werd naar de overleving op de leeftijd van 3 maanden. Twee groepen 
kinderen met een CHD werden vergeleken (1) kinderen behandeld in de periode voorafgaan-
de aan ECMO (1987-1990) en (2) kinderen behandeld in de periode waarin ECMO-behande-
ling ter beschikking stond (1991-1994) Gedurende de hele studieperiode (december 1987 tot 
juli 1994) werden alle patientjes, die binnen zes uur na de geboorte ernstige ademhalingspro-
blemen hadden als gevolg van een CHD, behandeld volgens hetzelfde protocol van preopera-
tive stabilisatie en uitgestelde chirurgische therapie. Het enige verschil betrof de toevoeging 
van ECMO in het behandehngsprotocol vanaf januari 1991. Alle patiënten (18 in de pre-
ECMO periode en 37 in de ECMO-penode) werden ingedeeld in dne categorieën, afhankelijk 
van hun reactie op de ingestelde conventionele behandeling. Uit dit onderzoek bleek dat voor 
die patientjes, die preoperatief niet gestabiliseerd konden worden door middel van conventio-
nele behandeling de overlevingskans toenam van 0% (0 overlevenden op 9 pasgeborenen) in 
de pre-ECMO periode tot 61% (11 overlevenden onder 18 patientjes) in de ECMO-penode. 
ECMO kan derhalve gezien worden als een waardevolle aanvulling op de behandelingsmoge-
lijkheden voor kinderen met een CHD. 
Aangezien bij alle kinderen, die slechts gestabiliseerd konden worden dankzij ECMO-behan-
deling en bij wie het middenrifdefect gesloten werd tijdens de ECMO-behandeling, ernstige 
bloedingscomplicaties optraden werd het gebruik van tranexaminezuur (TEA) ingevoerd m 
het behandelingsplan voor kinderen met een CHD. In hoofdstuk 8 wordt de effectiviteit van 
TEA nagegaan in een open studie, met gebruik van historische controles. Het postoperatieve 
bloedverlies en de transfusiebehoefte aan rode bloedcellen (RBC's) werden bestudeerd in 
twee patiëntengroepen. (1) patiënten die geen TEA kregen (n=9) en (2) patiënten die TEA 
kregen (n=10). Het bleek dat patiënten die TEA kregen veel minder postoperatief bloedverlies 
hadden (59 versus 390 ml) en een geringe RBC-transfusiebehoefte hadden dan patiënten die 
geen TEA kregen (1.13 versus 2.95 mg/kg/hr) TEA bleek derhalve effectief in het voorko-
men van bloedingscomplicaties, die kunnen optreden bij de chirurgische behandeling van het 
middenrifdefect tijdens ECMO. 
In hoofdstuk 9 wordt een onverwachte complicatie beschreven die optrad bij een patientje 
met een CHD na VA ECMO-behandeling. Dit patientje ontwikkelde een coarctatie van de 
aorta. Als gevolg van de toegepaste VA ECMO-behandeling was de rechter halsslagader 
onderbonden Bij resectie van de coarctatie en de hypoplastische aortaboog werden beper-
kingen ondervonden in de chirurgische behandeling, omdat de linker halsslagader niet afge-
klemd kon worden. 
Samenvatting 185 
Na de invoering van ECMO-behandeling werden meer kinderen met een recidief hernia 
diaphragmatica gezien. Dit vormde de aanleiding tot een retrospectieve studie, waarin risico-
factoren werden nagegaan voor het optreden van een recidief CHD. Resultaten van dit onder-
zoek worden beschreven in hoofdstuk 10. De medische dossiers van 66 CHD kinderen 
werden bekeken. Onderverdeling van de patientjes vond plaats op basis van ( 1 ) links- of 
rechtszijdig middenrifdefect, (2) de mogelijkheid van primaire sluiting van het middenrifde-
fect of het gebruik van een kunststof materiaal voor het sluiten van het defect, (3) de grootte 
van het middenrifdefect en (4) conventionele behandeling of ECMO-behandehng. Op grond 
van dit onderzoek bleek, dat rechtszijdige en grote, met behulp van kunststof materiaal 
gerepareerde defecten bij patiënten die ECMO-behandeling ondergingen een grotere kans 
hebben op het ontwikkelen van een recidief 
Nu met ECMO steeds meer patientjes met een CHD overleven, met name kinderen met grote 
middenrif defecten komen er ook meer vragen over de kwaliteit van overleving en over de 
mogelijk nadelige effecten van de ECMO-behandeling. In hoofdstuk 11 wordt de korte 
termijn follow-up besproken van CHD-kinderen die overleefden dankzij ECMO-behandehng. 
Er wordt daarbij een vergelijking gemaakt met de korte termijn follow-up van CHD-kinderen 
die in dezelfde periode (januari 1991-december 1996) overleefden met conventionele behan-
deling. De 23 overlevenden van de 29 ECMO behandelde kinderen werden opgenomen in een 
standaard ECMO-evaluatie protocol, zoals dit was vastgesteld voor de invoering van ECMO-
behandehng. Vijftien van de 17 CHD-kinderen die overleefden met conventionele behande-
ling (CB) konden meegenomen worden in een retrospectief follow-up onderzoek In de 
ECMO-groep werden meer complicaties vastgesteld dan in de CT-groep gedurende de eerste 
opnameperiode. Longproblemen bleken bij de ECMO behandelde kinderen vaker voor te 
komen dan bij de conventioneel behandelde kinderen (plm. 60% ten opzichte van 20 à 36%). 
De groei van de meeste CHD-patientjes bleek te stagneren. Bij ontslag en op de leeftijd van 1 
jaar waren respectievelijk 87% en 73% van de ECMO behandelde kinderen onder de PÍO van 
de gewichtscurve en respectievelijk 47% en 45% van de conventioneel behandelde kinderen. 
Voedingsproblemen, waaronder de noodzaak voor sondevoeding, de aanwezigheid van 
gastro-oesophageale reflux en slikproblemen werden vastgesteld bij 57% van de kinderen die 
behandeld werden met ECMO. Neurologische problemen op de leeftijd van 1 jaar bleken bij 
20% van de ECMO-kinderen en bij 36% van de conventioneel behandelde kinderen aanwezig 
te zijn. De mentale ontwikkeling van de kinderen die met ECMO behandeld waren was in 
67% van de gevallen normaal. De gemiddelde mentale ontwikkelmgsscore voor de ECMO-
kinderen was vergelijkbaar met die van normale leeftijdgenootjes- 99 (range 55-125) Opval-
lend was de achterstand in motorische ontwikkeling bij de CHD-kinderen, die dankzij ECMO 
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overleefden. In slechts 33% van de gevallen kon de motorische ontwikkeling als normaal 
geduid worden De gemiddelde motorische ontwikkehngsscore van deze kinderen viel meer 
dan één standaarddeviatie onder de gemiddelde norm van leeftijdgenootjes 0.73 (range 0.55 
tot 1.0) 
Deze bevindingen geven aan dat meer morbiditeit de prijs is voor de betere overleving. Met 
name ondervinden de CHD kinderen die dankzij ECMO overleven m de eerste opname 
periode meer complicaties en in het eerste levensjaar meer voedings- en ademhalingsproble-
men dan CHD kinderen die zonder ECMO overleven. Als gevolg van deze ademhahngs- (en 
voedingsproblemen blijft de motorische ontwikkeling in het eerste levensjaar achter ten 
opzichte van leeftijdgenootjes De mentale ontwikkeling van deze kinderen lijkt echter goed 
te zijn Er komen vooralsnog met meer neurologische stoornissen voor onder de CHD kinde-
ren die overleven met ECMO dan onder de CHD kinderen die overleven zonder ECMO. Deze 
kinderen lijken derhalve toch een goed levensperspectief te hebben. 
Conclusies 
In dit proefschrift wordt aangetoond dat ECMO de levenskansen voor kinderen met een 
aangeboren middenrifdefect verhoogt. De verbeterde overleving gaat ten koste van meer 
morbiditeit Vrijwel alle kinderen met een middenrifdefect die dankzij ECMO overleven 
hebben óf complicaties en nog meerdere operaties tijdens de eerste opnamepenode, óf hebben 
"restverschijnselen" in het eerste levensjaar in de vorm van voedings- en/of ademhalingspro-
blemen, gepaard gaande met een vertraagde motorische ontwikkeling. Deze complicaties en 
problemen vormen (soms) een zware belasting voor de ouders. Vooralsnog lijken echter de 
vooruitzichten voor deze kinderen goed te zijn. Er worden niet meer neurologische problemen 
gezien bij deze kinderen dan bij andere kinderen die in de neonatale fase medische en/of 
chirurgische behandeling hebben ondergaan. De mentale ontwikkeling van deze kinderen lijkt 
gelijkwaardig te zijn aan die van leeftijdgenootjes. 
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Dankwoord 
Bewust of onbewust hebben velen meegewerkt aan de totstandkoming van dit proef-
schrift. Veel woorden van dank zouden derhalve gesproken moeten worden. Het is echter 
onmogelijk ieder individueel te bedanken, zonder daarbij iemand "over het hoofd te zien". 
Zonder daarbij iemand te kort doen, wil ik een aantal mensen in het bijzonder bedanken. 
In de eerste plaats geldt dit voor de beide promotores. 
Prof. Dr. C. Festen, beste Kees, mijn bewondering voor jouw gedrevenheid en voor jouw 
persoonlijke inzet en zorg voor patientjes heeft mij destijds mede doen kiezen voor de kinder-
chirurgie. Ik had het gevoel, dat ik nog veel van je kon leren en dat er nog veel patientgebon-
den onderzoek gedaan kon worden. Toch heeft het nog tien jaren moeten duren alvorens wij 
het patientgebonden onderzoek zodanig gestalte konden geven dat daaruit dit proefschrift kon 
voortkomen. Jij was de initiator van "ECMO Nijmegen". ECMO als project voor ontwikke-
lingsgeneeskundig onderzoek werd met jou als projectleider naar Nijmegen gehaald. Jouw 
nauwgezetheid en niets aan het toeval overlatende streven naar perfectie hebben geleid tot een 
uitstekend klinisch ECMO program. 
Dr. W.B. Geven, beste Wil, je bent in de afgelopen jaren een belangrijk gezicht geweest van 
ECMO Nijmegen. Soms duidelijk zichtbaar en merkbaar, maar vaak ook onzichtbaar achter 
de schermen heb je je ingezet voor het hele ECMO gebeuren op vele fronten, vaak tot in de 
kleinste details. Jouw kennis van de long- en ECMO-physiologie is onmisbaar geweest bij de 
opzet van het ECMO program en is mede verantwoordelijk geweest voor de gunstige ECMO 
resultaten in Nijmegen. Nu je een andere weg hebt ingeslagen, zullen wij het zonder die 
motor en zonder dat brein moeten stellen. Wij hopen de komende jaren zonder jou de ingezet-
te lijn vast te kunnen houden. 
Drs. A.F.J. de Haan, beste Ton, jouw kijk op cijfers was verbazingwekkend; op sommige 
momenten ontwapenend, op andere momenten geestverruimend. Op grond van je analyse van 
cijfers en getallen trok jij conclusies en deed jij vaak voorstellen voor de klinsche behande-
ling, die uit de mond van een ervaren clinicus konden komen. Je zorgde steeds voor nieuwe 
openingen, indien ik vast dreigde te lopen in de rijstebrij van gegevens. Je stimulerende 
werking is van groot belang geweest in de voltooiing van dit werkstuk. 
Drs. G. Fons, beste Guus, jij hebt de grondslag gelegd voor het databestand van ons ECMO 
program. Je hebt daarmee een belangrijke bijdrage geleverd om de trein, die moest leiden tot 
dit proefschrift, op het spoor te zetten. Je betrokkenheid was hartverwarmend. Jouw 
efficiënte, nuchtere en "kraakheldere" werkwijze was verfrissend, je humor gaf veel kleur aan 
het ECMO gebeuren. 
Leden van de voormalige ECMO wetenschapscommissie, Prof. Dr. B. Oeseburg en Prof. 
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Dr.R.C.A. Sengers, beste Berend en beste Rob, voor de belangstelling van de wetenschappe­
lijke vorderingen op ECMO gebied en met name voor mijn aktiviteiten daarin ben ik jullie 
zeer erkentelijk. Jullie pleidooi voor en aandrang op de realisatie van mijn promotie vanuit 
het ECMO project hebben verplichtingen opgeroepen, waaraan ik heden, ik hoop naar wens, 
heb kunnen voldoen. 
Stafleden, fellows, AGNICTs , AGIO s en verpleegkundigen van de afdeling neonatologie 
(huidig werkplek management Prof. Dr M. v.d. Bor en Mw. Τ Vanlier), ik ben jullie veel 
dank verschuldigd voor alle hulp, die jullie mij veelal onbewust verleend hebben. Jullie 
voerden de dagelijkse ECMO behandelingen uit en hielden de registratie van de ECMO-run 
nauwkeurig bij Jullie notities en handelingen zijn de basisgegevens geweest, die ik heb 
kunnen bewerken voor dit proefschrift 
Mw Η Wilbers, beste Henriette, JIJ hebt je als een ware ECMO-coordinatnce gemanifes­
teerd. Je bent een belangrijke schakel bij de aanschaf en onderhoud van de apparatuur, bij de 
dagelijkse uitvoer van het ECMO program, bij het verzamelen en verwerken van gegevens, 
bij het signaleren van knelpunten, bij de scholing en bijscholing van verpleegkundigen en bij 
de vele experimenten Ik hoop dat de prettige samenwerking voortgezet zal worden de ko­
mende jaren. 
Mijn kinderchirurgische collegae, Drs. R S.V M. Sevenjnen en Dr. P.N.M.A. Rieu, beste 
René en beste Paul, reeds vele jaren (respectievelijk 24 en 10 jaren) delen wij onze werk-
zaamheden, waarbij wij elkaar steeds aanvullen. In nauw groepsverband hebben wij gezamen-
lijk gestreefd naar een hoog niveau van patiëntenzorg met een menselijke benadering. Ik heb 
van jullie altijd veel steun mogen ondervinden zowel bij de dagelijkse klinische werkzaamhe-
den, waaronder ECMO, als ook bij mijn poging vanuit ECMO een proefschrift te realiseren 
Vooral het laatste halve jaar hebben jullie vele klinische werkzaamheden van mij overgeno-
men om mij in de gelegenheid te stellen dit werkstuk af te ronden Ik ben jullie daarvoor 
dankbaar en hoop dat in de toekomst deze samenwerking op dezelfde goede wijze voortgezet 
kan worden 
Alle " ECMO- en CDH- kinderen", om wie al deze studies in dit proefschrift draaien. Jullie 
hebben samen met jullie ouders en met ons een nieuwe weg ingeslagen, die andere ervaringen 
opleverden het was lang met altijd een gemakkelijke weg Er zijn maar weinig mensen, die 
begrijpen, wat jullie hebben meegemaakt Wij hopen met eikaars steun de ingeslagen weg te 
kunnen vervolgen, immers- "samen uit, samen thuis". 
Medewerkers van het Centrale Dierenlaboratorium (hoofd Dr J. Koopman), de heren Th. 
Arts, F Philipsen en A Peters, beste Theo, Fred en Ton, met genoegen kijk ik terug op onze 
eerste ECMO stappen en de voorbereidingstijd van het ECMO program in het CDL. Een 
stukje nostalgie, een driedaagse ECMO sessie gedurende een lang weekend in het CDL, 
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gedurende dag en nacht met een oude fiets via het onderaardse gangenstelsel bloedgasjes 
wegbrengen naar het centraal laboratorium (CKCL). Jullie betrokkenheid en vakmanschap bij 
deze ECMO sessies, maar ook jullie ludieke oplossingen voor zich voordoende problemen 
zijn zeer gewaardeerd. 
Medewerkers van de afdeling Extracorporale Circulatie (hoofd P. Weerwind), beste perfusio-
nisten, ECMO heeft zeker een extra verzwaring van jullie taak betekend, maar ECMO heeft 
ongetwijfeld ook de grenzen van jullie werk verlegd, jullie kennis verdiept en nieuwe erva-
ringen opgeleverd. Jullie kennis, inbreng en betrokkenheid zullen ook in de toekomst op prijs 
gesteld worden. 
Drs. J. Collins, beste James, op spontane wijze hebjij aangeboden het manuscript te lezen en 
te corrigeren. Mochten er toch nog fouten in staan dan treft jou in elk geval geen blaam. 
Door vele mensen zijn van tijd tot tijd extra inspanningen geleverd voor ECMO in het 
algemeen of voor mij in het bijzonder. Ook deze mensen wil ik bedanken, zoals 
- Wil Hermans en Theo van Rijswijk van de Instrumentele Dienst Oost (hoofd A Steen-
veld) 
Doortje, Liset en Petra van het secretariaat Kinderchirurgie 
- Come van het secretariaat Neonatologie 
- Dhr. J. Meeuwissen van de Medische Fotografie 
- Medewerkers van het centrale OK-complex en Anaesthesie 
- Medewerkers van de Bloedtransfusiedienst, Radiologie en CKCL 
En dan het sluitstuk, zoals steeds als al het werk gedaan is, dan is er pas tijd voor het thuis-
front. Voor een deel zit dat in het karakter van het werk, voor een deel zit dat in het karakter 
van mijzelf. Voor jullie, die mij kennen, is het niet zo vreemd, dat ik juist dit werk doe 
Lieve Nicole, je hebt tot de dag van vandaag het gehele ECMO traject van dichtbij meege-
maakt, vanaf de eertse onzekere stappen op ECMO-gebied, de opzet van het ECMO program 
tot nu uiteindelijk deze dissertatie. Aanvankelijk was je alleen secretarieel sterk verbonden 
met ECMO. Dit werd anders, toen ik besloot via ECMO tot een promotie te komen. ECMO 
kreeg voor ons beiden ook een sterk emotionele betekenis. In vele opzichten heb ik een 
beroep op je gedaan. Ik veronderstelde niet alleen begrip voor mijn drukke werkzaamheden 
en daarnaast mijn promotiedrang, maar tevens verwachtte ik een gewillig oor en geduld, 
wanneer de zaken niet zo liepen, als ik wenste Met name als de werkzaamheden voor deze 
promotie gedurende weken en soms maanden noodgedwongen stil lagen Bovendien leverde 
je mij de hoog noodzakelijke secretariële ondersteuning voor de uitwerking van de diverse 
publicaties en uiteindelijk voor dit proefschrift. Derhalve is deze promotie niet alleen een 
kroon op mijn werk, maar vooral ook een kroon op jouw werk. Ik hoop, dat een zware last 
van ons is afgevallen en dat we weer meer tijd voor elkaar zullen krijgen. 
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Lieve Amber, Max, Barbara en Boukje, jullie hebben je vader vaak moeten missen Naast de 
drukke dagelijkse werkzaamheden en de - ook voor jullie - met zeer grote regelmaat terugke-
rende en zwaar belaste bereikbare diensten had die man het ook nog eens in zijn hoofd gezet 
carrière te maken en te promoveren Als hij dan thuis was, trok hij zich weer terug achter zijn 
werktafel op zolder, of was hij met zijn hoofd bij heel andere dingen Na vier mislukte 
pogingen tot een proefschrift ben ik er nu toch in geslaagd te promoveren. Ik hoop, dat ik nu 
meer rust zal hebben en meer tijd en aandacht aan jullie zal kunnen besteden. 
Deze dag is niet zo zeer een afsluiting, als wel een nieuw begin. 
Tenslotte vader, ik ben blij, dat je hier vandaag bent. Je hebt samen met "ons " moeder de 
basis gelegd. Het is jammer, dat moeder dit niet meer mee heeft kunnen maken 
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Curriculum Vitae 
Franciscus H.J.M, van der Staak werd op 17 september 1946 geboren te Vught. In 1964 
behaalde hij het eindexamen gymnasium β (beta) aan het St. Janslyceum te 's Hertogenbosch. 
In 1972 legde hij het artsexamen af aan de Katholieke Universiteit te Nijmegen. 
In 1972 en 1973 vervulde hij de militaire dienstplicht: eerst als keuringsarts bij het luchmacht 
selectie orgaan (LUSO) te Rijen later als basisarts op de Vliegbasis Deelen. 
In augustus 1973 startte hij de opleiding Algemene Heelkunde aan het St Radboud Acade­
misch Ziekenhuis te Nijmegen onder leiding van Prof. Dr. W.J.H. Schmidt. De opleiding 
werd voltooid onder leiding van Prof. Dr. H.H.M, de Boer. 
In het kader van de opleiding tot kinderchirurg en voor nadere specialisatie in de kinderonco-
Iogie liep hij van januari 1981 tot juli 1981 stage in 3 centra in de Verenigde Staten: Chil-
drens Hospital of Philadelphia (Prof. Dr. CE. Koop, Prof. Dr. G.J. D'Angio, Prof. Dr. A.E. 
Evans), Memorial Sloan Kettering (New York, Prof. Dr. Ph. Exelby) and children's Hospital 
of Los Angeles (Prof. Dr. M.W.M. Woolley). 
Sinds 1 augustus 1979 is hij als staflid werkzaam op de afdeling Kinderchirurgie van het 
Academisch Ziekenhuis Nijmegen St Radboud. (Hoofd: Prof. Dr. C. Festen). 
In 1988 werkte hij mee aan het opzetten van het ECMO project. In 1989 volgde hij een 
ECMO stage in Pittsburgh (PA). In 1990 slaagde de ECMO projectgroep (o.l.v. Prof. Dr. С 
Festen) erin ECMO als project voor ontwikkelingsgeneeskundig onderzoek naar Nijmegen te 
halen. De auteur behoorde tot één van de hoofdonderzoekers van dit ontwikkelingsgenees-
kundig onderzoek van de Gezondheidsraad. Vanuit dit project bewerkte hij de gegevens die 
betrekking hadden op patientjes met congenitale hernia diaphragmatica, van waaruit dit 
proefschrift tot stand kwam. 
Stellingen 
behorend bij het proefschrift 
Congenital Diaphragmatic Hernia 
and 
Extracorporeal Membrane Oxygenation 
F.HJ.M. van der Staak 
1 De overlevingskansen voor kinderen, die geboren worden met een midden-
rifdefect, zijn verbeterd door de invoering van extracorporele membraan-
oxygenatie 
dit proefschrift 
2 Het bli]ft moeilijk de ernst van een aandoening als congenitale hernia 
diaphragmatica te kwantificeren 
dit proefschrift 
3 Antifibnnolytische therapie kan bloedingscomplicaties, die kunnen op-
treden bi) de operatieve behandeling van een middenrifdefect tijdens 
extracorporele membraanoxygenatie , voorkomen 
dit proefschrift 
4 Meer morbiditeit is de prijs voor verminderde sterfte onder kinderen met 
een congenitale hernia diaphragmatica ten gevolge van behandeling met 
extracorporele membraanoxygenatie 
dit proefschrift 
5 Het succes van de behandeling met extracorporele membraanoxygenatie 
kan voor een deel toegeschreven worden aan de sterk geprotocolleerde 
opzet van de behandeling 
6 Bij een onbehandelbare obstipatie, een paradoxe diarree, een acute urine-
retentie of een eenzijdige bilvergroting is ook bij een kind een rectaal 
onderzoek absoluut geïndiceerd 
Staak Fvd, besten С Het sacrococcigeale teratoom 
een wondergezwel of een monstergezwel'' 
Ned Tiidschr Genceskd 128 1745 1748, 1984 
7 Zolang er geen fysisch-diagnostisch criterium bestaat, op grond waarvan 
een niet goed ingedaalde testis met voldoende zekerheid onderscheiden 
kan worden van een retractiele testis, blijft het zogenaamde ballenkaartje 
een bittere noodzaak 
8 Een pasgeborene, die gallig spuugt, behoeft een kinderchirurg. 
9 Het zonder meer samenbrengen van verschillende specialisten betekent op 
zich nog geen teamverband. 
Festen C. Geneeskunde w groepsverband. 
Openbare les 1976 
10 De worsteling tussen symbiose en autonomie is een permanent conflict, dat 
ieder mens met zich meedraagt. De stand in deze strijd is bepalend voor de 
kwaliteit van samenwerken, samenwonen en samenleven. 
11 De Nederlandse Vereniging voor Kinderchirurgie, geboren in 1981 en op-
gegroeid onder de vleugels van de moedervereniging (de Nederlandse Ver-
eniging voor Heelkunde) heeft de puberteit bijna doorlopen. Het resultaat 
van de opvoeding, t.w. een evenwichtige en volwassen relatie tussen beide 
verenigingen, gloort reeds. 
vrif naar : 
Hazebroek FW]. Kinderchirurgie, gisteren en morgen 
Ned Tijdschr Heeik 6: 78-79,1997 
12 Bereikbare diensten zijn een bron van spanningen en conflicten. Het ver-
wachtingspatroon dat betrokken partijen van deze dienst hebben, is onvol-
doende op elkaar afgestemd, terwijl de aard, de frequentie en de waar-
dering van de dienst onvoldoende zijn geregeld. 
13 Het verwerken van een groot databestand met een trage computer is als het 
eten van soep met een vork. 
14 Het gevoel van de recreatie-fietser en van de woon-werk-fietser, dat de wind 
zeer vaak tegen zit (zowel op de heen- als op de terugweg), kan weten-
schappelijk via de wetten van de mechanica ondersteund worden. 
15 Het Oudhollandse gezegde "de eerste klap is een daalder waard" is achter-
haald door het huidige professionele toptennis. 



